▁simul ect ▁may ▁har m ▁your ▁baby ▁ .
▁in ▁these ▁patients ▁ , ▁the ▁addition ▁of ▁riba vir in ▁to ▁vir af eron ▁increased ▁by ▁as ▁much ▁as ▁10- fold ▁the ▁ef fica cy ▁of ▁vir af eron ▁used ▁alone ▁in ▁the ▁treatment ▁of ▁chronic ▁hepatitis ▁c ▁( ▁4 8.6 ▁% ▁vs ▁ .
▁in ▁pig s ▁ , ▁the ▁withdraw al ▁period ▁in ▁me at ▁and ▁of fal ▁is ▁71 ▁days ▁ .
▁in ▁the ▁blood ▁pressure ▁studies ▁ , ▁kar ve a ▁was ▁more ▁effective ▁than ▁place bo ▁at ▁ reducing ▁dia sto lic ▁blood ▁pressure ▁and ▁had ▁similar ▁effects ▁to ▁the ▁other ▁medicine s ▁for ▁hyper tension ▁ .
▁typically ▁ , ▁such ▁reaction s ▁have ▁been ▁observe d ▁within ▁the ▁first ▁weeks ▁or ▁months ▁of ▁initiat ion ▁of ▁cart ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁8 ▁mg ▁of ▁la ctos e ▁and ▁3.3 ▁mg ▁of ▁hydro gen ated ▁cas tor ▁oil ▁ .
▁however ▁the ▁chemical ▁and ▁physical ▁stabilit y ▁of ▁the ▁premi x ▁solution ▁has ▁been ▁demonstrat ed ▁for ▁8 ▁hours ▁when ▁store d ▁either ▁between ▁2 ▁° ▁c ▁and ▁8 ▁° ▁c ▁or ▁at ▁room ▁temperature ▁( ▁below ▁25 ▁° ▁c ▁) ▁ .
▁in ▁clinic al ▁trial s ▁conduct ed ▁in ▁the ▁hepatitis ▁c ▁population ▁ , ▁patients ▁were ▁treated ▁with ▁vir af eron ▁alone ▁or ▁in ▁combination ▁with ▁riba vir in ▁for ▁one ▁year ▁ .
▁en ta ca pone ▁may ▁form ▁che late s ▁with ▁ir on ▁in ▁the ▁gastro inte stin al ▁tract ▁ .
▁ cyclo - oxy gen ase -2 ▁is ▁an ▁enzym e ▁that ▁increase s ▁at ▁infla mma tory ▁sites ▁and ▁in ▁ab normal ly ▁growing ▁cell s ▁ .
▁standard ▁ha e mat ological ▁tests ▁and ▁blood ▁che mist ries ▁( ▁complete ▁blood ▁count ▁and ▁differenti al ▁ , ▁plate let ▁count ▁ , ▁electro ly tes ▁ , ▁ liver ▁enzym es ▁ , ▁se rum ▁protein ▁ , ▁se rum ▁bilir u bin ▁and ▁se rum ▁creati nine ▁) ▁are ▁to ▁be ▁conduct ed ▁in ▁all ▁patients ▁prior ▁to ▁and ▁period ically ▁during ▁system ic ▁treatment ▁with ▁vir af eron ▁ .
▁para ffin ▁ , ▁liquid ▁mann ide ▁mono - ole ate ▁poly sor bate ▁80 ▁tro meta mol
▁patients ▁should ▁be ▁monitor ed ▁for ▁symptoms ▁of ▁con ges tive ▁heart ▁failure ▁during ▁ therapy ▁and ▁during ▁the ▁follow ▁up ▁period ▁ .
▁tum our ▁lys is ▁syndrome ▁is ▁a ▁potential ly ▁life - th rea te ning ▁complica tion ▁ , ▁caused ▁by ▁chemical ▁changes ▁in ▁the ▁blood ▁due ▁to ▁the ▁break down ▁of ▁dy ing ▁cancer ▁cell s ▁( ▁see ▁section ▁3 ▁) ▁ .
▁when ▁this ▁is ▁block ed ▁ , ▁no ▁ thro mbin ▁( ▁another ▁factor ▁) ▁can ▁be ▁produced ▁ , ▁and ▁no ▁clo t ▁can ▁be ▁for med ▁ .
▁the ▁possibility ▁of ▁multiple ▁medicinal ▁product ▁involve ment ▁should ▁be ▁considered ▁ .
▁animal ▁studies ▁showed ▁no ▁effect ▁of ▁trav o prost ▁on ▁fertil ity ▁at ▁dos es ▁more ▁than ▁250 ▁times ▁the ▁maximum ▁recommended ▁human ▁o cular ▁dose ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁geno toxic ity ▁ , ▁and ▁ toxic ity ▁to ▁reproduc tion ▁and ▁development ▁ .
▁doce ta xel ▁30 ▁mg ▁/ ▁m 2 ▁ad minister ed ▁week ly ▁for ▁the ▁first ▁5 ▁weeks ▁in ▁a ▁6 ▁week ▁cycle ▁for ▁5 ▁cycle s ▁ .
▁doce ta xel ▁win thro p ▁160 ▁mg ▁/ ▁8 ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁requires ▁no ▁prior ▁dilu tion ▁with ▁a ▁solve nt ▁and ▁is ▁ready ▁to ▁add ▁to ▁the ▁in fusion ▁solution ▁ .
▁cer enia ▁solution ▁for ▁inject ion ▁should ▁be ▁inject ed ▁sub cuta ne ously ▁or ▁intra ven ously ▁ , ▁once ▁daily ▁ , ▁at ▁a ▁dose ▁of ▁1 ▁mg ▁/ ▁kg ▁body weight ▁( ▁1 ▁ml ▁/ ▁10 ▁kg ▁body weight ▁) ▁for ▁up ▁to ▁5 ▁consecutiv e ▁days ▁ .
▁cd 4 ▁percent ▁ , ▁media n ▁[ ▁range ▁] ▁23. 3 ▁% ▁[ ▁0 ▁- ▁44 ▁]
▁apparent ▁clear ance ▁per ▁kg ▁body ▁weight ▁( ▁cl ▁/ ▁f ▁per ▁kg ▁) ▁was ▁comparable ▁between ▁the ▁s jia ▁and ▁cap s ▁population ▁( ▁0.0 04 ▁l ▁/ ▁d ▁per ▁kg ▁) ▁ .
▁in ▁the ▁ absence ▁of ▁compatibil ity ▁studies ▁ , ▁this ▁medicinal ▁product ▁must ▁not ▁be ▁ad minister ed ▁as ▁a ▁mix ture ▁with ▁other ▁medicinal ▁products ▁in ▁the ▁same ▁inject ion ▁ .
▁the ▁table ▁is ▁not ▁all - inclusiv e ▁ .
▁ma cu gen ▁is ▁not ▁recommended ▁during ▁breast feed ing ▁as ▁it ▁is ▁not ▁known ▁whether ▁ma cu gen ▁passe s ▁into ▁human ▁milk ▁ .
▁{ ▁10 ml ▁type ▁i ▁glass ▁vi al ▁}
▁au c ▁ ↓ ▁0 . 65 ▁( ▁0.5 9 -0 . 71 ▁)
▁medicine s ▁should ▁not ▁be ▁dispose d ▁via ▁was te water ▁or ▁household ▁was te ▁ .
▁fatal ▁cardiac ▁arrest ▁ , ▁life - th rea te ning ▁vent ri cular ▁ar rhythm ias ▁and ▁my o card ial ▁in far ction ▁may ▁result ▁from ▁the ▁is cha emia ▁induc ed ▁by ▁ pharma c ologic ▁stress ▁agents ▁ .
▁no ▁dose ▁adjust ments ▁are ▁needed ▁in ▁patients ▁with ▁mild ▁or ▁moderat e ▁im pair ment ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁sama rium ▁( ▁153 s m ▁) ▁le xi dron am ▁pe ntas o dium ▁: ▁1.3 ▁ gb q ▁/ ▁ml ▁at ▁reference ▁date ▁ . ▁( ▁correspond ing ▁to ▁20 ▁to ▁80 ▁μ g ▁/ ▁ml ▁of ▁sama rium ▁)
▁in ▁patients ▁with ▁seconda ry ▁hyper para thy roid ism ▁ren vela ▁should ▁be ▁used ▁within ▁the ▁context ▁of ▁a ▁multiple ▁ therapeut ic ▁approach ▁ , ▁which ▁could ▁include ▁calci um ▁as ▁supplement s ▁ , ▁1 , 25 ▁- ▁di hydro xy ▁vitamin ▁d 3 ▁or ▁one ▁of ▁its ▁analog ues ▁to ▁lower ▁the ▁intact ▁para thy roid ▁hormone ▁( ▁i p th ▁) ▁levels ▁ .
▁change ▁from ▁base line ▁in ▁s gr q ▁total ▁score ▁at ▁week ▁52
▁when ▁first ▁starting ▁treatment ▁with ▁re bi f ▁ , ▁the ▁dose ▁should ▁be ▁gradual ly ▁escala ted ▁in ▁order ▁to ▁allow ▁ta chy phy la xis ▁to ▁develop ▁thu s ▁ reducing ▁advers e ▁reaction s ▁ .
▁powder ▁in ▁a ▁vi al ▁( ▁glass ▁) ▁with ▁a ▁stopper ▁( ▁but yl ▁rub ber ▁) ▁and ▁solve nt ▁in ▁a ▁pre - fill ed ▁sy ringe ▁( ▁glass ▁) ▁with ▁attached ▁need le ▁with ▁plu nger ▁stopper ▁( ▁chlor o but yl ▁rub ber ▁) ▁and ▁need le - shield ▁( ▁natural ▁rub ber ▁) ▁in ▁a ▁pack ▁size ▁of ▁1 ▁and ▁10 ▁ .
▁cy p 2 c 19 ▁and ▁ab c b 1 ▁geno typ ing ▁of ▁10 , 285 ▁patients ▁in ▁plato ▁provided ▁associations ▁of ▁geno type ▁groups ▁with ▁plato ▁outcome s ▁ .
▁not ▁all ▁pack ▁size s ▁may ▁be ▁market ed ▁ .
▁as ▁long ▁as ▁the ▁capsule ▁is ▁empty ▁ , ▁you ▁have ▁received ▁enough ▁of ▁your ▁medicine ▁ .
▁zo lv ix ▁is ▁used ▁for ▁the ▁treatment ▁and ▁control ▁of ▁worm ▁infection s ▁of ▁the ▁gut ▁and ▁associated ▁disease s ▁in ▁she ep ▁ .
▁there ▁are ▁no ▁data ▁in ▁children ▁or ▁adolescents ▁with ▁a ▁history ▁of ▁cardiac ▁disease ▁ .
▁a ▁total ▁of ▁5 5.1 ▁% ▁of ▁patients ▁receiving ▁bi vali rudi n ▁experienced ▁at ▁least ▁one ▁advers e ▁event ▁and ▁ 8.7 ▁% ▁experienced ▁an ▁advers e ▁drug ▁reaction ▁ .
▁for ▁children ▁from ▁2 ▁years ▁through ▁5 ▁years ▁of ▁age ▁ , ▁a ▁single ▁dose ▁immun isation ▁schedule ▁was ▁used ▁ .
▁patients ▁who ▁experience ▁grade ▁3 ▁or ▁4 ▁sto mati tis ▁should ▁have ▁their ▁dose ▁decrease d ▁to ▁60 ▁mg ▁/ ▁m ▁2 ▁ .
▁patients ▁adding ▁in ove lon ▁also ▁had ▁a ▁4 2.5 ▁% ▁re duction ▁in ▁the ▁number ▁of ▁' ▁to nic - ato nic ▁' ▁se iz ures ▁( ▁a ▁common ▁type ▁of ▁fit ▁in ▁patients ▁with ▁len no x - ga sta ut ▁syndrome ▁that ▁often ▁involve s ▁the ▁patient ▁drop ping ▁to ▁the ▁floor ▁) ▁ , ▁compared ▁with ▁a ▁1.9 ▁% ▁increase ▁in ▁those ▁adding ▁place bo ▁ .
▁in ▁the ▁larger ▁study ▁a ▁re duction ▁of ▁21 ▁% ▁( ▁90 ▁% ▁ci ▁14 ▁% ▁ -27 ▁% ▁) ▁in ▁au c ▁of ▁sva ▁was ▁observe d ▁after ▁repeat ed ▁co - administration ▁of ▁sim vasta tin ▁40 ▁mg ▁and ▁feno fi bra te ▁145 ▁mg ▁in ▁the ▁evening ▁ .
▁for ▁the ▁full ▁list ▁of ▁all ▁side ▁effects ▁reported ▁with ▁son ata ▁ , ▁see ▁the ▁package ▁le a flet ▁ .
▁it ▁is ▁recommended ▁that ▁patients ▁who ▁have ▁pre - exist ing ▁cardiac ▁ab normal ities ▁have ▁electro card i ogram s ▁taken ▁prior ▁to ▁and ▁during ▁the ▁course ▁of ▁treatment ▁ .
▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁notice ▁any ▁of ▁the ▁following ▁side ▁effects ▁:
▁if ▁patients ▁must ▁temporar ily ▁stop ▁anti plate let ▁ therapy ▁ , ▁clo pido gre l ▁/ ▁a ce tyl sali cy lic ▁acid ▁zen tiva ▁should ▁be ▁dis continu ed ▁7 ▁days ▁prior ▁to ▁surgery ▁ .
▁the ▁educational ▁material ▁and ▁pre scribe r ▁check list ▁shall ▁contain ▁the ▁following ▁key ▁messages ▁:
▁with ▁one ▁hand ▁ , ▁pin ch ▁a ▁ fold ▁of ▁loo se ▁skin ▁ .
▁medicine s ▁that ▁may ▁induc e ▁" ▁ tors ades ▁de ▁point es ▁" ▁( ▁irregular ▁heart ▁beat ▁) ▁ , ▁such ▁as ▁anti ar rhythm ics ▁( ▁medicine s ▁used ▁to ▁treat ▁heart ▁problems ▁) ▁and ▁some ▁anti psy cho tics ▁;
▁in ▁a ▁poole d ▁data ▁set ▁of ▁clinic al ▁trial s ▁ , ▁the ▁overall ▁incide nce ▁of ▁opportun istic ▁infection s ▁was ▁0.0 9 ▁% ▁for ▁the ▁15 , 40 2 ▁subject s ▁who ▁received ▁eta ner cept ▁ .
▁this ▁presentation ▁should ▁be ▁pre scribe d ▁for ▁children ▁a ged ▁4 ▁years ▁and ▁older ▁ , ▁adolescents ▁and ▁adults ▁ .
▁if ▁you ▁have ▁missed ▁a ▁dose ▁of ▁insulin ▁human ▁win thro p ▁bas al ▁or ▁if ▁you ▁have ▁not ▁inject ed ▁enough ▁insulin ▁ , ▁your ▁blood ▁sugar ▁level ▁may ▁become ▁too ▁high ▁( ▁hyper gly ca emia ▁) ▁ .
▁no ▁clinic ally ▁significant ▁difference s ▁were ▁observe d ▁for ▁q t ▁ , ▁pr ▁ , ▁q rs ▁ , ▁or ▁q t c b ▁measure ments ▁between ▁du lo xe tine - tre ated ▁and ▁place bo - tre ated ▁patients ▁ .
▁in ▁clinic al ▁studies ▁iar s ▁were ▁usually ▁manage able ▁by ▁slow ing ▁the ▁rate ▁of ▁in fusion ▁and ▁by ▁( ▁pre - ▁) ▁treat ing ▁the ▁patient ▁with ▁anti hi stamine s ▁and ▁/ ▁or ▁anti py re tics ▁( ▁para ce ta mol ▁or ▁ibu profe n ▁) ▁ , ▁thu s ▁en a bling ▁the ▁patient ▁to ▁continue ▁treatment ▁ .
▁the ▁main ▁measure ▁of ▁effective ness ▁was ▁the ▁proportion ▁of ▁patients ▁who ▁were ▁cu red ▁63 ▁days ▁after ▁treatment ▁ .
▁when ▁expose d ▁to ▁the ▁virus ▁later ▁in ▁life ▁ , ▁the ▁cat ▁will ▁either ▁not ▁become ▁infect ed ▁or ▁have ▁a ▁much ▁less ▁serious ▁infection ▁ .
▁the ▁mean ▁volume ▁of ▁distribution ▁of ▁vil dag lip tin ▁at ▁stea dy - state ▁after ▁intra ven ous ▁administration ▁( ▁vs s ▁) ▁is ▁71 ▁litre s ▁ , ▁suggest ing ▁extra vas cular ▁distribution ▁ .
▁stomach ▁pain ▁ , ▁indi gestion ▁ , ▁heart burn
▁in ▁a ▁2- year ▁car cino geni city ▁study ▁in ▁rat s ▁ , ▁a ▁clear ▁increase ▁in ▁mostly ▁benign ▁thy mic ▁tu mo urs ▁was ▁record ed ▁at ▁all ▁os pem ife ne ▁dose ▁levels ▁ .
▁oly sio ▁is ▁not ▁recommended ▁in ▁patients ▁with ▁moderat e ▁or ▁severe ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁class ▁b ▁or ▁c ▁) ▁( ▁see ▁section s ▁4.2 ▁ , ▁4. 8 ▁and ▁5.2 ▁) ▁ .
▁insu man ▁com b ▁30 ▁is ▁suppli ed ▁in ▁pre - fill ed ▁pens ▁ , ▁solo star ▁ , ▁contain ing ▁3 ▁ml ▁suspens ion ▁ , ▁( ▁300 ▁iu ▁) ▁ .
▁novo norm ▁tablets ▁are ▁round ▁and ▁con ve x ▁and ▁en grave d ▁with ▁the ▁novo ▁nordisk ▁logo ▁( ▁a pis ▁bull ▁) ▁ .
▁race ▁had ▁no ▁effect ▁on ▁the ▁ pharma cok ine tics ▁of ▁af atin ib ▁based ▁on ▁a ▁population ▁ pharma cok ine tic ▁analysis ▁ , ▁including ▁patients ▁of ▁asian ▁ , ▁white ▁ , ▁and ▁black ▁ra cial ▁groups ▁ .
▁this ▁inter im ▁analysis ▁showed ▁a ▁ tt p ▁risk ▁re duction ▁of ▁45 ▁% ▁( ▁95 ▁% ▁ci ▁; ▁29- 57 ▁% ▁ , ▁p ▁< ▁0.0 001 ▁) ▁for ▁patients ▁treated ▁with ▁combination ▁ therapy ▁of ▁bort ez om ib ▁and ▁pe gy la ted ▁lipo som al ▁do xor ubi cin ▁ .
▁mate ver ▁250 ▁mg ▁film - co ated ▁tablets ▁mate ver ▁500 ▁mg ▁film - co ated ▁tablets ▁mate ver ▁750 ▁mg ▁film - co ated ▁tablets ▁mate ver ▁1000 ▁mg ▁film - co ated ▁tablets
▁a ▁decision ▁must ▁be ▁made ▁whether ▁to ▁dis continu e ▁breast - feed ing ▁or ▁to ▁dis continu e ▁/ ▁abs tain ▁from ▁des lor ata dine ▁ratio ph arm ▁5 ▁mg ▁film - co ated ▁tablets ▁ therapy ▁taking ▁into ▁account ▁the ▁benefit ▁of ▁breast ▁feed ing ▁for ▁the ▁child ▁and ▁the ▁benefit ▁of ▁ therapy ▁for ▁the ▁woman ▁ .
▁how ▁to ▁take ▁to bi ▁pod hal er
▁activity ▁measure ments ▁using ▁an ▁ion isation ▁cha mber ▁are ▁very ▁sensitive ▁to ▁geometri c ▁factors ▁and ▁ , ▁therefore ▁ , ▁should ▁be ▁perform ed ▁only ▁under ▁geometri c ▁conditions ▁which ▁have ▁been ▁appropriate ly ▁valida ted ▁ .
▁each ▁vi al ▁contain s ▁6. 25 ▁mg ▁of ▁pali ferm in
▁insu man ▁bas al ▁100 ▁iu ▁/ ▁ml ▁suspens ion ▁for ▁inject ion ▁in ▁a ▁cart ridge ▁insulin ▁human
▁interaction s ▁between ▁oral ▁contra cep tives ▁and ▁enzym e - indu cing ▁medicinal ▁products ▁may ▁lead ▁to ▁break through ▁ble ed ing ▁and ▁even ▁contra cep tive ▁failure ▁ .
▁because ▁of ▁the ▁small ▁sample ▁size ▁ , ▁no ▁definitiv e ▁conclusion s ▁can ▁be ▁draw n ▁from ▁these ▁data ▁ .
▁gi ot rif ▁as ▁mono therapy ▁is ▁indicate d ▁for ▁the ▁treatment ▁of
▁take ▁special ▁care ▁with ▁epi vir
▁there ▁was ▁a ▁statistic ally ▁significant ▁difference ▁for ▁the ▁25 ▁mg ▁dose ▁versus ▁place bo ▁for ▁the ▁li r ▁sub group ▁responder ▁rate ▁in ▁kodi ac ▁4 ▁( ▁p ▁= ▁0.0 02 ▁) ▁and ▁kodi ac ▁5 ▁( ▁p ▁= ▁0.0 14 ▁) ▁ .
▁a ▁second ▁course ▁of ▁treatment ▁may ▁be ▁given ▁at ▁the ▁discret ion ▁of ▁the ▁treat ing ▁physician ▁in ▁patients ▁where ▁additional ▁tum our ▁nec rosi s ▁and ▁remo val ▁is ▁de em ed ▁appropriate ▁ , ▁with ▁a ▁recommended ▁minimum ▁interval ▁of ▁4 ▁weeks ▁between ▁treatment s ▁ .
▁care ful ▁selection ▁of ▁blood ▁and ▁plasma ▁donor s ▁to ▁make ▁sure ▁those ▁at ▁risk ▁of ▁carry ing ▁infection s ▁are ▁exclu ded ▁ ,
▁this ▁could ▁lead ▁to ▁a ▁condition ▁where ▁the ▁tu mo urs ▁break ▁down ▁and ▁cause ▁unusual ▁levels ▁of ▁chemical s ▁in ▁the ▁blood ▁which ▁can ▁lead ▁to ▁ki dne y ▁failure ▁ .
▁gyn a ec ological ▁ha e mor r hage ▁menstrua l ▁disorder
▁pin ch ▁your ▁inject ion ▁site ▁to ▁create ▁a ▁firm ▁surface ▁ .
▁what ▁mix tar d ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁at ▁stea dy - state ▁au c ▁is ▁approximately ▁1.5 ▁ fold ▁increased ▁compared ▁to ▁the ▁single ▁dose ▁ .
▁emp licit i ▁should ▁be ▁initiat ed ▁at ▁an ▁in fusion ▁rate ▁of ▁0.5 ▁ml ▁/ ▁min ▁ .
▁the ▁recommended ▁dose ▁of ▁ava stin ▁when ▁used ▁in ▁addition ▁to ▁er lo tin ib ▁is ▁15 ▁mg ▁/ ▁kg ▁of ▁body ▁weight ▁given ▁once ▁every ▁3 ▁weeks ▁as ▁an ▁intra ven ous ▁in fusion ▁ .
▁the ▁primary ▁mode ▁of ▁action ▁of ▁the ▁fluor o quin olon es ▁involve s ▁interaction ▁with ▁enzym es ▁essential ▁for ▁major ▁d na ▁function s ▁such ▁as ▁re plication ▁ , ▁tran scription ▁and ▁reco mbin ation ▁ .
▁a ▁risk ▁management ▁plan ▁has ▁been ▁developed ▁to ▁ensure ▁that ▁ra xon e ▁is ▁used ▁as ▁safe ly ▁as ▁possible ▁ .
▁manufacture rs ▁of ▁the ▁bi ological ▁active ▁substance s ▁and ▁manufacture r ▁responsible ▁for ▁bat ch ▁release
▁the ▁more ▁' ▁white ▁active ▁tablets ▁' ▁are ▁missed ▁and ▁the ▁close r ▁the ▁missed ▁tablets ▁are ▁to ▁the ▁4 ▁yellow ▁place bo ▁tablets ▁ , ▁the ▁higher ▁the ▁risk ▁of ▁a ▁pre gna ncy ▁ .
▁she lf - life ▁after ▁first ▁opening ▁the ▁immediate ▁packaging ▁: ▁28 ▁days ▁ .
▁however ▁ , ▁should ▁this ▁happen ▁it ▁will ▁disappear ▁within ▁24 ▁hours ▁ .
▁kar vez ide ▁300 ▁mg ▁/ ▁25 ▁mg ▁may ▁be ▁ad minister ed ▁in ▁patients ▁in sufficient ly ▁control led ▁by ▁kar vez ide ▁300 ▁mg ▁/ ▁12. 5 ▁mg ▁ .
▁psychiatr ic ▁and ▁central ▁ner vous ▁system ▁:
▁animal ▁studies ▁have ▁shown ▁rever sible ▁effects ▁on ▁the ▁menstrua l ▁cycle ▁and ▁reduce d ▁female ▁fertil ity ▁in ▁mon key s ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁medicinal ▁products ▁with ▁dose ▁concentration ▁incompatibil ities ▁to ▁bi vali rudi n ▁ .
▁patients ▁should ▁be ▁advise d ▁to ▁not ify ▁their ▁pre scribi ng ▁physician ▁if ▁they ▁experience ▁these ▁symptoms ▁ .
▁how ▁does ▁doce ta xel ▁teva ▁work ▁?
▁breast ▁development ▁ , ▁ac ne ▁or ▁weight ▁gain ▁ .
▁the ▁incide nce ▁of ▁ad rs ▁reported ▁in ▁clinic al ▁trial s ▁is ▁tabula ted ▁by ▁fre que ncy ▁category ▁ .
▁how ▁to ▁store ▁lumi gan ▁0.3 ▁mg ▁/ ▁ml ▁single - dos e
▁ phen y to in ▁levels ▁should ▁be ▁monitor ed ▁when ▁co - ad minister ing ▁with ▁lo pina vir ▁/ ▁rito na vir ▁ .
▁th rush ▁( ▁vaginal ▁ye ast ▁infection ▁)
▁the ▁content s ▁of ▁a ▁vi al ▁should ▁be ▁used ▁immediately ▁after ▁piercing ▁the ▁rub ber ▁stopper ▁ .
▁drug ▁interaction s ▁: ▁epi vir ▁should ▁not ▁be ▁taken ▁with ▁any ▁other ▁medicinal ▁products ▁contain ing ▁la mi vu dine ▁or ▁medicinal ▁products ▁contain ing ▁em trici ta bine ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁jak avi ▁10 ▁mg ▁tablets
▁limited ▁experience ▁from ▁150 ▁pre gna ncy ▁outcome s ▁( ▁primari ly ▁based ▁on ▁spontane ous ▁report ing ▁and ▁literature ▁review ▁) ▁is ▁available ▁suggest ing ▁that ▁use ▁of ▁cere zy me ▁is ▁beneficia l ▁to ▁control ▁the ▁under ly ing ▁gauche r ▁disease ▁in ▁pre gna ncy ▁ .
▁your ▁doctor ▁will ▁decide ▁whether ▁treatment ▁has ▁to ▁be ▁stopped ▁ .
▁the ▁other ▁side ▁of ▁the ▁tablet ▁de bos sed ▁with ▁the ▁number ▁" ▁72 38 ▁ . ▁"
▁the ▁study ▁also ▁looked ▁at ▁the ▁number ▁of ▁patients ▁whose ▁infection ▁was ▁cu red ▁after ▁treatment ▁ .
▁what ▁is ▁the ▁risk ▁associated ▁with ▁sono vu e ▁?
▁any ▁un used ▁product ▁or ▁was te ▁material ▁should ▁be ▁dispose d ▁of ▁in ▁accordance ▁with ▁local ▁requirements ▁ .
▁the ▁usual ▁starting ▁dose ▁of ▁du lo xe tine ▁li lly ▁is ▁30 ▁mg ▁once ▁a ▁day ▁after ▁which ▁most ▁patients ▁will ▁receive ▁60 ▁mg ▁once ▁a ▁day ▁ , ▁but ▁your ▁doctor ▁will ▁pre scribe ▁the ▁dose ▁that ▁is ▁right ▁for ▁you ▁ .
▁pri tor plus ▁80 ▁mg ▁/ ▁25 ▁mg
▁in ▁laborator y ▁species ▁ , ▁after ▁intra - peri tone al ▁administration ▁ , ▁di note fur an ▁is ▁rapid ly ▁elimina ted ▁as ▁the ▁un change d ▁parent ▁mole cule ▁main ly ▁via ▁the ▁urin e ▁ .
▁multiple ▁sul fo transfer ase ▁( ▁sul t ▁) ▁enzym es ▁( ▁sul t 1 a 1 ▁ , ▁sul t 1 a 2 ▁ , ▁and ▁sul t 2 a 1 ▁) ▁are ▁involved ▁in ▁the ▁bio transform ation ▁of ▁ ted izol id ▁ , ▁to ▁form ▁an ▁in active ▁and ▁non - circ ul ating ▁sul pha te ▁conjuga te ▁found ▁in ▁the ▁ex cre ta ▁ .
▁7 28 ▁patients ▁received ▁ca tu max om ab ▁intra peri tone ally ▁ , ▁29 3 ▁patients ▁as ▁6 ▁hour ▁- ▁and ▁ 435 ▁patients ▁as ▁3 ▁hour ▁in fusion s ▁ .
▁within ▁each ▁fre que ncy ▁group ing ▁ , ▁advers e ▁reaction s ▁are ▁presente d ▁in ▁order ▁of ▁de cre as ing ▁serious ness ▁ .
▁feeling ▁sick ▁( ▁na use a ▁) ▁or ▁vom i ting ▁ , ▁loss ▁of ▁appetit e
▁the ▁other ▁ingredients ▁are ▁suc rose ▁ , ▁poly sor bate ▁80 ▁ , ▁mono ba sic ▁so dium ▁ phos pha te ▁and ▁di ba sic ▁so dium ▁ phos pha te ▁ .
▁cinq a ero ▁is ▁an ▁as th ma ▁medicine ▁that ▁is ▁used ▁to ▁treat ▁adults ▁with ▁a ▁particular ▁type ▁of ▁as th ma ▁called ▁eos ino phil ic ▁as th ma ▁ .
▁the ▁primary ▁end point ▁was ▁the ▁proportion ▁of ▁patients ▁who ▁were ▁ali ve ▁and ▁free ▁of ▁invasi ve ▁ventilator ▁support ▁ .
▁se rum ▁album in ▁was ▁found ▁to ▁significantly ▁affect ▁tri flu ri dine ▁clear ance ▁ , ▁with ▁a ▁negative ▁corre lation ▁ .
▁suicide ▁attempt ▁ , ▁de li rium ▁ , ▁mental ▁im pair ment
▁35 28 ▁bj ▁ut recht ▁the ▁ne ther lands
▁in ▁the ▁phase ▁i ii ▁impact - rs v ▁study ▁in ▁the ▁prematur e ▁and ▁bron chop ul mon ary ▁dys plas ia ▁pa e dia tric ▁population s ▁ , ▁the ▁proportion s ▁of ▁patients ▁in ▁the ▁place bo ▁and ▁pali viz um ab ▁groups ▁who ▁received ▁routine ▁child hood ▁vaccin es ▁ , ▁influenza ▁vaccin e ▁ , ▁bron chod ila tors ▁or ▁corti co steroid s ▁were ▁similar ▁and ▁no ▁incrementa l ▁increase ▁in ▁advers e ▁reaction s ▁was ▁observe d ▁among ▁patients ▁receiving ▁these ▁agents ▁ .
▁depression ▁ , ▁hostil ity ▁/ ▁aggressi on ▁ , ▁anxiety ▁ , ▁ insomni a ▁ , ▁ner vous ness ▁/ ▁irrita bility
▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁take ▁any ▁of ▁these ▁ .
▁other ▁information ▁about ▁xal up rine
▁co administration ▁with ▁a ▁high - fat ▁and ▁high - ca lor ie ▁meal ▁slow s ▁the ▁rate ▁of ▁ab sor p tion ▁ , ▁de cre as ing ▁mean ▁plasma ▁c max ▁by ▁approximately ▁27 ▁% ▁ , ▁but ▁has ▁minimal ▁effect ▁on ▁the ▁overall ▁extent ▁of ▁ab sor p tion ▁with ▁an ▁8 ▁% ▁decrease ▁in ▁mean ▁au c ▁ .
▁treatment ▁of ▁over dos e ▁with ▁har vo ni ▁consist s ▁of ▁general ▁support ive ▁measure s ▁including ▁monitoring ▁of ▁vital ▁sign s ▁as ▁well ▁as ▁observation ▁of ▁the ▁clinic al ▁status ▁of ▁the ▁patient ▁ .
▁you ▁can ▁see ▁how ▁much ▁ huma log ▁is ▁left ▁by ▁looking ▁at ▁the ▁gau ge ▁on ▁the ▁side ▁of ▁the ▁cart ridge ▁ .
▁bas al ▁cell ▁car cino ma ▁and ▁s quam ous ▁cell
▁the ▁sy ringe ▁inside ▁the ▁pen ▁is ▁made ▁from ▁clear ▁type ▁1 ▁glass ▁with ▁a ▁sta in less ▁steel ▁27 ▁gau ge ▁need le ▁ , ▁rub ber ▁need le ▁cover ▁ , ▁and ▁plastic ▁plu nger ▁ .
▁the ▁can ine ▁para in flu enza ▁virus ▁in ▁versi can ▁plus ▁pi ▁/ ▁l 4 r ▁is ▁ali ve ▁but ▁has ▁been ▁att en u ated ▁( ▁we ak en ed ▁) ▁so ▁that ▁it ▁does ▁not ▁cause ▁disease ▁; ▁it ▁is ▁combine d ▁with ▁killed ▁( ▁in activa ted ▁) ▁strain s ▁of ▁le pto spira ▁bacteria ▁and ▁rabi es ▁virus ▁ .
▁m n ▁results ▁yi eld ed ▁a ▁g mr ▁against ▁a ▁/ ▁tur key ▁/ ▁tur key ▁/ ▁05 ▁rang ing ▁from ▁1. 59 ▁to ▁2. 95 ▁ .
▁clinic al ▁ pharma c ology ▁studies ▁demonstrat e ▁that ▁the ▁matri x ▁alone ▁is ▁not ▁osteo in duc tive ▁and ▁is ▁no ▁longer ▁present ▁in ▁bio psi es ▁taken ▁as ▁early ▁as ▁16 ▁weeks ▁post - im plant ation ▁ .
▁the ▁white ▁to ▁off - white ▁cake ▁will ▁dis solve ▁completely ▁ .
▁iba ndro nic ▁acid ▁ therapy ▁should ▁only ▁be ▁initiat ed ▁by ▁physician s ▁experienced ▁in ▁the ▁treatment ▁of ▁cancer ▁ .
▁place bo ▁n ▁= ▁106
▁example s ▁are ▁: ▁chocolate ▁or ▁che rry ▁sy rup ▁ , ▁and ▁dessert ▁topp ings ▁such ▁as ▁caramel ▁or ▁fud ge ▁sauce ▁ .
▁no ▁patient ▁had ▁a ▁q t cf ▁> ▁480 ▁m sec ▁ .
▁the ▁other ▁ingredients ▁are ▁: ▁so dium ▁chlor ide ▁ , ▁po tas s ium ▁chlor ide ▁ , ▁magnesium ▁chlor ide ▁he xa hydrat e ▁ , ▁di so dium ▁ phos pha te ▁di hydrat e ▁ , ▁po tas s ium ▁di hydro gen ▁ phos pha te ▁and ▁water ▁for ▁inject ions ▁ .
▁the ▁active ▁substance s ▁are ▁per ▁dose ▁( ▁0.5 ▁ml ▁) ▁1 ▁:
▁there ▁are ▁no ▁specific ▁studies ▁which ▁address ▁local ▁ tolerance ▁in ▁animals ▁after ▁sub cuta ne ous ▁inject ion ▁ , ▁but ▁data ▁available ▁from ▁the ▁repeat ed - dos e ▁ toxic ity ▁studies ▁reveal ed ▁swe lling ▁and ▁infla mma tory ▁infiltra te ▁at ▁the ▁inject ion ▁sites ▁ .
▁severe ▁and ▁persist ent ▁pain ▁in ▁the ▁ab dom en ▁( ▁stomach ▁area ▁) ▁which ▁might ▁reach ▁through ▁to ▁your ▁back ▁ , ▁as ▁well ▁as ▁na use a ▁and ▁vom i ting ▁ , ▁as ▁it ▁could ▁be ▁a ▁sign ▁of ▁an ▁infla med ▁pan cre as ▁( ▁pan creati tis ▁) ▁ .
▁fa bra zy me ▁is ▁indicate d ▁in ▁adults ▁ , ▁children ▁and ▁adolescents ▁a ged ▁8 ▁years ▁and ▁older ▁ .
▁cases ▁of ▁ inflammation ▁of ▁the ▁pan cre as ▁( ▁pan creati tis ▁) ▁have ▁been ▁reported ▁in ▁patients ▁receiving ▁xe le via ▁( ▁see ▁section ▁4 ▁) ▁ .
▁ct c ▁non - ha e mat ological ▁ toxic ity ▁( ▁except ▁for ▁a lo pecia ▁ , ▁na use a ▁ , ▁vom i ting ▁)
▁if ▁you ▁forget ▁to ▁use ▁venta vis
▁elimina tion ▁from ▁blood ▁is ▁large ly ▁complete ▁within ▁24 ▁hours ▁ .
▁changes ▁in ▁the ▁electric al ▁activity ▁or ▁ab normal ▁ rhythm ▁of ▁the ▁heart ▁ .
▁as ▁as th ma ▁reli ever ▁ therapy ▁ , ▁patients ▁can ▁take ▁1 ▁or ▁2 ▁additional ▁in hal ations ▁of ▁bir es p ▁spir o max ▁160 ▁/ ▁4.5 ▁micro gram ▁only ▁to ▁reli eve ▁their ▁symptoms ▁ .
▁her cept in ▁is ▁a ▁solution ▁for ▁inject ion ▁that ▁is ▁suppli ed ▁in ▁a ▁glass ▁vi al ▁with ▁a ▁but yl ▁rub ber ▁stopper ▁contain ing ▁5 ▁ml ▁( ▁600 ▁mg ▁) ▁of ▁tras tuz um ab ▁ .
▁vas cular ▁disorder s ▁common ▁hyper tension ▁ , ▁flu shing ▁ , ▁blood ▁pressure ▁increased
▁alternative ly ▁ , ▁ab se a med ▁can ▁be ▁ad minister ed ▁at ▁an ▁initial ▁dose ▁of ▁450 ▁iu ▁/ ▁kg ▁sub cuta ne ously ▁once ▁week ly ▁ .
▁if ▁clinic ally ▁indicate d ▁ , ▁medicinal ▁products ▁that ▁alter ▁ha emos tas is ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁combination ▁with ▁possi a ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁experience ▁with ▁ex ta via ▁in ▁patients ▁with ▁multiple ▁sc ler osis ▁( ▁ms ▁) ▁is ▁limited ▁ , ▁consequent ly ▁those ▁advers e ▁events ▁which ▁occur ▁very ▁rare ly ▁may ▁not ▁yet ▁have ▁been ▁observe d ▁ .
▁doce ta xel ▁kabi ▁80 ▁mg ▁/ ▁4 ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁doce ta xel
▁treatment ▁should ▁not ▁be ▁initiat ed ▁in ▁patients ▁with ▁an ▁active ▁or ▁chronic ▁infection ▁( ▁see ▁section ▁4.3 ▁) ▁and ▁physician s ▁should ▁exercise ▁cau tion ▁when ▁ad minister ing ▁ri lona cept ▁regener on ▁to ▁patients ▁with ▁a ▁history ▁of ▁re curr ing ▁infection s ▁or ▁with ▁under ly ing ▁conditions ▁that ▁may ▁pred is pose ▁them ▁to ▁infection s ▁ .
▁the ▁active ▁substance ▁of ▁v pri v ▁is ▁ve lag lu cera se ▁alfa ▁ , ▁which ▁is ▁produced ▁by ▁gene ▁activa tion ▁technology ▁in ▁a ▁human ▁cell ▁line ▁ .
▁children ▁and ▁adolescents ▁a ged ▁between ▁12 ▁and ▁17 ▁years ▁and ▁we igh ing ▁at ▁least ▁40 ▁kg ▁can ▁take ▁the ▁adult ▁dose ▁of ▁one ▁tablet ▁( ▁50 ▁mg ▁) ▁ , ▁once ▁a ▁day ▁ .
▁however ▁ , ▁these ▁withdraw al ▁period s ▁in ▁ca ttle ▁are ▁only ▁valid ▁when ▁na x cel ▁has ▁been ▁inject ed ▁under ▁the ▁skin ▁in ▁non - ▁edib le ▁tissu e ▁at ▁the ▁recommended ▁location ▁( ▁the ▁base ▁of ▁the ▁ear ▁) ▁ .
▁stoc rin ▁oral ▁solution ▁( ▁30 ▁mg ▁/ ▁ml ▁) ▁dose ▁( ▁ml ▁)
▁check ▁the ▁liquid ▁in ▁the ▁pre - fill ed ▁sy ringe
▁the ▁report ing ▁rate ▁is ▁class ified ▁as ▁very ▁common ▁( ▁ ≥ ▁1 ▁/ ▁10 ▁) ▁ , ▁common ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁un com mon ▁( ▁ ≥ ▁1 ▁/ ▁1,000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁ , ▁rare ▁( ▁ ≥ ▁1 ▁/ ▁10,000 ▁to
▁one ▁vi al ▁of ▁solution ▁for ▁inject ion ▁or ▁in fusion ▁contain s ▁5 ▁million ▁iu ▁of ▁reco mbin ant ▁inter fer on ▁alfa -2 b ▁produced ▁in ▁e . ▁ coli ▁by ▁reco mbin ant ▁d na ▁technology ▁ , ▁in ▁0.5 ▁ml ▁of ▁solution ▁ .
▁in ▁ toxic ology ▁studies ▁ , ▁plasma ▁volume ▁exp an sion ▁with ▁ha e modi lu tion ▁ , ▁ana emia ▁ , ▁and ▁rever sible ▁ecce n tric ▁cardiac ▁hyper trop hy ▁was ▁consistent ly ▁apparent ▁after ▁repeat ed ▁dos ing ▁of ▁mi ce ▁ , ▁rat s ▁ , ▁dog s ▁ , ▁and ▁mon key s ▁ .
▁excess ▁volume ▁to ▁be ▁exp elle d ▁ .
▁by ▁comparison ▁ , ▁vor apa xar ▁exposure ▁( ▁au c ▁and ▁c max ▁) ▁is ▁estima ted ▁to ▁be ▁19 -21 ▁% ▁lower ▁in ▁patients ▁with ▁a ▁body ▁weight ▁of ▁> ▁100 ▁kg ▁compared ▁to ▁those ▁we igh ing ▁60 -100 ▁kg ▁ .
▁ni tric ▁oxid e ▁may ▁react ▁with ▁oxygen ▁form ing ▁nit rogen ▁ dioxid e ▁that ▁may ▁cause ▁air way ▁irrita tion ▁ .
▁1 ▁day ▁from ▁the ▁activity ▁reference ▁time ▁state d ▁on ▁the ▁label ▁ .
▁you ▁do ▁not ▁need ▁to ▁take ▁another ▁tablet ▁if ▁you ▁were ▁sick ▁more ▁than ▁1 ▁hour ▁after ▁taking ▁tru vada ▁ .
▁conditions ▁leading ▁to ▁de hydrat ion ▁such ▁as ▁e mesi s ▁ , ▁di ar r ho e a ▁or ▁sto mati tis ▁ , ▁can ▁increase ▁the ▁ toxic ity ▁of ▁met ho tre xa te ▁due ▁to ▁eleva ted ▁levels ▁of ▁the ▁active ▁substance ▁ .
▁other ▁information ▁about ▁ne x gard ▁:
▁dis continu ation ▁of ▁vir af eron ▁ therapy ▁has ▁not ▁rever sed ▁thy roid ▁dys function ▁occur ring ▁during ▁treatment ▁( ▁also ▁see ▁children ▁and ▁adolescents ▁ , ▁thy roid ▁monitoring ▁) ▁ .
▁y mp tom s ▁that ▁suggest ▁changes ▁in ▁normal ▁brain ▁function ▁( ▁head ach es ▁ , ▁vision ▁changes ▁ , ▁confusion ▁ , ▁or ▁se iz ures ▁) ▁ , ▁and ▁high ▁blood ▁pressure ▁ ,
▁please ▁consult ▁your ▁doctor ▁if ▁you ▁or ▁your ▁family ▁tend ▁to ▁suffer ▁from ▁ble ed ing ▁problems ▁or ▁you ▁are ▁taking ▁medicine s ▁to ▁thi n ▁the ▁blood ▁for ▁any ▁reason ▁ .
▁do ▁not ▁increase ▁the ▁total ▁dose ▁of ▁el oc ta ▁to ▁control ▁your ▁ble ed ▁without ▁talking ▁to ▁your ▁doctor ▁ .
▁in ▁children ▁( ▁from ▁2 ▁to ▁10 ▁years ▁of ▁age ▁) ▁ , ▁the ▁side ▁effects ▁that ▁were ▁reported ▁during ▁clinic al ▁trial s ▁are ▁listed ▁below ▁ .
▁dose ▁adjust ments ▁at ▁the ▁start ▁of ▁a ▁subsequent ▁cycle ▁should ▁be ▁based ▁on ▁na dir ▁ha e mat ologic ▁count s ▁or ▁maximum ▁non - ha e mat ologic ▁ toxic ity ▁from ▁the ▁preced ing ▁cycle ▁of ▁ therapy ▁ .
▁the ▁use ▁of ▁ avana fil ▁with ▁kale tra
▁always ▁keep ▁with ▁you ▁the ▁lys od ren ▁patient ▁card ▁included ▁at ▁the ▁end ▁of ▁this ▁le a flet ▁ .
▁medicinal ▁product ▁by ▁ therapeut ic ▁areas ▁( ▁dose ▁)
▁a ▁herbal ▁medicine ▁ , ▁used ▁to ▁treat ▁depression ▁ .
▁no ▁pattern ▁was ▁identified ▁in ▁the ▁causes ▁of ▁death ▁ .
▁the ▁first ▁inject ion ▁is ▁given ▁from ▁one ▁month ▁of ▁age ▁in ▁animals ▁that ▁have ▁never ▁been ▁expose d ▁to ▁the ▁disease ▁ , ▁and ▁from ▁two - and - a - hal f ▁months ▁if ▁the ▁animal ▁' s ▁mother ▁is ▁already ▁immun e ▁to ▁the ▁disease ▁ .
▁if ▁you ▁experience ▁these ▁side ▁effects ▁ , ▁you ▁must ▁not ▁drive ▁or ▁operate ▁machine ry ▁ .
▁however ▁ , ▁should ▁it ▁be ▁necessary ▁to ▁end ▁treatment ▁ , ▁implant s ▁may ▁be ▁sur g ically ▁removed ▁by ▁a ▁veterinar ian ▁ .
▁the ▁active ▁substance s ▁in ▁von cento ▁ , ▁human ▁coa g ulation ▁factor ▁vii i ▁and ▁human ▁von ▁will e brand ▁factor ▁ , ▁are ▁coa g ulation ▁factors ▁( ▁substance s ▁that ▁help ▁the ▁blood ▁to ▁clo t ▁) ▁ .
▁serious ▁and ▁occasion ally ▁fatal ▁hyper sensitiv ity ▁( ▁ana phy la ctic ▁) ▁reaction s ▁have ▁been ▁reported ▁in ▁patients ▁receiving ▁ therapy ▁with ▁beta - lac tam s ▁ .
▁pre gabal in ▁oral ▁bio ava il ability ▁is ▁estima ted ▁to ▁be ▁ ≥ ▁90 ▁% ▁and ▁is ▁independent ▁of ▁dose ▁ .
▁take ▁special ▁care ▁with ▁vist ide
▁treatment ▁with ▁sax ag lip tin ▁5 ▁mg ▁once ▁daily ▁produced ▁clinic ally ▁relevant ▁and ▁statistic ally ▁significant ▁improvement s ▁in ▁ha emo glob in ▁a 1 c ▁( ▁h ba 1 c ▁) ▁ , ▁fast ing ▁plasma ▁gluco se ▁( ▁f p g ▁) ▁and ▁post p randi al ▁gluco se ▁( ▁pp g ▁) ▁compared ▁to ▁place bo ▁in ▁combination ▁with ▁met form in ▁( ▁initial ▁or ▁add - on ▁ therapy ▁) ▁ .
▁19. 0 ▁% ▁p ▁= ▁ 0.00 21 ▁; ▁blood ▁trans fusion s ▁: ▁6.2 ▁% ▁vs ▁ .
▁it ▁explain s ▁how ▁the ▁committee ▁for ▁medicinal ▁products ▁for ▁human ▁use ▁( ▁ch mp ▁) ▁assess ed ▁the ▁medicine ▁to ▁reach ▁its ▁opinion ▁in ▁f avour ▁of ▁gran ting ▁a ▁marketing ▁author isation ▁and ▁its ▁recommendations ▁on ▁the ▁conditions ▁of ▁use ▁for ▁in ove lon ▁ .
▁rem s ima ▁should ▁be ▁ad minister ed ▁intra ven ously ▁over ▁a ▁2 ▁hour ▁period ▁ .
▁if ▁itp ▁ons et ▁is ▁confirm ed ▁ , ▁appropriate ▁medical ▁intervention ▁should ▁be ▁prompt ly ▁initiat ed ▁ , ▁including ▁immediate ▁refer ral ▁to ▁a ▁specialist ▁ .
▁ potent ▁cy p 3 a 4 ▁induc ers ▁such ▁as ▁rif ampi cin ▁ , ▁ phen oba rbi tal ▁ , ▁carb amaz e pine ▁ , ▁ phen y to in ▁or ▁st ▁joh n ▁' s ▁ wort ▁are ▁not ▁recommended ▁ .
▁please ▁ask ▁your ▁doctor ▁how ▁this ▁may ▁affect ▁you ▁ , ▁especially ▁if ▁you ▁are ▁planning ▁on ▁having ▁children ▁in ▁the ▁future ▁ .
▁study ▁cl dt 600 a 230 3 ▁included ▁h be ag - posi tive ▁patients ▁from ▁studies ▁n v -02 b - 007 ▁( ▁glob e ▁) ▁or ▁n v -02 b -01 5 ▁for ▁off - tre at ment ▁follow ▁up ▁ .
▁replace ▁the ▁mouth piece ▁and ▁repeat ▁steps ▁7 ▁ , ▁8 ▁and ▁9 ▁ .
▁e po etin ▁alfa ▁he xal ▁contain s ▁less ▁than ▁1 ▁mm ol ▁so dium ▁( ▁23 ▁mg ▁) ▁per ▁dose ▁i . e . ▁essential ly ▁" ▁so dium ▁free ▁ . ▁"
▁severe ▁hypo gly ca e mic ▁episode s ▁ , ▁where ▁the ▁patient ▁is ▁not ▁able ▁to ▁treat ▁himself ▁ , ▁can ▁be ▁treated ▁with ▁glu ca gon ▁( ▁0.5 ▁to ▁1 ▁mg ▁) ▁given ▁intra mus cular ly ▁or ▁sub cuta ne ously ▁by ▁a ▁train ed ▁person ▁ , ▁or ▁with ▁gluco se ▁given ▁intra ven ously ▁by ▁a ▁health care ▁professional ▁ .
▁because ▁of ▁the ▁nature ▁of ▁the ▁advers e ▁events ▁seen ▁with ▁the ▁combination ▁of ▁eta ner cept ▁and ▁anak in ra ▁ therapy ▁ , ▁similar ▁ toxic ities ▁may ▁also ▁result ▁from ▁the ▁combination ▁of ▁anak in ra ▁and ▁other ▁t n f - anta gon ists ▁ .
▁in ▁particular ▁ , ▁please ▁inform ▁your ▁doctor ▁in ▁case ▁of ▁di ar r ho e a ▁ , ▁so res ▁in ▁the ▁mouth ▁ , ▁feeling ▁of ▁nu mb ness ▁or ▁pin s ▁and ▁need les ▁ , ▁fe ver ▁and ▁give ▁her ▁/ ▁him ▁results ▁of ▁your ▁blood ▁tests ▁ .
▁the ▁medicine ▁should ▁be ▁introduce d ▁into ▁the ▁tube ▁leaving ▁the ▁body ▁( ▁arterial ▁line ▁) ▁at ▁the ▁start ▁of ▁the ▁di al ysis ▁session ▁ .
▁if ▁any ▁of ▁the ▁side ▁effects ▁become ▁serious ▁ , ▁or ▁if ▁you ▁notice ▁any ▁other ▁side ▁effects ▁not ▁listed ▁in ▁this ▁le a flet ▁ , ▁please ▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁ .
▁do ▁not ▁use ▁in ▁horse s ▁suffering ▁from ▁gastro inte stin al ▁disorder s ▁such ▁as ▁irrita tion ▁and ▁ha e mor r hage ▁ , ▁im pair ed ▁he pati c ▁ , ▁cardiac ▁or ▁renal ▁function ▁and ▁ha e mor r hagi c ▁disorder s ▁ .
▁the ▁blood - to - plasma ▁ratio ▁of ▁ni lo tin ib ▁is ▁0 . 71 . ▁plasma ▁protein ▁ binding ▁is ▁approximately ▁98 ▁% ▁on ▁the ▁basis ▁of ▁in ▁vi tro ▁experiment s ▁ .
▁when ▁ad minister ed ▁1 ▁or ▁4 ▁hours ▁after ▁10 ▁m c g ▁li xis en ati de ▁ , ▁c max ▁of ▁para ce ta mol ▁was ▁decrease d ▁by ▁29 ▁% ▁and ▁31 ▁% ▁respective ly ▁and ▁media n ▁t max ▁was ▁de lay ed ▁by ▁2.0 ▁and ▁1. 75 ▁hours ▁respective ly ▁ .
▁children ▁with ▁poly arti cular ▁juvenil e ▁ idio pathi c ▁ar thri tis
▁why ▁has ▁at ri ance ▁been ▁approved ▁?
▁after ▁oral ▁( ▁and ▁intra ven ous ▁) ▁administration ▁tel mis ar tan ▁is ▁nearly ▁exclusive ly ▁ex cre ted ▁with ▁the ▁fa e ces ▁ , ▁main ly ▁as ▁un change d ▁compound ▁ .
▁this ▁vaccin e ▁has ▁been ▁pre scribe d ▁for ▁your ▁child ▁only ▁ .
▁combination ▁ therapy ▁with ▁riba vir in ▁: ▁also ▁see ▁riba vir in ▁sp c ▁if ▁inter fer on ▁alfa -2 b ▁is ▁to ▁be ▁ad minister ed ▁in ▁combination ▁with ▁riba vir in ▁in ▁patients ▁with ▁chronic ▁hepatitis ▁c ▁ .
▁iu ▁/ ▁kg ▁/ ▁h ▁) ▁adjust ing ▁according ▁to
▁patients ▁who ▁took ▁the ▁combination ▁of ▁kis ply x ▁and ▁ever ol imus ▁lived ▁for ▁an ▁average ▁of ▁14. 6 ▁months ▁without ▁their ▁disease ▁getting ▁worse ▁ , ▁compared ▁with ▁7. 4 ▁months ▁for ▁the ▁patients ▁who ▁took ▁kis ply x ▁alone ▁and ▁5.5 ▁months ▁for ▁the ▁patients ▁who ▁took ▁ever ol imus ▁alone ▁ .
▁during ▁the ▁course ▁of ▁treatment ▁ , ▁appropriate ▁determina tion ▁of ▁factor ▁ ix ▁levels ▁is ▁advise d ▁to ▁guide ▁the ▁dose ▁to ▁be ▁ad minister ed ▁and ▁the ▁fre que ncy ▁of ▁repeat ed ▁in fusion s ▁ .
▁eur arte sim ▁should ▁not ▁be ▁used ▁during ▁pre gna ncy ▁in ▁situations ▁where ▁other ▁suitable ▁and ▁effective ▁anti - ▁mala rial s ▁are ▁available ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁once ▁bro ach ed ▁use ▁immediately ▁ .
▁select ▁an ▁inject ion ▁site ▁for ▁your ▁first ▁inject ion ▁ .
▁while ▁you ▁are ▁taking ▁revol ade ▁ , ▁you ▁will ▁be ▁under ▁the ▁care ▁of ▁a ▁doctor ▁with ▁specialist ▁experience ▁in ▁treat ing ▁your ▁condition ▁ .
▁data ▁from ▁a ▁ pharma cok ine tic ▁study ▁in ▁el der ly ▁subject s ▁( ▁ ≥ ▁65 ▁years ▁of ▁age ▁ , ▁n ▁= ▁26 ▁) ▁indicate d ▁that ▁the ▁apparent ▁stea dy - state ▁clear ance ▁of ▁pali peri done ▁following ▁in vega ▁administration ▁was ▁20 ▁% ▁lower ▁compared ▁to ▁that ▁of ▁adult ▁subject s ▁( ▁18 -45 ▁years ▁of ▁age ▁ , ▁n ▁= ▁28 ▁) ▁ .
▁very ▁common ▁side ▁effects ▁( ▁may ▁affect ▁more ▁than ▁1 ▁in ▁10 ▁people ▁) ▁are ▁:
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁ , ▁the ▁bottle ▁label ▁and ▁/ ▁or ▁the ▁bli ster ▁after ▁exp ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁rev atio ▁on ▁28 ▁octo ber ▁2005 ▁ .
▁six ▁of ▁the ▁studies ▁compared ▁lyx umi a ▁with ▁place bo ▁( ▁a ▁dum my ▁treatment ▁) ▁ , ▁used ▁alone ▁or ▁when ▁added ▁to ▁met form in ▁ , ▁a ▁sul phon y lu rea ▁ , ▁bas al ▁insulin ▁ , ▁or ▁a ▁combination ▁of ▁two ▁of ▁these ▁medicine s ▁ , ▁in ▁patients ▁in ▁whom ▁previous ▁treatment ▁had ▁failed ▁ .
▁each ▁single - dos e ▁kit ▁has ▁everything ▁you ▁need ▁for ▁your ▁week ly ▁dose ▁of ▁byd ure on ▁ .
▁based ▁on ▁a ▁load ing ▁dose ▁of ▁8 ▁mg ▁tras tuz um ab ▁/ ▁kg ▁body ▁weight ▁ , ▁or ▁a ▁subsequent ▁3- week ly ▁dose ▁of ▁6 ▁mg ▁tras tuz um ab ▁/ ▁kg ▁body ▁weight ▁:
▁this ▁is ▁followed ▁by ▁a ▁continuo us ▁in fusion ▁of ▁2.0 ▁micro gram ▁/ ▁kg ▁per ▁minute ▁which ▁is ▁continued ▁for ▁up ▁to ▁72 ▁hours ▁ , ▁until ▁the ▁start ▁of ▁surgery ▁ , ▁or ▁until ▁dis charge ▁from ▁the ▁hospital ▁ , ▁which ever ▁occur s ▁first ▁ .
▁persist ent ▁cry ing ▁ lasting ▁3 ▁hours ▁or ▁more ▁within ▁48 ▁hours ▁of ▁vaccin ation
▁tel ▁ . ▁: ▁+ ▁48 ▁22 ▁6 99 ▁0 ▁6 99
▁the ▁reference ▁medicine ▁for ▁omni trop e ▁is ▁geno trop in ▁ .
▁each ▁vi al ▁contain s ▁1 ▁mg ▁to pote can ▁( ▁as ▁hydro ch lor ide ▁) ▁ .
▁antibiotic s ▁used ▁to ▁treat ▁bacteria l ▁infection s ▁contain ing ▁:
▁gastro inte stin al ▁ toxic ity ▁ , ▁including ▁na use a ▁ , ▁di ar r ho e a ▁ , ▁vom i ting ▁and ▁con s tip ation ▁are ▁very ▁common ▁with ▁bort ez om ib ▁treatment ▁ .
▁low ▁blood ▁pressure ▁ , ▁hot ▁flu sh ▁ , ▁blood ▁ves sels ▁ inflammation
▁the ▁potential ▁risk ▁for ▁humans ▁is ▁still ▁un know n ▁ .
▁other ▁information ▁about ▁no bi vac ▁l 4 ▁:
▁thu s ▁ , ▁the ▁results ▁from ▁this ▁sub set ▁are ▁in ▁line ▁with ▁the ▁overall ▁trial ▁results ▁ .
▁date ▁of ▁first ▁author isation ▁: ▁8 ▁januar y ▁2007 ▁date ▁of ▁latest ▁rene wal ▁: ▁22 ▁march ▁2012
▁speak ▁to ▁your ▁doctor ▁for ▁advice ▁ .
▁if ▁you ▁are ▁breast - feed ing ▁during ▁pro lia ▁treatment ▁ , ▁please ▁inform ▁your ▁doctor ▁ .
▁it ▁helps ▁to ▁prevent ▁your ▁bone s ▁from ▁breaking ▁( ▁fra c tures ▁) ▁ .
▁ sime pre vir ▁does ▁not ▁inhibi t ▁o ct 2 ▁in ▁vi tro ▁ .
▁if ▁you ▁have ▁these ▁sign s ▁ , ▁you ▁should ▁follow ▁standard ▁hygien e ▁practice s ▁to ▁prevent ▁viral ▁transmission ▁to ▁others ▁ .
▁advers e ▁reaction s ▁reported ▁in ▁2,7 99 ▁patients ▁treated ▁with ▁pe mbro liz um ab ▁in ▁clinic al ▁trial s ▁are ▁reported ▁in ▁table ▁2 ▁ .
▁do ▁not ▁use ▁an ▁oral ▁follow - up ▁ therapy ▁using ▁melo xi cam ▁or ▁other ▁ nsa ids ▁in ▁cat s ▁ , ▁as ▁no ▁safe ▁dos age ▁for ▁repeat ed ▁oral ▁administration ▁has ▁been ▁established ▁ .
▁other ▁information ▁about ▁ze ffi x ▁:
▁each ▁hard ▁capsule ▁contain s ▁either ▁25 ▁mg ▁ , ▁50 ▁mg ▁ , ▁75 ▁mg ▁ , ▁100 ▁mg ▁ , ▁150 ▁mg ▁ , ▁200 ▁mg ▁ , ▁225 ▁mg ▁ , ▁300 ▁mg ▁of ▁pre gabal in ▁ .
▁in hal ation ▁of ▁high ▁dos es ▁of ▁beta 2- ad r energi c ▁ago nist s ▁may ▁produce ▁increase s ▁in ▁plasma ▁gluco se ▁ .
▁the ▁main ▁measure ▁of ▁effective ness ▁was ▁the ▁proportion ▁of ▁patients ▁who ▁developed ▁protect ive ▁levels ▁of ▁anti bo dies ▁against ▁the ▁hepatitis ▁b ▁virus ▁ .
▁all ▁strength s ▁of ▁mira pe xin ▁are ▁available ▁in ▁aluminium ▁bli ster ▁strip s ▁of ▁10 ▁tablets ▁per ▁strip ▁ , ▁in ▁carton s ▁contain ing ▁1 ▁ , ▁3 ▁or ▁10 ▁bli ster ▁strip s ▁( ▁10 ▁ , ▁30 ▁or ▁100 ▁prolong ed - release ▁tablets ▁) ▁ .
▁pack ▁size s ▁of ▁14 ▁ , ▁28 ▁ , ▁56 ▁ , ▁168 ▁modifi ed - release ▁tablets ▁and ▁32 ▁x ▁1 ▁modifi ed - release ▁tablets ▁in ▁a ▁perfor ated ▁unit ▁dose ▁bli ster ▁ .
▁table ▁4 ▁: ▁ef fica cy ▁results ▁for ▁study ▁vi ▁( ▁wa 1992 4 ▁)
▁however ▁ , ▁since ▁market ▁introduc tion ▁ , ▁increased ▁in r ▁( ▁international ▁normal ized ▁ratio ▁) ▁has ▁been ▁reported ▁spontane ously ▁during ▁con com i tant ▁use ▁of ▁war far in ▁and ▁ex en ati de ▁ .
▁sign s ▁of ▁osteo ne cro sis ▁include ▁:
▁scientific ▁conclusion s ▁and ▁ground s ▁recommend ing ▁the ▁variation ▁to ▁the ▁terms ▁of ▁the ▁marketing ▁author isation
▁immun e ▁response ▁to ▁a ▁/ ▁vietnam ▁/ ▁11 94 ▁/ ▁2004 ▁( ▁d 42 ▁)
▁dra xx in ▁100 ▁mg ▁/ ▁ml ▁solution ▁for ▁inject ion ▁for ▁ca ttle ▁ , ▁pig s ▁and ▁she ep ▁tu la thro my cin
▁solution ▁store d ▁at ▁room ▁temperature
▁vir af eron ▁ , ▁60 ▁million ▁iu ▁solution ▁for ▁inject ion ▁ , ▁multi dos e ▁pen
▁150 ▁mg ▁twice ▁week ly ▁on ▁set ▁days ▁is
▁da biga tran ▁et ex ila te ▁110 ▁mg ▁twice ▁daily
▁light ▁yellow ▁op a que ▁cap ▁and ▁body ▁ , ▁capsule ▁size ▁3 ▁( ▁15. 9 ▁mm ▁x ▁ 5.8 ▁mm ▁) ▁ , ▁filled ▁with ▁white ▁to ▁nearly ▁white ▁colour ed ▁powder ▁ .
▁mar ixin o ▁is ▁a ▁' ▁generic ▁medicine ▁' ▁ .
▁to ▁minimi se ▁any ▁possible ▁risk ▁ , ▁men ▁wish ing ▁to ▁father ▁a ▁child ▁should ▁consider ▁dis continu ing ▁use ▁of ▁le flu nom ide ▁and ▁taking ▁cole styr amine ▁8 ▁g ▁3 ▁times ▁daily ▁for ▁11 ▁days ▁or ▁50 ▁g ▁of ▁activa ted ▁powder ed ▁char co al ▁4 ▁times ▁daily ▁for ▁11 ▁days ▁ .
▁advers e ▁reaction s ▁specifically ▁associated ▁with ▁over dos e ▁of ▁ca y ston ▁have ▁not ▁been ▁identified ▁ .
▁nerv e ▁damage ▁in ▁arms ▁and ▁leg s ▁ , ▁para ly sed ▁face
▁overall ▁ , ▁el tro mbo pag ▁was ▁ad minister ed ▁to ▁27 7 ▁itp ▁patients ▁for ▁at ▁least ▁6 ▁months ▁and ▁202 ▁patients ▁for ▁at ▁least ▁1 ▁year ▁ .
▁ta fin lar ▁can ▁cause ▁heart ▁problems ▁ , ▁or ▁make ▁existing ▁heart ▁problems ▁worse ▁ , ▁in ▁people ▁taking ▁ta fin lar ▁in ▁combination ▁with ▁tram etin ib ▁ .
▁how ▁zal trap ▁is ▁given
▁stabili se ▁the ▁skin ▁by ▁spread ing ▁it ▁or ▁pin ching ▁up ▁a ▁large ▁area ▁ .
▁l vd ▁100 ▁mg ▁once ▁daily
▁there ▁is ▁no ▁relevant ▁use ▁of ▁hum ira ▁in ▁the ▁pa e dia tric ▁population ▁for ▁the ▁indica tions ▁of ▁an ky los ing ▁ spon dy liti s ▁and ▁ps oria tric ▁ar thri tis ▁ .
▁each ▁pre - fill ed ▁pen ▁deliver s ▁225 ▁iu ▁fol li trop in ▁alfa ▁ , ▁equivalent ▁to ▁16. 5 ▁micro gram s ▁per ▁0.3 75 ▁ml ▁ .
▁for ▁active ▁immun isation ▁of ▁pig s ▁over ▁the ▁age ▁of ▁3 ▁weeks ▁against ▁por cine ▁circo virus ▁type ▁2 ▁( ▁pc v 2 ▁) ▁ .
▁it ▁is ▁not ▁known ▁whether ▁i del alis ib ▁and ▁its ▁metabol ites ▁are ▁ex cre ted ▁in ▁human ▁milk ▁ .
▁cho le sta gel ▁can ▁induc e ▁or ▁worse n ▁present ▁con s tip ation ▁ .
▁studies ▁have ▁not ▁been ▁conduct ed ▁to ▁evaluat e ▁car cino ge nic ▁potential ▁or ▁effects ▁on ▁fertil ity ▁ .
▁see ▁package ▁le a flet ▁for ▁further ▁information ▁on ▁suc rose
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁nivo lum ab ▁b ms ▁ .
▁gli di pion ▁may ▁be ▁used ▁on ▁its ▁own ▁in ▁patients ▁who ▁are ▁un able ▁to ▁take ▁met form in ▁ , ▁and ▁where ▁treatment ▁with ▁die t ▁and ▁exercise ▁has ▁failed ▁to ▁control ▁blood ▁sugar ▁or ▁may ▁be ▁added ▁to ▁other ▁ therapie s ▁( ▁such ▁as ▁met form in ▁ , ▁sul phon y lu rea ▁or ▁insulin ▁) ▁which ▁have ▁failed ▁to ▁provide ▁ sufficient ▁control ▁of ▁blood ▁sugar ▁ .
▁the ▁potential ▁risk s ▁and ▁benefits ▁associated ▁with ▁co - administration ▁of ▁le di pas vir ▁/ ▁sof os bu vir ▁with ▁stri bild ▁should ▁be ▁considered ▁ , ▁particularly ▁in ▁patients ▁at ▁increased ▁risk ▁of ▁renal ▁dys function ▁ .
▁iba ndro nic ▁acid ▁accord ▁6 ▁mg ▁concentrat e ▁for ▁solution ▁for ▁in fusion
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁som ac ▁control ▁ .
▁the ▁active ▁substance ▁in ▁to pote can ▁teva ▁ , ▁to pote can ▁ , ▁is ▁an ▁anti cancer ▁medicine ▁that ▁be long s ▁to ▁the ▁group ▁' ▁topo i some rase ▁inhibi tors ▁' ▁ .
▁the ▁recon stitu ted ▁solution ▁ , ▁if ▁not ▁used ▁immediately ▁ , ▁should ▁be ▁protected ▁from ▁direct ▁sun light ▁and ▁store d ▁refrigera ted ▁at ▁2 ▁c ▁- 8 ▁c ▁ .
▁key tru da ▁was ▁also ▁effective ▁in ▁the ▁larger ▁group ▁of ▁patients ▁with ▁lung ▁cancer ▁ , ▁including ▁those ▁whose ▁tu mo urs ▁were ▁not ▁strong ly ▁positive ▁for ▁p d - l 1 ▁ .
▁in ▁the ▁severe ▁form ▁of ▁cap s ▁ , ▁long - term ▁treatment ▁improve s ▁the ▁system ic ▁infla mma tory ▁organ ▁manifestation s ▁of ▁the ▁eye ▁ , ▁inner ▁ear ▁ , ▁and ▁c ns ▁ .
▁the ▁studies ▁looked ▁at ▁the ▁change ▁in ▁the ▁den s ity ▁of ▁the ▁bone s ▁in ▁the ▁spin e ▁and ▁the ▁hip ▁over ▁two ▁years ▁ .
▁hold ▁the ▁bir d ▁with ▁its ▁head ▁til ted ▁to ▁one ▁side ▁ .
▁ir besar tan ▁zen tiva ▁75 ▁mg ▁tablets ▁are ▁white ▁to ▁off - white ▁ , ▁bi con ve x ▁ , ▁and ▁ oval - sha ped ▁with ▁a ▁heart ▁de bos sed ▁on ▁one ▁side ▁and ▁the ▁number ▁27 71 ▁en grave d ▁on ▁the ▁other ▁side ▁ .
▁in ▁addition ▁ , ▁in ▁a ▁26 ▁week ▁car cino geni city ▁study ▁using ▁the ▁hetero zy go us ▁p 53 ▁( ▁+ ▁/ ▁- ▁) ▁mouse ▁model ▁ , ▁riba vir in ▁did ▁not ▁produce ▁tu mo urs ▁at ▁the ▁maximal ly ▁to ler ated ▁dose ▁of ▁300 ▁mg ▁/ ▁kg ▁( ▁plasma ▁exposure ▁factor ▁approximately ▁2.5 ▁compared ▁to ▁human ▁exposure ▁) ▁ .
▁en roll ed ▁subject s ▁1 ▁) ▁met ▁d s m - iv ▁criteri a ▁for ▁schi zo aff ective ▁disorder ▁ , ▁as ▁confirm ed ▁by ▁the ▁structure d ▁clinic al ▁interview ▁for ▁d s m - iv ▁disorder s ▁ , ▁2 ▁) ▁had ▁a ▁positive ▁and ▁negative ▁syndrome ▁scale ▁( ▁pan s s ▁) ▁total ▁score ▁of ▁at ▁least ▁60 ▁ , ▁and ▁3 ▁) ▁had ▁prominent ▁mood ▁symptoms ▁as ▁confirm ed ▁by ▁a ▁score ▁of ▁at ▁least ▁16 ▁on ▁the ▁young ▁ mania ▁rating ▁scale ▁( ▁ym rs ▁) ▁and ▁/ ▁or ▁hamil ton ▁rating ▁scale ▁21 ▁for ▁depression ▁( ▁ham - d ▁21 ▁) ▁ .
▁continued ▁la mi vu dine ▁treatment ▁for ▁an ▁additional ▁2 ▁years ▁in ▁patients ▁who ▁had ▁failed ▁to ▁achieve ▁h be ag ▁ser o con version ▁in ▁the ▁initial ▁1 ▁year ▁control led ▁studies ▁result ed ▁in ▁further ▁improvement ▁in ▁ brid ging ▁fibro sis ▁ .
▁for ▁patients ▁who ▁have ▁reside d ▁in ▁or ▁travel led ▁to ▁region s ▁where ▁invasi ve ▁fun gal ▁infection s ▁such ▁as ▁his to plas mos is ▁ , ▁co cci dio ido my cos is ▁ , ▁or ▁blas to my cos is ▁are ▁ende mic ▁ , ▁the ▁benefits ▁and ▁risk s ▁of ▁rem s ima ▁treatment ▁should ▁be ▁carefully ▁considered ▁before ▁initiat ion ▁of ▁rem s ima ▁ therapy ▁ .
▁ lon que x ▁6 ▁mg ▁solution ▁for ▁inject ion
▁he pati c ▁failure ▁( ▁see ▁section ▁4.4 ▁) ▁ , ▁hepatitis ▁ , ▁auto im mu ne ▁hepatitis
▁talk ▁to ▁your ▁doctor ▁if ▁you ▁have ▁ear ▁pain ▁ , ▁dis charge ▁from ▁the ▁ear ▁ , ▁and ▁/ ▁or ▁an ▁ear ▁infection ▁ .
▁per tus sis ▁to xo id 1 ▁25 ▁micro gram s
▁un open ed ▁vi als ▁3 ▁years
▁administration ▁of ▁a ▁two - fold ▁over dos e ▁may ▁be ▁followed ▁in ▁most ▁animals ▁by ▁a ▁local ▁reaction ▁at ▁the ▁inject ion ▁site ▁ .
▁a ▁significant ▁decrease ▁in ▁plasma ▁concentration s ▁of ▁ata zana vir ▁and ▁a ▁marked ▁increase ▁of ▁tip rana vir ▁and ▁rito na vir ▁concentration s ▁was ▁observe d ▁when ▁a pti vus ▁ , ▁associated ▁with ▁low ▁dose ▁rito na vir ▁ , ▁was ▁co - ▁ad minister ed ▁with ▁ata zana vir ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁ riste mpa ▁on ▁13 ▁april ▁2015 ▁ .
▁all ▁events ▁were ▁resolve d ▁without ▁se que la e ▁following ▁treatment ▁ .
▁the ▁full ▁e par ▁for ▁viva nza ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁in ▁the ▁four th ▁study ▁ , ▁previously ▁treated ▁patients ▁with ▁wild - type ▁ras ▁receiving ▁vec tib ix ▁in ▁combination ▁with ▁fol fir i ▁lived ▁for ▁16. 2 ▁months ▁compared ▁with ▁13. 9 ▁months ▁in ▁patients ▁receiving ▁fol fir i ▁alone ▁ .
▁how ▁is ▁som ac ▁control ▁used ▁?
▁s wens weg ▁5 ▁ , ▁20 31 ga ▁haar lem ▁the ▁ne ther lands
▁ath ens ▁- ▁gre ece ▁τη λ ▁: ▁+ ▁30 ▁210 ▁62 195 20
▁the ▁marketing ▁author isation ▁was ▁rene wed ▁on ▁14 ▁februar y ▁2001 ▁and ▁on ▁14 ▁februar y ▁2006 ▁ .
▁le di pas vir ▁and ▁sof os bu vir ▁are ▁substrat es ▁of ▁drug ▁transporter ▁p - gp ▁and ▁ bc rp ▁while ▁g s -33 100 7 ▁is ▁not ▁ .
▁date ▁on ▁which ▁the ▁package ▁le a flet ▁was ▁last ▁approved
▁it ▁was ▁generally ▁more ▁effective ▁than ▁place bo ▁and ▁as ▁effective ▁as ▁other ▁pain kill ers ▁ .
▁what ▁is ▁revi nty ▁el lip ta ▁and ▁what ▁is ▁it ▁used ▁for ▁?
▁p leri xa for - indu ced ▁leuk o cy tos is ▁and ▁eleva tions ▁in ▁circula ting ▁ha e mato po ie tic ▁pro gen itor ▁cell ▁levels ▁are ▁thought ▁to ▁result ▁from ▁a ▁disrupt ion ▁of ▁c x cr 4 ▁ binding ▁to ▁its ▁cogn ate ▁liga nd ▁ , ▁result ing ▁in ▁the ▁appearance ▁of ▁both ▁mature ▁and ▁pluri potent ▁cell s ▁in ▁the ▁system ic ▁circulation ▁ .
▁in ▁patients ▁with ▁cr vo ▁ , ▁a ▁block age ▁occur s ▁in ▁the ▁main ▁blood ▁ves sel ▁that ▁transport s ▁blood ▁away ▁from ▁the ▁retin a ▁ .
▁gastro inte stin al ▁perfor ation ▁or ▁fi stu la e ▁have ▁been ▁reported ▁in ▁patients ▁treated ▁with ▁len vati ni b ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁in ▁the ▁si rius ▁study ▁( ▁see ▁" ▁clinic al ▁ef fica cy ▁and ▁safety ▁ , ▁" ▁below ▁) ▁5 ▁patients ▁with ▁geno type ▁1 ▁infection ▁re lapse d ▁after ▁treatment ▁with ▁le di pas vir ▁/ ▁sof os bu vir ▁with ▁or ▁without ▁riba vir in ▁ .
▁the ▁sever ity ▁of ▁advers e ▁events ▁of ▁doce ta xel ▁my lan ▁may ▁be ▁increased ▁when ▁doce ta xel ▁my lan ▁is ▁given ▁in ▁combination ▁with ▁other ▁che mo therapeut ic ▁agents ▁ .
▁the ▁ pharma cok ine tics ▁in ▁other ▁race s ▁has ▁not ▁been ▁evaluat ed ▁ .
▁1 ▁ser o protec tion ▁rate ▁: ▁proportion ▁of ▁subject s ▁with ▁ha e mag glut in ation ▁inhibi tion ▁( ▁hi ▁) ▁titre ▁1 ▁: ▁40 ▁; ▁2 boo ster ▁ser o con version ▁rate ▁: ▁proportion ▁of ▁subject s ▁who ▁were ▁either ▁ser o nega tive ▁at ▁pre - boo ster ▁and ▁have ▁a ▁protect ive ▁post - vac cin ation ▁titre ▁of ▁1 ▁: ▁40 ▁ , ▁or ▁who ▁were ▁ser o posi tive ▁at ▁pre - boo ster ▁and ▁have ▁a ▁4- ▁ fold ▁increase ▁in ▁titre ▁;
▁abil ify ▁10 ▁mg ▁oro dis per sible ▁tablets ▁abil ify ▁15 ▁mg ▁oro dis per sible ▁tablets ▁abil ify ▁30 ▁mg ▁oro dis per sible ▁tablets
▁these ▁conditions ▁can ▁cause ▁de hydrat ion ▁ .
▁in gel vac ▁circo flex ▁suspens ion ▁for ▁inject ion ▁for ▁pig s
▁if ▁a ▁severe ▁ir r ▁ , ▁ana phy la ctic ▁reaction ▁ , ▁or ▁other ▁severe ▁reaction ▁occur s ▁ , ▁administration ▁of ▁en tyvi o ▁must ▁be ▁dis continu ed ▁immediately ▁and ▁appropriate ▁treatment ▁initiat ed ▁( ▁e . g . ▁ , ▁e pine ph rine ▁and ▁anti hi stamine s ▁) ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁when ▁imati ni b ▁was ▁combine d ▁with ▁high ▁dose ▁che mo therapy ▁in ▁ph ▁+ ▁all ▁patients ▁ , ▁trans ient ▁ liver ▁ toxic ity ▁in ▁the ▁form ▁of ▁trans amin ase ▁eleva tion ▁and ▁hyper bili ru bina emia ▁were ▁observe d ▁ .
▁risk ▁management ▁plan ▁( ▁r mp ▁)
▁these ▁serious ▁side ▁effects ▁are ▁un com mon ▁ .
▁co - administration ▁of ▁dom peri done ▁with ▁inci vo ▁should ▁be ▁avoid ed ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁side ▁effects ▁for ▁which ▁fre que ncy ▁is ▁not ▁known ▁( ▁cannot ▁be ▁estima ted ▁from ▁available ▁data ▁) ▁are ▁:
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁ac tel sar ▁h ct ▁contain s
▁orang e ▁ , ▁film - co ated ▁ , ▁modifi ed ▁capsule ▁shape d ▁tablets ▁ , ▁de bos sed ▁with ▁g s ▁ fc 2 ▁on ▁one ▁side ▁ .
▁in ▁population ▁ pharma cok ine tic ▁analysis ▁in ▁h c v - infect ed ▁patients ▁ , ▁el bas vir ▁and ▁gra zo pre vir ▁au cs ▁were ▁25 ▁% ▁and ▁10 ▁% ▁higher ▁ , ▁respective ly ▁ , ▁in ▁di al ysis - dependent ▁patients ▁and ▁46 ▁% ▁and ▁40 ▁% ▁higher ▁ , ▁respective ly ▁ , ▁in ▁non - dia lys is - dependent ▁patients ▁with ▁severe ▁renal ▁im pair ment ▁compared ▁to ▁el bas vir ▁and ▁gra zo pre vir ▁au c ▁in ▁patients ▁without ▁severe ▁renal ▁im pair ment ▁ .
▁continue ▁to ▁take ▁me man tine ▁accord ▁as ▁long ▁as ▁it ▁is ▁of ▁benefit ▁to ▁you ▁ .
▁the ▁observe d ▁advers e ▁effect ▁level ▁for ▁em bry o - fo e tal ▁ toxic ity ▁in ▁this ▁study ▁was ▁10 ▁μ g ▁/ ▁kg ▁/ ▁day ▁ , ▁which ▁corresponde d ▁to ▁a ▁system ic ▁exposure ▁of ▁approximately ▁3 ▁- ▁5 ▁times ▁the ▁exposure s ▁observe d ▁in ▁patients ▁treated ▁with ▁the ▁clinic al ▁dose ▁ .
▁the ▁conditions ▁of ▁the ▁tha li domi de ▁cel gene ▁pre gna ncy ▁pre vention ▁programme ▁must ▁be ▁fulfill ed ▁for ▁all ▁male ▁and ▁female ▁patients ▁ .
▁a ▁study ▁in ▁children ▁with ▁pah ▁will ▁also ▁be ▁carried ▁out ▁to ▁collect ▁further ▁long - term ▁safety ▁data ▁in ▁this ▁population ▁ .
▁quin s air ▁is ▁taken ▁in ▁alternat ing ▁cycle s ▁of ▁28 ▁days ▁on ▁treatment ▁followed ▁by ▁28 ▁days ▁off ▁treatment ▁ .
▁clinic al ▁monitoring ▁is ▁recommended ▁upon ▁co - ▁administration ▁with ▁evo ta z ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁other ▁alimentar y ▁tract ▁and ▁metabolism ▁products ▁ , ▁various ▁alimentar y ▁tract ▁and ▁metabolism ▁products ▁ , ▁at c ▁code ▁: ▁a 16 ax 10 ▁ .
▁exposure ▁to ▁the ▁pro - drug ▁is ▁less ▁than ▁5 ▁% ▁relative ▁to ▁the ▁active ▁metabol ite ▁ .
▁in ▁the ▁second ▁study ▁ , ▁the ▁difference ▁between ▁the ▁total ▁number ▁of ▁re jec tions ▁for ▁the ▁two ▁medicine ▁combination s ▁was ▁not ▁considered ▁to ▁be ▁relevant ▁ .
▁hyper sensitiv ity ▁( ▁allergi c ▁reaction s ▁) ▁: ▁hyper sensitiv ity ▁or ▁allergi c ▁reaction s ▁( ▁which ▁may ▁include ▁ang io ede ma ▁ , ▁bur ning ▁and ▁sting ing ▁at ▁the ▁in fusion ▁site ▁ , ▁chill s ▁ , ▁flu shing ▁ , ▁general ised ▁ur tica ria ▁ , ▁head ache ▁ , ▁hi ves ▁ , ▁hypo tension ▁ , ▁le thar gy ▁ , ▁na use a ▁ , ▁rest less ness ▁ , ▁ta chy car dia ▁ , ▁tight ness ▁of ▁the ▁che st ▁( ▁including ▁che st ▁pain ▁and ▁che st ▁disco m fort ▁) ▁ , ▁back ▁pain ▁ , ▁ting ling ▁ , ▁vom i ting ▁ , ▁w hee zing ▁) ▁have ▁been ▁observe d ▁ , ▁and ▁may ▁in ▁some ▁cases ▁progress ▁to ▁severe ▁ana phy la xis ▁( ▁including ▁shock ▁) ▁ .
▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁any ▁of ▁the ▁side ▁effects ▁listed ▁gets ▁severe ▁or ▁trouble some ▁ , ▁or ▁if ▁you ▁notice ▁any ▁side ▁effects ▁not ▁listed ▁in ▁this ▁le a flet ▁ .
▁the ▁tablets ▁should ▁prefer ably ▁be ▁taken ▁with ▁food ▁ .
▁at ▁14 ▁days ▁after ▁initiat ion ▁of ▁treatment ▁ , ▁16. 7 ▁- ▁2 5.0 ▁% ▁morbi d ity ▁and ▁0.3 ▁- ▁ 3.9 ▁% ▁mortal ity ▁were ▁observe d ▁in ▁the ▁treated ▁group ▁in ▁comparison ▁to ▁5 0.0 ▁- ▁5 3.3 ▁% ▁morbi d ity ▁and ▁0.3 ▁- ▁4.5 ▁% ▁mortal ity ▁in ▁an ▁un tre ated ▁group ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁taxa nes ▁ , ▁at c ▁code ▁: ▁l 01 cd ▁02 ▁mechanism ▁of ▁action
▁sp ▁= ▁ser o protec tion ▁sc ▁= ▁ser o con version
▁as ▁with ▁other ▁cy to toxic ▁medicinal ▁products ▁ , ▁to pote can ▁may ▁cause ▁fo e tal ▁har m ▁and ▁therefore ▁women ▁of ▁child be aring ▁potential ▁should ▁be ▁advise d ▁to ▁avoid ▁becoming ▁pregnant ▁during ▁ therapy ▁with ▁to pote can ▁ .
▁if ▁you ▁have ▁been ▁told ▁by ▁your ▁doctor ▁that ▁you ▁have ▁in tolerance ▁to ▁some ▁sugar s ▁ , ▁contact ▁your ▁doctor ▁before ▁taking ▁pi og lita zone ▁kr ka ▁ .
▁detailed ▁information ▁on ▁this ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁( ▁ema ▁) ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu
▁your ▁doctor ▁will ▁advise ▁on ▁which ▁hi v ▁medicine s ▁can ▁be ▁combine d ▁with ▁edu rant ▁and ▁together ▁you ▁will ▁decide ▁which ▁combination ▁fit s ▁your ▁needs ▁best ▁ .
▁pe metre x ed ▁med ac ▁100 ▁mg ▁contain s ▁less ▁than ▁1 ▁mm ol ▁so dium ▁( ▁23 ▁mg ▁) ▁per ▁vi al ▁ , ▁i . e . ▁essential ly ▁' ▁so dium - free ▁' ▁ .
▁getting ▁the ▁kwi k pen ▁ready ▁to ▁use ▁( ▁please ▁see ▁user ▁manual ▁)
▁dys ge usia ▁ , ▁di zzi ness ▁ , ▁visual ▁field ▁defect
▁gala fold ▁contain s ▁the ▁active ▁substance ▁mig ala stat ▁ .
▁in ▁a ▁mouse ▁th igh ▁infection ▁model ▁of ▁s . ▁aur eus ▁ , ▁the ▁anti bac teria l ▁activity ▁of ▁ ted izol id ▁was ▁reduce d ▁in ▁the ▁ absence ▁of ▁granul o cy tes ▁ .
▁due ▁to ▁the ▁presence ▁of ▁asa ▁ , ▁met ho tre xa te ▁used ▁at ▁dos es ▁higher ▁than ▁20 ▁mg ▁/ ▁week ▁should ▁be ▁used ▁with ▁cau tion ▁with ▁the ▁combination ▁of ▁clo pido gre l ▁/ ▁a ce tyl sali cy lic ▁acid ▁as ▁it ▁can ▁inhibi t ▁renal ▁clear ance ▁of ▁met ho tre xa te ▁ , ▁which ▁may ▁lead ▁to ▁bone ▁mar row ▁ toxic ity ▁ .
▁30 ▁mg ▁( ▁suspens ion ▁or ▁capsule s ▁) ▁once ▁week ly
▁white ▁to ▁almost ▁white ▁ , ▁round ▁film - co ated ▁tablet ▁with ▁a ▁diameter ▁of ▁8 ▁mm ▁and ▁a ▁break - mark ▁on ▁one ▁side ▁of ▁the ▁tablet ▁ .
▁ask ▁your ▁ pharma ci st ▁how ▁to ▁dispose ▁of ▁medicine s ▁you ▁no ▁longer ▁use ▁ .
▁3 ▁my o card ial ▁in far ction ▁has ▁been ▁reported ▁ , ▁particularly ▁in ▁patients ▁with ▁previous ▁cardiovascular ▁history ▁ , ▁sometimes ▁within ▁48 ▁hours ▁after ▁the ▁in fusion ▁ .
▁to ▁get ▁the ▁most ▁benefit ▁from ▁the ▁medicine ▁ , ▁it ▁should ▁be ▁used ▁regularly ▁and ▁at ▁the ▁same ▁time ▁every ▁day ▁ .
▁each ▁ml ▁contain s ▁10 ▁mg ▁of ▁me cas er min ▁ .
▁the ▁half - life ▁was ▁prolong ed ▁from ▁ 3.7 ▁to ▁6. 0 ▁hours ▁with ▁concurrent ▁keto con a zole ▁administration ▁ .
▁this ▁document ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁dat s can ▁ .
▁bri vara ce tam ▁is ▁we ak ly ▁ bound ▁( ▁ ≤ ▁20 ▁% ▁) ▁to ▁plasma ▁protein s ▁ .
▁ therapy ▁should ▁be ▁interrupt ed ▁if ▁the ▁patient ▁' s ▁temperature ▁is ▁ ≥ ▁3 8.5 oc . ▁patients ▁should ▁be ▁evaluat ed ▁for ▁sign s ▁and ▁symptoms ▁of ▁infection ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁the ▁impact ▁of ▁treatment ▁with ▁kin eret ▁on ▁pre - exist ing ▁malign an cy ▁has ▁not ▁been ▁studie d ▁ .
▁no ▁vir ologic ▁data ▁in ▁week ▁48 ▁window
▁if ▁your ▁child ▁has ▁hepatitis ▁b ▁infection ▁ , ▁your ▁child ▁' s ▁doctor ▁will ▁carefully ▁consider ▁the ▁best ▁treatment ▁for ▁them ▁ .
▁you ▁may ▁feel ▁di zzy ▁after ▁having ▁my oce t ▁ .
▁you ▁may ▁become ▁de hydrat ed ▁( ▁los ing ▁too ▁much ▁fluid ▁) ▁if ▁vom i ting ▁or ▁di ar r ho e a ▁are ▁prolong ed . ▁if ▁you ▁have ▁im pair ed ▁ liver ▁function ▁ .
▁do ▁not ▁stop ▁taking ▁ gile nya ▁or ▁change ▁your ▁dose ▁without ▁talking ▁to ▁your ▁doctor ▁first ▁ .
▁therefore ▁ , ▁breast - feed ing ▁may ▁be ▁continued ▁during ▁the ▁vaccin ation ▁schedule ▁ .
▁mito tane ▁has ▁not ▁been ▁studie d ▁in ▁a ▁comprehensive ▁clinic al ▁development ▁program ▁ .
▁these ▁medicine s ▁are ▁often ▁given ▁for ▁relief ▁of ▁che st ▁pain ▁( ▁or ▁" ▁ang ina ▁pec toris ▁" ▁) ▁ .
▁geno toxic ity ▁studies ▁have ▁been ▁perform ed ▁: ▁although ▁in ▁published ▁studies ▁using ▁cyst e amine ▁ , ▁in duction ▁of ▁chr o mos ome ▁aber ration s ▁in ▁culture d ▁eu kar yo tic ▁cell ▁lines ▁has ▁been ▁reported ▁ , ▁specific ▁studies ▁with ▁cyst e amine ▁bit art rate ▁did ▁not ▁show ▁any ▁mu tage nic ▁effects ▁in ▁the ▁am es ▁test ▁or ▁any ▁cla sto ge nic ▁effect ▁in ▁the ▁mouse ▁micro nu cle us ▁test ▁ .
▁z yka dia ▁is ▁for ▁oral ▁use ▁ .
▁you ▁should ▁ask ▁your ▁doctor ▁how ▁soon ▁after ▁delivery ▁you ▁can ▁start ▁taking ▁e vra ▁;
▁the ▁agency ▁' s ▁committee ▁for ▁medicinal ▁products ▁for ▁human ▁use ▁( ▁ch mp ▁) ▁decided ▁that ▁ky pro lis ▁' ▁benefits ▁are ▁greater ▁than ▁its ▁risk s ▁and ▁recommended ▁that ▁it ▁be ▁approved ▁for ▁use ▁in ▁the ▁eu ▁ .
▁in ▁case ▁of ▁accident al ▁self - in je ction ▁ , ▁medical ▁advice ▁should ▁be ▁so ught ▁immediately ▁and ▁the ▁package ▁le a flet ▁or ▁the ▁label ▁should ▁be ▁shown ▁to ▁the ▁doctor ▁ .
▁risk ▁increase s ▁substantial ly ▁as ▁b mi ▁ris es ▁ .
▁eleva tions ▁in ▁am yla se ▁and ▁lip ase ▁were ▁trans ient ▁and ▁mostly ▁of ▁mild ▁or ▁moderat e ▁sever ity ▁ .
▁population ▁ pk ▁model ing ▁indicate s ▁that ▁exposure ▁approximately ▁double s ▁in ▁patients ▁with ▁severe ▁renal ▁im pair ment ▁( ▁cr cl ▁15 ▁- ▁29 ▁ml ▁/ ▁min ▁) ▁relative ▁to ▁patients ▁with ▁normal ▁renal ▁function ▁ .
▁the ▁full ▁e par ▁for ▁ons en al ▁can ▁be ▁found ▁here ▁ .
▁as ▁an ▁aid ▁in ▁the ▁treatment ▁of ▁separa tion - related ▁disorder s ▁in ▁combination ▁with ▁behaviour al ▁modification ▁techniques ▁ .
▁you ▁have ▁uns table ▁ang ina ▁pec toris ▁( ▁new ▁or ▁increasing ▁che st ▁pain ▁) ▁you ▁are ▁at ▁risk ▁of ▁blood ▁clo ts ▁in ▁the ▁ve ins ▁( ▁deep ▁ve nous ▁ thro mbo sis ▁) ▁- ▁for ▁example ▁ , ▁if ▁you ▁have ▁had ▁clo ts ▁before ▁ .
▁advers e ▁reaction s ▁were ▁evaluat ed ▁in ▁pa e dia tric ▁patients ▁receiving ▁palo nos et ron ▁for ▁up ▁to ▁4 ▁che mo therapy ▁cycle s ▁ .
▁table ▁9 ▁key ▁ef fica cy ▁results ▁for ▁the ▁non - in feri or ity ▁analysis ▁of ▁study ▁no 16 967
▁although ▁radi um -22 3 ▁is ▁predomina nt ly ▁an ▁al pha ▁emit ter ▁ , ▁gamma ▁and ▁beta ▁radi ation ▁is ▁associated ▁with ▁the ▁de ca y ▁of ▁radi um -22 3 ▁and ▁its ▁radio active ▁daughter ▁iso top es ▁ .
▁inf lec tra ▁works ▁by ▁block ing ▁the ▁action ▁of ▁a ▁protein ▁called ▁' ▁tum our ▁nec rosi s ▁factor ▁al pha ▁' ▁( ▁t n f α ▁) ▁ .
▁the ▁need ▁to ▁consider ▁ thro mbo prop hy la xis ▁after ▁care ful ▁assessment ▁of ▁a ▁patient ▁' s ▁risk ▁factors
▁after ▁surgery ▁ , ▁you ▁will ▁be ▁pre scribe d ▁a ▁course ▁of ▁medicine s ▁to ▁ensure ▁full ▁hea ling ▁: ▁antibiotic s ▁to ▁reduce ▁the ▁chance ▁of ▁an ▁infection ▁and ▁steroid s ▁to ▁reduce ▁swe lling ▁and ▁irrita tion ▁ .
▁the ▁most ▁common ▁side ▁effects ▁with ▁kar vez ide ▁( ▁seen ▁in ▁between ▁1 ▁and ▁10 ▁patients ▁in ▁100 ▁) ▁are ▁di zzi ness ▁ , ▁na use a ▁( ▁feeling ▁sick ▁) ▁or ▁vom i ting ▁ , ▁ab normal ▁urin ation ▁ , ▁fatigue ▁( ▁tired ness ▁) ▁ , ▁and ▁increase s ▁in ▁blood ▁u rea ▁nit rogen ▁( ▁bun ▁ , ▁a ▁break down ▁product ▁of ▁protein ▁) ▁ , ▁creati nine ▁( ▁a ▁break down ▁product ▁of ▁muscle ▁) ▁and ▁creati ne ▁kina se ▁( ▁an ▁enzym e ▁found ▁in ▁muscle s ▁) ▁ .
▁opportun istic ▁infection s ▁such ▁as ▁pc p ▁should ▁be ▁considered ▁in ▁the ▁differenti al ▁ diagnos is ▁ .
▁the ▁observe d ▁mean ▁( ▁s d ▁) ▁activity ▁time ▁profile ▁following ▁a ▁single ▁dose ▁of ▁al pro lix ▁in ▁patients ▁with ▁severe ▁ha emo phil ia ▁b ▁is ▁shown ▁below ▁( ▁see ▁table ▁6 ▁) ▁ .
▁side ▁effects ▁reported ▁common ly ▁( ▁may ▁affect ▁1 ▁in ▁10 ▁people ▁)
▁the ▁other ▁ingredients ▁are ▁: ▁thi om er sal ▁ , ▁so dium ▁chlor ide ▁ , ▁po tas s ium ▁chlor ide ▁ , ▁po tas s ium ▁di hydro gen ▁ phos pha te ▁ , ▁di so dium ▁ phos pha te ▁di hydrat e ▁ , ▁magnesium ▁chlor ide ▁he xa hydrat e ▁ , ▁calci um ▁chlor ide ▁di hydrat e ▁ , ▁so dium ▁cit rate ▁ , ▁ci tric ▁acid ▁and ▁water ▁for ▁inject ions ▁ .
▁a ▁95 ▁% ▁confidence ▁interval ▁for ▁difference ▁in ▁proportion s ▁b ▁the ▁pre - spec ified ▁equivale nce ▁ bound ary ▁was ▁ ± ▁10 ▁%
▁when ▁changing ▁from ▁another ▁insulin ▁regime n ▁to ▁ry zo deg ▁ , ▁dose ▁re duction ▁of ▁total ▁insulin ▁needs ▁to ▁be ▁considered ▁on ▁an ▁individual ▁basis ▁ , ▁in ▁order ▁to ▁minimi se ▁the ▁risk ▁of ▁hypo gly ca emia ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁photo dynamic ▁ therapy ▁with ▁photo bar r ▁is ▁a ▁two - s tage ▁process ▁requiri ng ▁administration ▁of ▁both ▁medicinal ▁product ▁and ▁light ▁ .
▁difficult y ▁in ▁seeing ▁well ▁at ▁night ▁or ▁in ▁dim ▁light
▁the ▁observe d ▁pattern ▁of ▁increased ▁risk ▁may ▁be ▁due ▁to ▁an ▁earlier ▁ diagnos is ▁of ▁breast ▁cancer ▁in ▁co c ▁users ▁ , ▁the ▁bi ological ▁effects ▁of ▁co cs ▁or ▁a ▁combination ▁of ▁both ▁ .
▁plato ▁included ▁patients ▁with ▁base line ▁con ges tive ▁heart ▁failure ▁ , ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁ , ▁or ▁as th ma ▁; ▁these ▁patients ▁ , ▁and ▁the ▁el der ly ▁ , ▁were ▁more ▁likely ▁to ▁report ▁dys p no e a ▁ .
▁experience ▁with ▁dos es ▁higher ▁than ▁the ▁recommended ▁ therapeut ic ▁dose ▁is ▁limited ▁ .
▁mechan istic ▁studies ▁reveal ed ▁a ▁rat ▁specific ▁mechanism ▁which ▁is ▁considered ▁to ▁be ▁of ▁low ▁relevan ce ▁for ▁humans ▁ .
▁25 ▁% ▁of ▁the ▁insulin ▁is ▁disso l ved ▁in ▁water ▁; ▁the ▁other ▁75 ▁% ▁is ▁present ▁as ▁ tiny ▁crystal s ▁of ▁insulin ▁pro tamine ▁ .
▁kar ve a ▁be long s ▁to ▁a ▁group ▁of ▁medicine s ▁known ▁as ▁ang io ten sin - ii ▁receptor ▁anta gon ists ▁ .
▁anti - hb s ▁response s ▁to ▁pro com va x ▁in ▁infants ▁previously ▁vaccin ated ▁with ▁hepatitis ▁b ▁vaccin e
▁the ▁principal ▁route ▁of ▁metabolism ▁was ▁hydro lys is ▁of ▁the ▁s - ▁fluor om et hyl ▁carb oth io ate ▁function ▁to ▁form ▁the ▁17 ▁- car box y lic ▁acid ▁metabol ite ▁ .
▁to ▁remove ▁air ▁bu bble s ▁from ▁the ▁sy ringe ▁ , ▁hold ▁the ▁sy ringe ▁with ▁the ▁need le ▁point ing ▁up ▁ .
▁a ▁trans place n tal ▁geno toxic ity ▁study ▁conduct ed ▁in ▁mon key s ▁compared ▁zid ovu dine ▁alone ▁with ▁the ▁combination ▁of ▁zid ovu dine ▁and ▁la mi vu dine ▁at ▁human - e qui valent ▁exposure s ▁ .
▁el der ly ▁ , ▁he pat ically ▁or ▁renal ly ▁im pair ed ▁patients ▁:
▁lack ▁of ▁energy ▁block ed ▁nos e ▁ .
▁if ▁hypo tension ▁occur s ▁ , ▁the ▁patient ▁should ▁be ▁placed ▁in ▁a ▁su pine ▁position ▁ , ▁with ▁salt ▁and ▁volume ▁replace ments ▁given ▁quickly ▁ .
▁what ▁de x dor ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁you ▁will ▁be ▁asked ▁to ▁take ▁pre medic ation ▁consist ing ▁of ▁an ▁oral ▁corti co steroid ▁such ▁as ▁de xa met has one ▁ , ▁one ▁day ▁prior ▁to ▁doce ta xel ▁accord ▁administration ▁and ▁to ▁continue ▁for ▁one ▁or ▁two ▁days ▁after ▁it ▁in ▁order ▁to ▁minimi se ▁certain ▁unde sir able ▁effects ▁which ▁may ▁occur ▁after ▁the ▁in fusion ▁of ▁doce ta xel ▁accord ▁in ▁particular ▁allergi c ▁reaction s ▁and ▁fluid ▁re tention ▁( ▁swe lling ▁of ▁the ▁hands ▁ , ▁feet ▁ , ▁leg s ▁or ▁weight ▁gain ▁) ▁ .
▁if ▁you ▁miss ▁a ▁gaz y varo ▁treatment
▁radi ation ▁protection ▁precau tions ▁in ▁accordance ▁with ▁national ▁regulations ▁must ▁therefore ▁be ▁taken ▁ .
▁nature ▁and ▁content s ▁of ▁container
▁no ▁definitiv e ▁conclusion ▁on ▁advers e ▁effects ▁can ▁be ▁draw n ▁on ▁the ▁male ▁reproduc tive ▁organ s ▁in ▁cyn om ol gus ▁mon key ▁repeat ed ▁dose ▁ toxic ity ▁study ▁ .
▁di ar r ho e a ▁ , ▁gastro - o es op hage al ▁ref lux ▁disease ▁ , ▁ret ching ▁ , ▁vom i ting b
▁for ▁reach ing ▁the ▁needed ▁dos es ▁ , ▁different ▁patch es ▁of ▁neu pro ▁are ▁available ▁ , ▁each ▁rele as ing ▁a ▁different ▁amount ▁of ▁the ▁active ▁substance ▁per ▁day ▁: ▁2 ▁mg ▁/ ▁24 ▁h ▁ , ▁4 ▁mg ▁/ ▁24 ▁h ▁ , ▁6 ▁mg ▁/ ▁24 ▁h ▁and ▁8 ▁mg ▁/ ▁24 ▁h ▁ .
▁epi le psy ▁is ▁a ▁condition ▁where ▁the ▁patients ▁have ▁repeat ed ▁fit s ▁( ▁se iz ures ▁) ▁ .
▁during ▁treatment ▁ , ▁o cular ▁advers e ▁reaction s ▁( ▁con jun cti viti s ▁ , ▁dry ▁eye ▁ , ▁kera titi s ▁) ▁have ▁been ▁reported ▁in ▁some ▁patients ▁( ▁see ▁section ▁4. 8 ▁) ▁which ▁may ▁affect ▁patients ▁ability ▁to ▁drive ▁or ▁use ▁machines ▁ .
▁if ▁renal ▁ab normal ities ▁are ▁suspect ed ▁or ▁detect ed ▁then ▁consultation ▁with ▁a ▁nep hro logist ▁should ▁be ▁obtain ed ▁to ▁consider ▁interrupt ion ▁of ▁te no fo vir ▁di so prox il ▁fumar ate ▁treatment ▁ .
▁se rum ▁levels ▁of ▁l h ▁ , ▁f sh ▁and ▁progesteron e ▁were ▁not ▁significantly ▁affected ▁ .
▁the ▁ab sor p tion ▁and ▁elimina tion ▁are ▁complete ▁approximately ▁six ▁to ▁eight ▁months ▁after ▁the ▁last ▁inject ion ▁ .
▁after ▁single ▁dose ▁oral ▁administration ▁of ▁[ ▁14 c ▁] ▁- ril pi vir ine ▁ , ▁on ▁average ▁85 ▁% ▁and ▁6.1 ▁% ▁of ▁the ▁radio activ ity ▁could ▁be ▁re trie ved ▁in ▁fa e ces ▁and ▁urin e ▁ , ▁respective ly ▁ .
▁do ▁not ▁use ▁in ▁bir ds ▁in ▁la y ▁and ▁within ▁4 ▁weeks ▁before ▁the ▁ons et ▁of ▁the ▁la ying ▁period ▁ .
▁in ▁the ▁event ▁of ▁over dos age ▁there ▁may ▁be ▁an ▁increased ▁risk ▁of ▁ble ed ing ▁ .
▁following ▁sub cuta ne ous ▁administration ▁of ▁recommended ▁dos es ▁ , ▁se rum ▁concentration s ▁were ▁maintain ed ▁above ▁10 ▁ng ▁/ ▁ml ▁for ▁8 ▁to ▁16 ▁hours ▁ .
▁after ▁the ▁second ▁dose ▁ , ▁the ▁rates ▁were ▁around ▁99 ▁% ▁for ▁me as les ▁ , ▁100 ▁% ▁for ▁mum ps ▁ , ▁98 ▁% ▁for ▁rub ella ▁ , ▁and ▁99 ▁% ▁for ▁chicken po x ▁ .
▁it ▁is ▁important ▁to ▁take ▁this ▁medicine ▁every ▁day ▁ , ▁as ▁long ▁as ▁your ▁doctor ▁pre scribe s ▁it ▁for ▁you ▁ .
▁outcome ▁for ▁patients ▁without ▁sv r 12
▁the ▁rate ▁of ▁ex ace rb ations ▁in ▁the ▁place bo ▁arm ▁increased ▁with ▁increasing ▁base line ▁blood ▁eos ino phil ▁count ▁ .
▁eu ▁/ ▁1 ▁/ ▁04 ▁/ ▁29 2 ▁/ ▁ 001 ▁- ▁carton ▁with ▁14 ▁tablets ▁eu ▁/ ▁1 ▁/ ▁04 ▁/ ▁29 2 ▁/ ▁ 002 ▁- ▁carton ▁with ▁28 ▁tablets ▁eu ▁/ ▁1 ▁/ ▁04 ▁/ ▁29 2 ▁/ ▁ 003 ▁- ▁carton ▁with ▁84 ▁tablets ▁eu ▁/ ▁1 ▁/ ▁04 ▁/ ▁29 2 ▁/ ▁ 004 ▁- ▁bottle ▁with ▁30 ▁tablets
▁the ▁occur r ence ▁of ▁these ▁neo plas ms ▁is ▁associated ▁with ▁the ▁panto pra zole - indu ced ▁changes ▁in ▁the ▁break down ▁of ▁ thyr ox ine ▁in ▁the ▁rat ▁ liver ▁ .
▁the ▁clinic al ▁relevan ce ▁of ▁these ▁observation s ▁remain s ▁un know n ▁ .
▁patients ▁and ▁care rs ▁should ▁be ▁made ▁aware ▁that ▁behaviour al ▁symptoms ▁of ▁impuls e ▁control ▁disorder s ▁including ▁path ological ▁gambling ▁ , ▁increased ▁libido ▁ , ▁hyper sexual ity ▁ , ▁comp ul sive ▁spending ▁or ▁buying ▁ , ▁bin ge ▁eating ▁and ▁comp ul sive ▁eating ▁can ▁occur ▁in ▁patients ▁treated ▁with ▁dop amine ▁ago nist s ▁including ▁pra mi pe xo le ▁ .
▁troba lt ▁can ▁affect ▁the ▁results ▁of ▁some ▁tests ▁ .
▁each ▁pre - fill ed ▁sy ringe ▁contain s ▁6 ▁mg ▁lip eg fil gra s tim ▁in ▁ 0.6 ▁ml ▁solution ▁ .
▁two ▁dos es ▁of ▁ra ne xa ▁( ▁750 ▁and ▁1000 ▁mg ▁twice ▁a ▁day ▁) ▁were ▁compared ▁with ▁place bo ▁( ▁a ▁dum my ▁treatment ▁) ▁as ▁an ▁add - on ▁to ▁common ly ▁used ▁medicine s ▁for ▁ang ina ▁pec toris ▁( ▁at eno lol ▁ , ▁am lo di pine ▁or ▁dil tia zem ▁) ▁ .
▁if ▁you ▁experience ▁this ▁symptom ▁for ▁the ▁first ▁time ▁ , ▁talk ▁to ▁your ▁doctor ▁as ▁soon ▁as ▁possible ▁ .
▁ pharma ce u tical ▁form ▁in hal ation ▁powder ▁ , ▁pre - dis pen sed ▁ .
▁similar ▁effects ▁in ▁re duction ▁of ▁moderat e ▁and ▁severe ▁ex ace rb ations ▁were ▁observe d ▁in ▁this ▁sub group ▁as ▁compared ▁with ▁the ▁overall ▁population ▁ .
▁system ic ▁exposure ▁to ▁ade fo vir ▁was ▁not ▁affected ▁when ▁10 ▁mg ▁ade fo vir ▁di pi vo xil ▁was ▁taken ▁with ▁a ▁high ▁fat ▁meal ▁ .
▁no ▁dos age ▁adjust ment ▁necessary ▁ .
▁for ▁breast ▁ , ▁non - s mall ▁cell ▁lung ▁ , ▁gas tric ▁ , ▁and ▁head ▁and ▁ne ck ▁cancer s ▁ , ▁pre medic ation ▁consist ing ▁of ▁an ▁oral ▁corti co steroid ▁ , ▁such ▁as ▁de xa met has one ▁16 ▁mg ▁per ▁day ▁( ▁e . g ▁ .
▁§ ▁includes ▁reasons ▁such ▁as ▁with dre w ▁consent ▁ , ▁loss ▁to ▁follow - up ▁ , ▁protocol ▁devi ation ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁geno toxic ity ▁and ▁car cino ge nic ▁potential ▁ .
▁the ▁marketing ▁author isation ▁holder ▁( ▁mah ▁) ▁should ▁ensure ▁that ▁ , ▁at ▁launch ▁and ▁there a fter ▁ , ▁all ▁health care ▁professionals ▁who ▁are ▁expected ▁to ▁use ▁and ▁/ ▁or ▁pre scribe ▁cap re lsa ▁are ▁provided ▁with ▁an ▁educational ▁pack ▁ .
▁pri tor plus ▁with ▁food ▁and ▁alcohol
▁to ▁recon stitu te ▁the ▁vaccin e ▁ , ▁use ▁the ▁solve nt ▁provided ▁ .
▁the ▁solution ▁is ▁not ▁disco lou red ▁or ▁cloud y ▁and ▁does ▁not ▁contain ▁any ▁foreign ▁parti cles ▁the ▁solution ▁is ▁not ▁f rozen ▁ .
▁ pharma cok ine tic ▁studies ▁indicate ▁that ▁ime pito in ▁is ▁well ▁absorb ed ▁( ▁> ▁92 ▁% ▁) ▁after ▁oral ▁administration ▁and ▁that ▁no ▁prono un ced ▁first ▁pass ▁effect ▁occur s ▁ .
▁these ▁blood ▁tests ▁will ▁be ▁in ▁addition ▁to ▁the ▁tests ▁which ▁are ▁normal ly ▁done ▁to ▁monitor ▁your ▁ms ▁ .
▁in ▁pup s ▁of ▁mi ce ▁treated ▁with ▁an ▁anti body ▁analog ue ▁of ▁efa liz um ab ▁ , ▁a ▁decrease ▁in ▁t - cell ▁dependent ▁immun ity ▁was ▁observe d ▁up ▁to ▁at ▁least ▁11 ▁weeks ▁of ▁age ▁ .
▁un com mon ▁: ▁ rash ▁and ▁pru ritu s
▁take ▁eli quis ▁as ▁recommended ▁for ▁the ▁following ▁:
▁the ▁effects ▁of ▁fil gra s tim ▁on ▁neutro p enia ▁due ▁to ▁bone ▁mar row ▁infiltra ting ▁infection ▁or ▁malign an cy ▁have ▁not ▁been ▁well ▁established ▁ .
▁resist ance ▁in ▁vi tro ▁: ▁( ▁dolu te grav ir ▁)
▁trans place n tal ▁metas tas es ▁of ▁malign ant ▁melan oma ▁can ▁occur ▁ .
▁a sept ically ▁add ▁steril e ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁ , ▁if ▁needed ▁ , ▁to ▁the ▁radio label led ▁product ▁in ▁the ▁til mano cept ▁powder ▁vi al ▁to ▁bring ▁the ▁volume ▁to ▁the ▁recon stitu ted ▁vi al ▁volume ▁of ▁0.1 25 ▁ml ▁ , ▁ 0.6 25 ▁ml ▁ , ▁or ▁1. 25 ▁ml ▁prior ▁to ▁fill ing ▁the ▁patient ▁dose ▁in ▁sy ringe ▁( ▁s ▁) ▁ .
▁includes ▁patients ▁co - infect ed ▁with ▁human ▁immun o de fici en cy ▁virus ▁( ▁hi v ▁) ▁and ▁patients ▁with ▁re current ▁h c v ▁post - liver ▁transplant ▁( ▁see ▁section ▁4.4 ▁ . ▁) ▁ .
▁results ▁from ▁week ▁54 ▁( ▁ac r 20 ▁ , ▁total ▁van ▁der ▁hei jde - mod ified ▁sharp ▁score ▁and ▁haq ▁) ▁are ▁shown ▁in ▁table ▁3 ▁ .
▁in ▁the ▁prior - nn rti ▁strat um ▁ , ▁response ▁rates ▁were ▁9 8.9 ▁% ▁vs ▁97 . 4 ▁% ▁for ▁a trip la ▁and ▁s br ▁patients ▁respective ly ▁; ▁a ▁difference ▁( ▁95 ▁% ▁ci ▁) ▁of ▁1.4 ▁% ▁( ▁- 4.0 ▁% ▁ , ▁ 6.9 ▁% ▁) ▁] ▁ .
▁diagram s ▁a ▁and ▁b ▁show ▁you ▁all ▁the ▁different ▁parts ▁of ▁the ▁pen ▁and ▁the ▁inject ion ▁need le ▁ .
▁why ▁has ▁o laza x ▁been ▁approved ▁?
▁novom ix ▁50 ▁pen fill ▁is ▁designed ▁to ▁be ▁used ▁with ▁novo ▁nordisk ▁insulin ▁delivery ▁systems ▁and ▁novo fine ▁or ▁novo tw ist ▁need les ▁ .
▁the ▁safety ▁of ▁the ▁veterinar y ▁medicinal ▁product ▁has ▁not ▁been ▁established ▁during ▁pre gna ncy ▁and ▁lac tation ▁ .
▁when ▁turning ▁the ▁dose ▁se lector ▁be ▁care ful ▁not ▁to ▁push ▁the ▁push - ▁button ▁as ▁insulin ▁will ▁come ▁out ▁ .
▁among ▁all ▁random ised ▁patients ▁analyse d ▁according ▁to ▁itt ▁ , ▁primary ▁events ▁occur red ▁in ▁26 9 ▁on ▁ri varo xa ban ▁( ▁2. 12 ▁% ▁per ▁year ▁) ▁and ▁30 6 ▁on ▁war far in ▁( ▁2. 42 ▁% ▁per ▁year ▁) ▁( ▁hr ▁0 . 88 ▁; ▁95 ▁% ▁ci ▁ , ▁0 . 74 ▁- ▁1. 03 ▁; ▁p ▁< ▁0.0 01 ▁for ▁non - in feri or ity ▁; ▁p ▁= ▁0.1 17 ▁for ▁superior ity ▁) ▁ .
▁before ▁each ▁treatment ▁with ▁doce ta xel ▁win thro p ▁ , ▁you ▁will ▁have ▁blood ▁tests ▁to ▁check ▁that ▁you ▁have ▁enough ▁blood ▁cell s ▁and ▁ sufficient ▁ liver ▁function ▁to ▁receive ▁doce ta xel ▁win thro p ▁ .
▁random ized ▁and ▁treated ▁patients
▁un fold ▁and ▁la y ▁flat
▁the ▁user ▁should ▁take ▁the ▁last ▁missed ▁tablet ▁as ▁soon ▁as ▁she ▁remember s ▁ , ▁even ▁if ▁this ▁means ▁taking ▁two ▁tablets ▁at ▁the ▁same ▁time ▁ .
▁your ▁doctor ▁will ▁tell ▁you ▁how ▁much ▁ cina cal cet ▁my lan ▁you ▁must ▁take ▁ .
▁if ▁you ▁have ▁taken ▁too ▁much ▁sebi vo ▁ , ▁or ▁if ▁someone ▁else ▁accident ally ▁takes ▁your ▁tablets ▁ , ▁go ▁to ▁your ▁doctor ▁or ▁hospital ▁for ▁advice ▁straight ▁away ▁ .
▁further more ▁ , ▁ex folia tive ▁skin ▁reaction s ▁are ▁known ▁for ▁di pe pti dy l ▁pep tida se -4 ▁( ▁d pp 4 ▁) ▁inhibi tors ▁ .
▁table ▁3 ▁ef fica cy ▁results ▁( ▁punct ure - free ▁survival ▁and ▁time ▁to ▁first ▁need ▁for ▁ therapeut ic ▁as cite s ▁punct ure ▁) ▁of ▁study ▁i p - rem - ac -01
▁dog s ▁of ▁various ▁breed s ▁ , ▁a ges ▁and ▁weight s ▁were ▁treated ▁with ▁prom eris ▁duo ▁or ▁with ▁other ▁medicine s ▁author ised ▁in ▁the ▁european ▁union ▁( ▁eu ▁) ▁for ▁fle a ▁and ▁ti ck ▁in fest ation ▁ .
▁zo le dro nic ▁acid ▁4 ▁mg ▁was ▁also ▁studie d ▁in ▁a ▁double - blind ▁ , ▁random ised ▁ , ▁place bo - control led ▁trial ▁in ▁228 ▁patients ▁with ▁document ed ▁bone ▁metas tas es ▁from ▁breast ▁cancer ▁to ▁evaluat e ▁the ▁effect ▁of ▁zo le dro nic ▁acid ▁4 ▁mg ▁on ▁the ▁skelet al ▁related ▁event ▁( ▁s re ▁) ▁rate ▁ratio ▁ , ▁calcula ted ▁as ▁the ▁total ▁number ▁of ▁s re ▁events ▁( ▁exclu ding ▁hyper cal ca emia ▁and ▁adjust ed ▁for ▁prior ▁fra c ture ▁) ▁ , ▁divide d ▁by ▁the ▁total ▁risk ▁period ▁ .
▁this ▁may ▁be ▁months ▁from ▁now ▁ .
▁as ▁a ▁result ▁ , ▁it ▁inhibi ts ▁the ▁growth ▁of ▁tum our ▁cell s ▁and ▁eventually ▁kill s ▁them ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁rasi lam lo ▁on ▁14 ▁april ▁2011 ▁ .
▁ma vac ox ib ▁act s ▁by ▁prefer ential ▁inhibi tion ▁of ▁co x -2 - media ted ▁pro stag land in ▁synth es is ▁ .
▁c pm ▁( ▁300 ▁mg ▁/ ▁m 2 ▁ , ▁i v ▁) ▁: ▁days ▁29 -33 ▁mes na ▁i v ▁days ▁29 -33
▁fluid ▁in ▁the ▁li ning ▁of ▁the ▁heart ▁( ▁per ica rdi al ▁ef fusion ▁)
▁ana emia ▁symptoms ▁and ▁se que la e ▁may ▁var y ▁with ▁age ▁ , ▁gender ▁and ▁overall ▁burde n ▁of ▁disease ▁; ▁a ▁physician ▁' s ▁evaluation ▁of ▁the ▁individual ▁patient ▁' s ▁clinic al ▁course ▁and ▁condition ▁is ▁necessary ▁ .
▁when ▁a ▁single ▁125 ▁mg ▁dose ▁of ▁apre pitan t ▁was ▁ad minister ed ▁on ▁day ▁5 ▁of ▁a ▁10- day ▁regime n ▁of ▁400 ▁mg ▁/ ▁day ▁of ▁keto con a zole ▁ , ▁a ▁strong ▁cy p 3 a 4 ▁inhibi tor ▁ , ▁the ▁au c ▁of ▁apre pitan t ▁increased ▁approximately ▁5- fold ▁and ▁the ▁mean ▁terminal ▁half - life ▁of ▁apre pitan t ▁increased ▁approximately ▁3- fold ▁ .
▁damage d ▁nerv es ▁in ▁your ▁skin ▁may ▁occur ▁as ▁a ▁result ▁of ▁a ▁variety ▁of ▁disease s ▁such ▁as ▁ shing les ▁ , ▁hi v ▁infection ▁ , ▁diabetes ▁ , ▁certain ▁medicine s ▁and ▁other ▁conditions ▁ .
▁tek tur na ▁is ▁used ▁to ▁treat ▁essential ▁hyper tension ▁( ▁high ▁blood ▁pressure ▁) ▁ . ▁' ▁essential ▁' ▁means ▁that ▁the ▁hyper tension ▁has ▁no ▁obvious ▁cause ▁ .
▁the ▁risk ▁of ▁hypo gly ca emia ▁in ▁type ▁2 ▁diabet ic ▁patients ▁may ▁be ▁increased ▁by ▁stre nu ous ▁physical ▁exercise ▁ , ▁or ▁in gestion ▁of ▁alcohol ▁ .
▁how ▁to ▁take ▁tel mis ar tan ▁teva
▁ ≤ ▁100 , 000 ▁/ ▁mm 3 . ▁c ▁m cy r ▁combine s ▁both ▁complete ▁( ▁0 ▁% ▁ph ▁+ ▁meta phase s ▁) ▁and ▁parti al ▁( ▁> ▁0 ▁% ▁ -35 ▁% ▁) ▁response s ▁ .
▁refer ▁to ▁the ▁patient ▁le a flet ▁for ▁more ▁detailed ▁instructions ▁for ▁use ▁ .
▁the ▁ diagnos is ▁of ▁l pl d ▁has ▁to ▁be ▁confirm ed ▁by ▁genetic ▁testing ▁ .
▁common ▁side ▁effects ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁: ▁di ar r ho e a ▁ , ▁abdominal ▁pain ▁ , ▁indi gestion ▁or ▁heart burn ▁ .
▁gastro inte stin al ▁ha e mor r hage ▁ , ▁regardless ▁of ▁causa li ty ▁ , ▁was ▁reported ▁in ▁3 ▁% ▁of ▁these ▁patients ▁ .
▁lo xi com ▁contain s ▁melo xi cam ▁ , ▁which ▁be long s ▁to ▁a ▁class ▁of ▁medicine s ▁called ▁non - steroid al ▁anti - ▁infla mma tory ▁drugs ▁( ▁ nsa ids ▁) ▁ .
▁2 ▁advers e ▁reaction ▁observe d ▁with ▁ulu nar ▁bre ezh a ler ▁and ▁at ▁least ▁one ▁of ▁the ▁individual ▁component s ▁ .
▁inject ▁/ ▁inf use ▁the ▁recon stitu ted ▁solution ▁into ▁the ▁ve in ▁following ▁the ▁instructions ▁given ▁to ▁you ▁by ▁your ▁doctor ▁ .
▁this ▁could ▁cause ▁che st ▁pain ▁ , ▁breath less ness ▁ , ▁stroke ▁or ▁heart ▁attack ▁[ ▁see ▁also ▁section ▁2 ▁under ▁" ▁blood ▁clo tting ▁problems ▁( ▁ thro mbo e mbol ic ▁events ▁) ▁" ▁] ▁ .
▁within ▁less ▁than ▁12 ▁hours ▁after ▁regular ▁schedule d ▁time ▁: ▁patients ▁should ▁take ▁the ▁dose ▁immediately ▁and ▁then ▁take ▁the ▁next ▁dose ▁at ▁the ▁regular ▁schedule d ▁time ▁ .
▁these ▁will ▁be ▁done ▁every ▁month ▁for ▁the ▁first ▁4 ▁months ▁of ▁treatment ▁ , ▁then ▁every ▁3 ▁months ▁after ▁that ▁ , ▁as ▁patients ▁taking ▁stay ve er ▁may ▁get ▁ana emia ▁ .
▁a comp lia ▁is ▁not ▁recommended ▁for ▁use ▁in ▁children ▁below ▁age ▁18 ▁due ▁to ▁a ▁lack ▁of ▁data ▁on ▁ef fica cy ▁and ▁safety ▁ .
▁if ▁a ▁ thro mbo phil ic ▁defect ▁is ▁identified ▁which ▁segrega tes ▁with ▁ thro mbo sis ▁in ▁family ▁members ▁or ▁if ▁the ▁defect ▁is ▁' ▁severe ▁' ▁( ▁e . g . ▁ , ▁anti thro mbin ▁ , ▁protein ▁s ▁ , ▁or ▁protein ▁c ▁de fici e ncies ▁or ▁a ▁combination ▁of ▁defect s ▁) ▁hormone ▁ therapy ▁is ▁contra indica ted ▁ .
▁you ▁should ▁take ▁xe lo da ▁no ▁later ▁than ▁30 ▁minutes ▁after ▁meal s ▁ .
▁form ▁a ▁skin ▁ fold ▁by ▁pin ching ▁the ▁skin ▁between ▁thu mb ▁and ▁for e finger ▁ .
▁3 ▁to ▁12 ▁years ▁( ▁n ▁= ▁36 ▁)
▁rano lazi ne ▁ , ▁via ▁its ▁action ▁to ▁decrease ▁the ▁late ▁so dium ▁current ▁ , ▁is ▁considered ▁to ▁reduce ▁these ▁intra cel lular ▁ion ic ▁im balance s ▁during ▁is cha emia ▁ .
▁in ove lon ▁may ▁cause ▁di zzi ness ▁ , ▁som nol ence ▁and ▁blu r red ▁vision ▁ .
▁single ▁im ▁inject ion ▁before ▁surgery ▁ .
▁swe lling ▁ , ▁ inflammation ▁sting ing ▁ , ▁ting ling ▁ble ed ing
▁if ▁you ▁develop ▁sign s ▁or ▁symptoms ▁of ▁ki dne y ▁sto nes ▁( ▁pain ▁in ▁your ▁side ▁ , ▁blood ▁in ▁your ▁urin e ▁ , ▁pain ▁when ▁you ▁urin ate ▁) ▁ , ▁please ▁inform ▁your ▁doctor ▁immediately ▁ .
▁what ▁het li oz ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁prohibi tion ▁of ▁sale ▁ , ▁supply ▁and ▁/ ▁or ▁use
▁for ▁symptom a tic ▁hypo thy roid ism ▁ , ▁nivo lum ab ▁should ▁be ▁with held ▁ , ▁and ▁thy roid ▁hormone ▁replace ment ▁should ▁be ▁initiat ed ▁as ▁needed ▁ .
▁do ▁not ▁put ▁the ▁cap ▁back ▁on ▁because ▁it ▁may ▁damage ▁the ▁need le ▁inside ▁the ▁pre - fill ed ▁pen ▁ .
▁in ▁case ▁of ▁suspect ed ▁over dos e ▁ , ▁tag ris so ▁should ▁be ▁with held ▁and ▁symptom a tic ▁treatment ▁initiat ed ▁ .
▁it ▁should ▁be ▁not ed ▁that ▁patients ▁using ▁beta - block ers ▁do ▁not ▁necessarily ▁respond ▁to ▁the ▁beta - ago nist s ▁usually ▁used ▁for ▁the ▁treatment ▁of ▁hyper sensitiv ity ▁reaction s ▁ .
▁in ▁case ▁of ▁over dos e ▁ , ▁immediately ▁stop ▁the ▁in fusion ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁this ▁test ▁should ▁not ▁affect ▁your ▁ability ▁to ▁drive ▁or ▁use ▁machines ▁ .
▁dyna stat ▁must ▁not ▁be ▁used ▁in ▁patients ▁with ▁severe ▁ liver ▁problems ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁taking ▁me man tine ▁accord
▁nos e ▁ble ed s ▁ , ▁small ▁red ▁or ▁pur ple ▁spot s ▁caused ▁by ▁ble ed ing ▁under ▁the ▁skin
▁if ▁you ▁have ▁something ▁called ▁" ▁ec lamp sia ▁" ▁which ▁is ▁similar ▁to ▁" ▁severe ▁pre - ec lamp sia ▁" ▁but ▁you ▁would ▁also ▁have ▁fit s ▁( ▁convuls ions ▁) ▁ .
▁advers e ▁reaction s ▁from ▁phase ▁i ii ▁studies ▁during ▁the ▁entire ▁treatment ▁period s
▁if ▁you ▁are ▁allergi c ▁to ▁iba ndro nic ▁acid ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁that ▁are ▁listed ▁in ▁section ▁6 ▁if ▁you ▁have ▁ , ▁or ▁have ▁ever ▁had ▁low ▁levels ▁of ▁calci um ▁in ▁your ▁blood ▁ .
▁oral ▁studies ▁in ▁pregnant ▁rat s ▁and ▁rabbi ts ▁gave ▁no ▁indica tion ▁of ▁ter ato ge nic ▁potential ▁on ▁the ▁part ▁of ▁ri va stig mine ▁ .
▁50 ▁x ▁1 ▁tablets ▁( ▁unit ▁dose ▁)
▁like ▁all ▁medicine s ▁ , ▁this ▁medicine ▁can ▁cause ▁side ▁effects ▁ , ▁but ▁not ▁everyone ▁gets ▁them ▁ .
▁in ▁very ▁rare ▁cases ▁ , ▁a ▁brief ▁period ▁of ▁hyper sa liv ation ▁may ▁occur ▁if ▁the ▁animal ▁li cks ▁the ▁application ▁site ▁immediately ▁after ▁treatment ▁ .
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁sti var ga ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁cerebro vas cular ▁accident ▁ , ▁arteri os cle rosi s ▁ , ▁ray na ud ▁' s ▁ phen ome non ▁ , ▁live do ▁reti cular is ▁ , ▁te lang i ecta sia
▁ki dne y ▁problems ▁ , ▁including ▁ki dne y ▁failure ▁or ▁if ▁you ▁have ▁ever ▁received ▁di al ysis
▁if ▁you ▁are ▁breast - feed ing ▁or ▁planning ▁to ▁breast - feed ▁ , ▁ask ▁your ▁doctor ▁or ▁ pharma ci st ▁for ▁advice ▁before ▁taking ▁this ▁medicine ▁because ▁it ▁might ▁har m ▁your ▁baby ▁ .
▁your ▁doctor ▁will ▁take ▁a ▁blood ▁sample ▁to ▁test ▁how ▁well ▁your ▁ liver ▁is ▁working ▁( ▁your ▁ liver ▁function ▁) ▁ .
▁changes ▁in ▁blood ▁test ▁results ▁for ▁ liver ▁ , ▁ki dne y ▁ , ▁white ▁blood ▁cell s ▁( ▁low ▁) ▁ , ▁blood ▁so dium ▁and ▁magnesium ▁( ▁low ▁) ▁ , ▁cholesterol ▁( ▁high ▁) ▁and ▁thy roid ▁stimula ting ▁hormone ▁( ▁high ▁) ▁changes ▁in ▁blood ▁test ▁results ▁for ▁ki dne y ▁function ▁and ▁ki dne y ▁failure
▁following ▁the ▁administration ▁of ▁a ▁double ▁dose ▁of ▁vaccin e ▁ , ▁no ▁side - effect s ▁other ▁than ▁those ▁described ▁under ▁section ▁ 4.6 ▁have ▁been ▁observe d ▁ .
▁reproduc tion ▁studies ▁have ▁been ▁conduct ed ▁in ▁cyn om ol gus ▁mon key s ▁at ▁dos es ▁up ▁to ▁25 ▁times ▁that ▁of ▁the ▁week ly ▁human ▁maintenance ▁dose ▁of ▁2 ▁mg ▁/ ▁kg ▁her cept in ▁intra ven ous ▁formula tion ▁and ▁have ▁reveal ed ▁no ▁evidence ▁of ▁im pair ed ▁fertil ity ▁or ▁har m ▁to ▁the ▁fet us ▁ .
▁her 2 ▁is ▁found ▁in ▁large ▁amount s ▁on ▁the ▁surface ▁of ▁some ▁cancer ▁cell s ▁where ▁it ▁stimula tes ▁their ▁growth ▁ .
▁y entre ve ▁is ▁indicate d ▁in ▁adults ▁ .
▁a ▁very ▁rare ▁side ▁effect ▁that ▁may ▁show ▁up ▁in ▁blood ▁tests ▁is ▁: ▁a ▁failure ▁of ▁the ▁bone ▁mar row ▁to ▁produce ▁new ▁red ▁blood ▁cell s ▁( ▁pure ▁red ▁cell ▁a plas ia ▁) ▁ .
▁women ▁must ▁use ▁effective ▁contra ception ▁during ▁treatment ▁with ▁armi s arte ▁ .
▁this ▁vaccin e ▁contain s ▁trace ▁residu es ▁of ▁gent ami cin ▁and ▁ben zona se ▁ .
▁i clusi g ▁may ▁be ▁ad minister ed ▁with ▁or ▁without ▁food ▁ .
▁if ▁a ▁person ▁accident ally ▁takes ▁the ▁medicine ▁ , ▁se ek ▁medical ▁advice ▁immediately ▁and ▁show ▁the ▁package ▁le a flet ▁or ▁the ▁label ▁to ▁a ▁doctor ▁ .
▁children ▁and ▁adolescents ▁up ▁to ▁18 ▁years ▁of ▁age ▁who ▁we igh ▁at ▁least ▁33 ▁kg ▁and ▁who ▁are ▁able ▁to ▁swa llow ▁hard ▁capsule s ▁: ▁one ▁200 ▁mg ▁hard ▁capsule ▁ , ▁each ▁day ▁with ▁or ▁without ▁food ▁ .
▁very ▁common ▁side ▁effects ▁( ▁may ▁affect ▁more ▁than ▁1 ▁in ▁10 ▁people ▁) ▁include ▁weight ▁gain ▁; ▁sleep ines s ▁; ▁and ▁increase s ▁in ▁levels ▁of ▁pro lac tin ▁in ▁the ▁blood ▁ .
▁therefore ▁ , ▁it ▁is ▁recommended ▁that ▁cau tion ▁should ▁be ▁exercise d ▁if ▁ne vana c ▁is ▁ad minister ed ▁con com i tant ly ▁with ▁corti co steroid s ▁ , ▁particularly ▁in ▁patients ▁at ▁high ▁risk ▁for ▁cor ne al ▁advers e ▁reaction s ▁described ▁below ▁ .
▁patients ▁with ▁renal ▁or ▁he pati c ▁im pair ment
▁patients ▁previously ▁treated ▁with ▁imi glu cera se ▁received ▁a ▁media n ▁of ▁8 ▁ve lag lu cera se ▁alfa ▁in fusion s ▁with ▁media n ▁du ration ▁of ▁treatment ▁of ▁15. 1 ▁weeks ▁ .
▁in ▁meta static ▁colore c tal ▁cancer ▁ , ▁xe lo da ▁taken ▁on ▁its ▁own ▁has ▁been ▁compared ▁with ▁the ▁combination ▁of ▁5- ▁fu ▁and ▁foli nic ▁acid ▁in ▁two ▁studies ▁in vol ving ▁1,2 07 ▁patients ▁ .
▁other ▁information ▁about ▁sil den a fil ▁act avis
▁do ▁not ▁free ze ▁ , ▁to ▁prevent ▁damage ▁to ▁the ▁solve nt ▁vi al ▁ .
▁other ▁psychiatr ic ▁conditions ▁for ▁which ▁du lo xe tine ▁is ▁pre scribe d ▁can ▁also ▁be ▁associated ▁with ▁an ▁increased ▁risk ▁of ▁suicide - related ▁events ▁ .
▁the ▁trud ex a ▁vi al ▁is ▁a ▁glass ▁vi al ▁contain ing ▁a ▁solution ▁of ▁ada lim um ab ▁ .
▁within ▁each ▁fre que ncy ▁group ing ▁ , ▁advers e ▁reaction s ▁are ▁presente d ▁in ▁order ▁of ▁de cre as ing ▁serious ness ▁ .
▁not ▁all ▁pack ▁size s ▁may ▁be ▁market ed ▁ .
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁zosta va x ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁at ▁least ▁once ▁a ▁year ▁in ▁patients ▁with ▁normal ▁renal ▁function ▁at ▁least ▁two ▁to ▁four ▁times ▁a ▁year ▁in ▁patients ▁with ▁se rum ▁creati nine ▁levels ▁at ▁the ▁upp er ▁limit ▁of ▁normal ▁and ▁in ▁el der ly ▁patients ▁ .
▁" ▁how ▁to ▁use ▁venta vis ▁" ▁) ▁ .
▁kry ste xx a ▁contain s ▁an ▁enzym e ▁called ▁uri case ▁that ▁transform s ▁the ▁u ric ▁acid ▁into ▁a ▁substance ▁called ▁allan to in ▁ , ▁which ▁can ▁be ▁removed ▁easily ▁in ▁the ▁urin e ▁ .
▁twenty ▁procedure s ▁were ▁major ▁including ▁13 ▁or tho pa e dic ▁and ▁3 ▁dental ▁surge ries ▁ .
▁di zzi ness ▁ , ▁head ache ▁ , ▁psycho motor ▁hyper activ ity
▁treatment ▁of ▁children ▁2 ▁years ▁and ▁above ▁( ▁especially ▁in ▁those ▁in ▁the ▁2 -7 ▁age ▁range ▁and ▁/ ▁or ▁we igh ing ▁< ▁20 ▁kg ▁) ▁is ▁not ▁recommended ▁because ▁of ▁the ▁potential ▁for ▁central ▁ner vous ▁system - related ▁side ▁effects ▁( ▁see ▁section ▁ 4.9 ▁) ▁ .
▁system ic ▁lup us ▁er y thema tos us ▁ , ▁va scul itis ▁ , ▁rhe um ato id ▁ar thri tis ▁( ▁new ▁or ▁ag grav ated ▁) ▁ , ▁vo gt - ko yana gi - hara da ▁syndrome ▁ , ▁a cute ▁hyper sensitiv ity ▁reaction s ▁including ▁ur tica ria ▁ , ▁ang io ede ma ▁ , ▁bron cho con stri ction ▁ , ▁ana phy la xis ▁§
▁ ↓ ▁c max ▁0.5 7 ▁( ▁0 . 44 ▁ , ▁0 . 75 ▁)
▁the ▁content ▁of ▁one ▁tube ▁cover s ▁a ▁treatment ▁area ▁of ▁25 ▁cm 2 ▁ .
▁if ▁you ▁take ▁more ▁traz ec ▁than ▁you ▁should
▁brin a ves s ▁20 ▁mg ▁/ ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁ver na kalan t ▁hydro ch lor ide
▁you ▁can ▁also ▁report ▁side ▁effects ▁directly ▁via ▁the ▁national ▁report ing ▁system ▁listed ▁in ▁appen di x ▁v . ▁by ▁report ing ▁side ▁effects ▁you ▁can ▁help ▁provide ▁more ▁information ▁on ▁the ▁safety ▁of ▁this ▁medicine ▁ .
▁vitamin ▁d 3 ▁may ▁increase ▁the ▁magnitud e ▁of ▁hyper cal ca emia ▁and ▁/ ▁or ▁hyper cal ci uria ▁when ▁ad minister ed ▁to ▁patients ▁with ▁disease ▁associated ▁with ▁un regula ted ▁over product ion ▁of ▁calci tri ol ▁( ▁e . g . ▁leuk a emia ▁ , ▁lymph oma ▁ , ▁sar co idos is ▁) ▁ .
▁ existence ▁of ▁ , ▁or ▁history ▁of ▁severe ▁psychiatr ic ▁condition ▁ , ▁particularly ▁severe ▁depression ▁ , ▁suicida l ▁idea tion ▁ , ▁or ▁suicide ▁attempt ▁ .
▁response ▁rates ▁are ▁presente d ▁in ▁table ▁10 ▁ .
▁in ▁follow - up ▁visit s ▁at ▁3 ▁months ▁and ▁12 ▁months ▁after ▁the ▁day ▁of ▁surgery ▁or ▁of ▁burn ▁injury ▁the ▁treated ▁wo und ▁halve s ▁were ▁found ▁to ▁be ▁equal ▁in ▁the ▁majority ▁of ▁patients ▁with ▁regard ▁to ▁pigment ation ▁ , ▁red ness ▁ , ▁texture ▁and ▁hair ▁growth ▁of ▁the ▁regenera ted ▁epi der mis ▁ .
▁what ▁li pro log ▁bas al ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁can cidas ▁contain s ▁no ▁preserva tives ▁ .
▁these ▁anti bo dies ▁may ▁induc e ▁clinic al ▁allergi c ▁reaction s ▁ , ▁in activa te ▁the ▁en zy matic ▁activity ▁or ▁accelerat e ▁the ▁elimina tion ▁of ▁as para gina se ▁ .
▁final ▁study ▁report ▁- ▁by ▁q 2 ▁2022 ▁ .
▁ enza lut ami de ▁is ▁poor ly ▁water ▁solu ble ▁ .
▁very ▁rare ▁side ▁effects ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10,000 ▁people ▁) ▁include ▁: ▁severe ▁skin ▁reaction ▁such ▁as ▁skin ▁ rash ▁ , ▁ul ce ration ▁and ▁bli s tering ▁which ▁may ▁involve ▁ul cer s ▁of ▁the ▁mouth ▁ , ▁nos e ▁ , ▁genital ia ▁ , ▁hands ▁ , ▁feet ▁and ▁eyes ▁( ▁red ▁and ▁swo llen ▁eyes ▁) ▁ .
▁combination ▁of ▁ata zana vir ▁with ▁or ▁without ▁rito na vir ▁and ▁cri xi van ▁are ▁not ▁recommended ▁due ▁to ▁increased ▁risk ▁of ▁hyper bili rub in emia ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁in ▁one ▁main ▁study ▁ , ▁65 ▁% ▁of ▁patients ▁given ▁de x dor ▁maintain ed ▁the ▁required ▁level ▁of ▁sed ation ▁compared ▁with ▁65 ▁% ▁of ▁those ▁receiving ▁propo fol ▁ .
▁ hla - b ▁* ▁5 701 ▁status ▁must ▁always ▁be ▁document ed ▁prior ▁to ▁initiat ing ▁ therapy ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁are ▁given ▁my oce t
▁you ▁do ▁not ▁need ▁to ▁prepare ▁revi nty ▁el lip ta ▁in ▁any ▁special ▁way ▁ , ▁not ▁even ▁the ▁first ▁time ▁you ▁use ▁it ▁ .
▁when ▁i pre ziv ▁was ▁co ad minister ed ▁with ▁chlor tali done ▁ , ▁the ▁fre que ncies ▁of ▁blood ▁creati nine ▁increased ▁and ▁hypo tension ▁were ▁increased ▁from ▁un com mon ▁to ▁common ▁ .
▁oral ly ▁ad minister ed ▁bis phos phon ates ▁may ▁cause ▁local ▁irrita tion ▁of ▁the ▁upp er ▁gastro inte stin al ▁mu cosa ▁ .
▁the ▁body ▁is ▁im print ed ▁with ▁" ▁5 ▁mg ▁ , ▁" ▁the ▁sch ering - pl ough ▁logo ▁and ▁two ▁strip es ▁ .
▁excessive ▁gluco cor tico id ▁ therapy ▁will ▁inhibi t ▁the ▁growth - promo ting ▁effect ▁of ▁h gh ▁ .
▁this ▁medicinal ▁product ▁contain s ▁0.0 14 ▁mm ol ▁so dium ▁( ▁0.3 22 ▁mg ▁) ▁per ▁pre - fill ed ▁sy ringe ▁ , ▁i . e . ▁essential ly ▁' ▁so dium - ▁free ▁' ▁ .
▁feeling ▁or ▁being ▁very ▁sick
▁op atan ol ▁contain s ▁ben zal kon ium ▁chlor ide ▁which ▁may ▁cause ▁eye ▁irrita tion ▁ .
▁withdraw ▁the ▁sy ringe ▁and ▁disc ard ▁it ▁ .
▁cy mbal ta ▁60 ▁mg ▁is ▁available ▁in ▁pack s ▁of ▁28 ▁ , ▁56 ▁ , ▁84 ▁ , ▁98 ▁ , ▁100 ▁( ▁each ▁pack ▁contain s ▁5 ▁carton s ▁of ▁20 ▁capsule s ▁) ▁and ▁500 ▁capsule s ▁( ▁each ▁pack ▁contain s ▁25 ▁carton s ▁of ▁20 ▁capsule s ▁) ▁ .
▁open ▁the ▁mix 2 vi al ▁package ▁by ▁peeling ▁off ▁the ▁lid ▁ .
▁changes ▁in ▁tests ▁which ▁measure ▁how ▁well ▁your ▁blood ▁clo ts ▁ .
▁if ▁con com i tant ▁ therapy ▁with ▁la mi vu dine ▁/ ▁zid ovu dine ▁teva ▁and ▁any ▁of ▁these ▁medicinal ▁products ▁is ▁necessary ▁then ▁extra ▁care ▁should ▁be ▁taken ▁in ▁monitoring ▁renal ▁function ▁and ▁ha e mat ological ▁parameter s ▁and ▁ , ▁if ▁required ▁ , ▁the ▁dos age ▁of ▁one ▁or ▁more ▁agents ▁should ▁be ▁reduce d ▁ .
▁powder ▁for ▁solution ▁for ▁in fusion ▁1 ▁vi al
▁the ▁main ▁safety ▁issues ▁were ▁considered ▁manage able ▁and ▁adequat ely ▁address ed ▁by ▁risk ▁minim isation ▁measure s ▁ .
▁all ▁patients ▁received ▁riba vir in ▁( ▁1000 ▁or ▁1200 ▁mg ▁/ ▁day ▁) ▁in ▁combination ▁with ▁pe ga sys ▁ .
▁reference ▁guide ▁- ▁read ▁all ▁instructions ▁found ▁in ▁the ▁carton ▁before ▁use
▁you ▁have ▁had ▁an ▁allergi c ▁reaction ▁to ▁other ▁a zole s . ▁you ▁are ▁suffering ▁from ▁ , ▁or ▁have ▁ever ▁suffer ed ▁from ▁ liver ▁disease ▁ .
▁pa e dia tric ▁ul cer ative ▁col itis ▁patients
▁close ▁monitoring ▁of ▁ liver ▁enzym es ▁should ▁be ▁considered ▁if ▁the ▁two ▁medicinal ▁products ▁are ▁used ▁con com i tant ly ▁ .
▁di fic lir ▁is ▁used ▁in ▁adults ▁to ▁treat ▁infection s ▁of ▁the ▁li ning ▁of ▁the ▁colon ▁( ▁large ▁inte s tine ▁) ▁with ▁certain ▁bacteria ▁called ▁clo stri dium ▁difficile ▁ .
▁the ▁vaccin ated ▁ki tten s ▁were ▁house d ▁for ▁up ▁to ▁28 ▁weeks ▁with ▁a ▁group ▁of ▁ki tten s ▁who ▁were ▁infect ed ▁with ▁fel v ▁ .
▁common ▁hepatitis ▁( ▁including ▁severe ▁and ▁life - th rea te ning ▁he pato toxic ity ▁) ▁( ▁1.9 ▁% ▁) ▁un com mon ▁ja undi ce
▁immun e ▁response s ▁as ▁measure d ▁by ▁i gg ▁g m cs ▁were ▁assess ed ▁in ▁168 -21 1 ▁ evalua ble ▁subject s ▁approximately ▁1 ▁month ▁after ▁vaccin ation ▁ .
▁the ▁date ▁should ▁be ▁added ▁as ▁soon ▁as ▁the ▁in hal er ▁has ▁been ▁removed ▁from ▁the ▁tra y ▁ .
▁mus culos kelet al ▁and ▁connect ive ▁tissu e ▁disorder s
▁multi pack ▁500 ml ▁ , ▁compris ing ▁10 ▁pack s ▁ , ▁each ▁contain ing ▁1 ▁bottle ▁with ▁50 ▁ml ▁oral ▁solution ▁ .
▁az oo sper mia ▁has ▁been ▁reported ▁in ▁male ▁cyst inos is ▁patients ▁ .
▁detailed ▁information ▁on ▁this ▁medicine ▁is ▁available ▁on ▁the ▁european ▁medicine s ▁agency ▁web ▁site ▁: ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁ .
▁concentration s ▁may ▁be ▁decrease d ▁ .
▁alternative ▁combination s ▁that ▁do ▁not ▁include ▁these ▁metabol ic ▁induc ers ▁should ▁be ▁used ▁where ▁possible ▁in ▁ini - re si stant ▁patients ▁ .
▁stop ▁taking ▁jina rc ▁and ▁immediately ▁contact ▁a ▁doctor ▁or ▁go ▁to ▁the ▁near est ▁hospital ▁if ▁you ▁:
▁in ▁both ▁studies ▁ , ▁du lo xe tine ▁li lly ▁60 ▁mg ▁once ▁daily ▁and ▁60 ▁mg ▁twice ▁daily ▁significantly ▁reduce d ▁pain ▁compared ▁with ▁place bo ▁ .
▁if ▁you ▁cannot ▁see ▁the ▁expira tion ▁date ▁through ▁the ▁view ing ▁window ▁ , ▁hold ▁the ▁pre - fill ed ▁sy ringe ▁by ▁its ▁body ▁and ▁rota te ▁the ▁need le ▁cover ▁to ▁line ▁up ▁the ▁expira tion ▁date ▁to ▁the ▁view ing ▁window ▁ .
▁as ▁with ▁other ▁large ▁protein s ▁elimina tion ▁of ▁ri lona cept ▁is ▁expected ▁to ▁be ▁via ▁prote oly tic ▁cata bol ism ▁and ▁target ▁media ted ▁clear ance ▁ .
▁it ▁is ▁not ▁yet ▁established ▁whether ▁or ▁not ▁treatment ▁with ▁go nado trop ins ▁increase s ▁the ▁risk ▁of ▁these ▁tu mo urs ▁in ▁infer tile ▁women ▁ .
▁it ▁may ▁have ▁been ▁accident ally ▁f rozen ▁ .
▁the ▁gre y ▁sy ringe ▁plu nger ▁should ▁be ▁push ed ▁all ▁the ▁way ▁to ▁the ▁need le ▁end ▁of ▁the ▁sy ringe ▁ .
▁ca ttle ▁( ▁dair y ▁co ws ▁and ▁hei fers ▁)
▁insu man ▁in fus at ▁must ▁only ▁be ▁used ▁if ▁the ▁solution ▁is ▁clear ▁ , ▁colour less ▁ , ▁with ▁no ▁solid ▁parti cles ▁visible ▁ , ▁and ▁if ▁it ▁is ▁of ▁a ▁water - like ▁consiste ncy ▁ .
▁zo le dro nic ▁acid ▁my lan ▁can ▁be ▁used ▁to ▁prevent ▁bone ▁complica tions ▁in ▁adults ▁with ▁advanced ▁cancer ▁that ▁is ▁affect ing ▁the ▁bone ▁ .
▁neu pop eg ▁is ▁used ▁to ▁reduce ▁the ▁du ration ▁of ▁neutro p enia ▁( ▁low ▁white ▁blood ▁cell ▁count ▁) ▁and ▁the ▁occur r ence ▁of ▁febr ile ▁neutro p enia ▁( ▁low ▁white ▁blood ▁cell ▁count ▁with ▁a ▁fe ver ▁) ▁which ▁can ▁be ▁caused ▁by ▁the ▁use ▁of ▁cy to toxic ▁che mo therapy ▁( ▁medicine s ▁that ▁destroy ▁rapid ly ▁growing ▁cell s ▁) ▁ .
▁for ▁the ▁full ▁list ▁of ▁all ▁side ▁effects ▁reported ▁with ▁kar ve a ▁ , ▁see ▁the ▁package ▁le a flet ▁ .
▁( ▁rare ▁- ▁may ▁affect ▁up ▁to ▁1 ▁in ▁1,000 ▁people ▁)
▁you ▁may ▁also ▁notice ▁other ▁effects ▁not ▁listed ▁here ▁ .
▁ ks ▁= ▁0 . 45 ▁in ▁term ▁infants ▁to ▁1 ▁year ▁old ▁; ▁ ks ▁= ▁0.5 5 ▁in ▁children ▁to ▁less ▁than ▁13 ▁years ▁and ▁in ▁ adolescent ▁female ▁; ▁ ks ▁= ▁ 0.7 ▁in ▁ adolescent ▁male
▁if ▁this ▁occur s ▁ , ▁turn ▁the ▁vi al ▁up right ▁and ▁pull ▁the ▁pis ton ▁up ▁the ▁sy ringe ▁barre l ▁ .
▁if ▁you ▁experience ▁any ▁of ▁these ▁ , ▁talk ▁to ▁your ▁doctor ▁as ▁soon ▁as ▁possible ▁ .
▁interaction s ▁with ▁other ▁drug ▁types ▁were ▁not ▁specifically ▁investiga ted ▁ .
▁why ▁is ▁trans larna ▁approved ▁?
▁response s ▁were ▁observe d ▁at ▁the ▁first ▁assessment ▁( ▁week ▁4 ▁) ▁after ▁the ▁initial ▁si mpon i ▁administration ▁ .
▁if ▁treatment ▁with ▁an ▁h mg - co a ▁reduc tase ▁inhibi tor ▁is ▁indicate d ▁ , ▁flu vasta tin ▁or ▁prava stat in ▁is ▁recommended ▁ .
▁when ▁ ritu xim ab ▁is ▁used ▁in ▁combination ▁with ▁vel cade ▁ , ▁ hb v ▁screening ▁must ▁always ▁be ▁perform ed ▁in ▁patients ▁at ▁risk ▁of ▁infection ▁with ▁ hb v ▁before ▁initiat ion ▁of ▁treatment ▁ .
▁treatment - corre cted ▁change ▁from ▁base line ▁in ▁h ba 1 c ▁( ▁% ▁) ▁† ▁( ▁1- side d ▁ci ▁)
▁the ▁clinic ally ▁relevant ▁advers e ▁reaction s ▁observe d ▁in ▁four ▁major ▁studies ▁ , ▁the ▁capri e ▁study ▁( ▁a ▁study ▁compar ing ▁clo pido gre l ▁alone ▁to ▁asa ▁) ▁and ▁the ▁cure ▁ , ▁clar ity ▁and ▁com mit ▁studies ▁( ▁studies ▁compar ing ▁clo pido gre l ▁plus ▁asa ▁to ▁asa ▁alone ▁) ▁are ▁discuss ed ▁below ▁ .
▁what ▁do ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁fos avance
▁rota rix ▁oral ▁suspens ion ▁in ▁pre - fill ed ▁oral ▁applica tor ▁rota virus ▁vaccin e ▁ , ▁live
▁very ▁rare ▁ drow si ness ▁ , ▁ insomni a ▁ , ▁fa in ting ▁ , ▁reduce d ▁sense ▁of ▁taste
▁patients ▁of ▁4 ▁years ▁and ▁older ▁un able ▁to ▁swa llow ▁a genera se ▁capsule s ▁: ▁the ▁recommended ▁dose ▁of ▁a genera se ▁oral ▁solution ▁is ▁17 ▁mg ▁( ▁1.1 ▁ml ▁) ▁/ ▁kg ▁three ▁times ▁a ▁day ▁ , ▁in ▁combination ▁with ▁other ▁anti ret rovi ral ▁agents ▁ , ▁without ▁exceed ing ▁a ▁total ▁daily ▁dose ▁of ▁2 800 ▁mg ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁special ▁precau tions ▁for ▁disposa l
▁preparation ▁of ▁the ▁1 ▁mg ▁vi al ▁: ▁add ▁1.0 ▁ml ▁of ▁steril e ▁ , ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁so dium ▁chlor ide ▁solution ▁for ▁inject ion ▁to ▁the ▁vi al ▁contain ing ▁the ▁vel cade ▁powder ▁ .
▁three ▁dog s ▁had ▁se iz ure - like ▁activity ▁; ▁however ▁ , ▁relation ▁to ▁treatment ▁could ▁not ▁be ▁established ▁ .
▁record ▁the ▁treatment ▁day ▁number ▁( ▁1 ▁) ▁ , ▁date ▁( ▁2 ▁) ▁and ▁time ▁( ▁3 ▁) ▁of ▁your ▁inject ion ▁ .
▁diagnostic ▁tools ▁designed ▁to ▁detect ▁le ish mania ▁anti bo dies ▁( ▁sla ▁or ▁i fat ▁or ▁ rk - 39 ▁rapid ▁diagnostic ▁tests ▁) ▁should ▁be ▁suitable ▁to ▁en able ▁discrimina tion ▁between ▁dog s ▁vaccin ated ▁with ▁this ▁vaccin e ▁and ▁dog s ▁infect ed ▁with ▁le ish mania ▁infant um ▁ .
▁location ▁of ▁primary ▁les ion ▁ , ▁n ▁( ▁% ▁) ▁stomach
▁in ly ta ▁3 ▁mg ▁film - co ated ▁tablet
▁if ▁you ▁have ▁ liver ▁problems
▁your ▁doctor ▁may ▁continue ▁to ▁give ▁you ▁du lo xe tine ▁li lly ▁when ▁you ▁are ▁feeling ▁better ▁to ▁prevent ▁your ▁depression ▁or ▁anxiety ▁from ▁return ing
▁tablet ▁coa ting ▁: ▁la ctos e ▁mono hydrat e ▁( ▁see ▁section ▁2 ▁' ▁duo pla vin ▁contain s ▁la ctos e ▁' ▁) ▁ , ▁hy pro mel lose ▁( ▁e 464 ▁) ▁ , ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁ , ▁tri ace tin ▁( ▁e 15 18 ▁) ▁ , ▁red ▁ir on ▁oxid e ▁( ▁e 172 ▁)
▁apply ▁topic al ▁ana e sthetic ▁to ▁treatment ▁area ▁ .
▁for ▁the ▁full ▁list ▁of ▁all ▁side ▁effects ▁reported ▁with ▁rem s ima ▁ , ▁see ▁the ▁package ▁le a flet ▁ .
▁if ▁you ▁have ▁a ▁history ▁of ▁irregular ▁heart ▁beat ▁( ▁at rial ▁fi bril lation ▁) ▁or ▁severe ▁heart ▁failure ▁ , ▁which ▁makes ▁you ▁short ▁of ▁breath ▁and ▁may ▁lead ▁to ▁swo llen ▁leg s
▁submit ▁the ▁final ▁study ▁report ▁from ▁the ▁mari anne ▁study ▁once ▁available
▁among ▁these ▁conditions ▁are ▁b k ▁virus - as soci ated ▁nep hro pathy ▁and ▁j c ▁virus - as soci ated ▁progressive ▁multi fo cal ▁leuk o ence pha lo pathy ▁( ▁pm l ▁) ▁ .
▁the ▁measure s ▁taken ▁are ▁considered ▁effective ▁for ▁envelop ed ▁virus es ▁such ▁as ▁human ▁immun o de fici en cy ▁virus ▁( ▁hi v ▁ , ▁the ▁aid s ▁virus ▁) ▁ , ▁hepatitis ▁b ▁virus ▁and ▁hepatitis ▁c ▁virus ▁( ▁ liver ▁ inflammation ▁) ▁ , ▁and ▁for ▁the ▁non - en velo ped ▁hepatitis ▁a ▁virus ▁and ▁par vo virus ▁b 19 ▁ .
▁vaccin es ▁work ▁by ▁' ▁teaching ▁' ▁the ▁immun e ▁system ▁( ▁the ▁body ▁' s ▁natural ▁de f ences ▁) ▁how ▁to ▁defend ▁itself ▁against ▁a ▁disease ▁ .
▁tel mis ar tan ▁teva ▁ pharma ▁20 ▁mg ▁tablets ▁are ▁white ▁to ▁off ▁white ▁ , ▁ oval ▁shape d ▁tablets ▁; ▁one ▁side ▁of ▁the ▁tablet ▁is ▁de bos sed ▁with ▁the ▁number ▁" ▁93 ▁ . ▁"
▁mean ▁3- n - ace tyl ▁ami fam pri dine ▁ pk ▁parameter s
▁each ▁tablet ▁contain s ▁ 297 ▁mg ▁la ctos e ▁ .
▁re duction ▁in ▁blood ▁cell ▁count s ▁( ▁plate let s ▁ , ▁red ▁and ▁/ ▁or ▁white ▁blood ▁cell s ▁) ▁ , ▁increased ▁white ▁blood ▁cell s
▁each ▁0.5 ▁ml ▁cep lene ▁dose ▁is ▁inject ed ▁slowly ▁ , ▁over ▁5 -15 ▁minutes ▁ .
▁carton s ▁contain ▁56 ▁film - co ated ▁tablets ▁ .
▁these ▁decrease s ▁in ▁blood ▁pressure ▁are ▁consistent ▁with ▁the ▁vaso dila tory ▁effects ▁of ▁sil den a fil ▁ , ▁probably ▁due ▁to ▁increased ▁c g mp ▁levels ▁in ▁vas cular ▁smooth ▁muscle ▁ .
▁this ▁change ▁is ▁not ▁expected ▁to ▁have ▁clinic al ▁consequences ▁ .
▁ps oria tic ▁ar thri tis ▁in ▁patients ▁from ▁the ▁age ▁of ▁12 ▁years
▁pen ile ▁model ing ▁helps ▁reli eve ▁curva ture ▁de form ity ▁and ▁straight en ▁the ▁pen ile ▁s haft ▁ .
▁the ▁predict ivit y ▁of ▁the ▁finding s ▁for ▁humans ▁is ▁not ▁known ▁ .
▁if ▁you ▁accident ally ▁take ▁too ▁much ▁tri zi vir ▁ , ▁tell ▁your ▁doctor ▁or ▁your ▁ pharma ci st ▁ , ▁or ▁contact ▁your ▁near est ▁hospital ▁emergency ▁department ▁for ▁further ▁advice ▁ .
▁do ▁not ▁use ▁for ▁more ▁than ▁5 ▁days ▁after ▁first ▁use ▁( ▁either ▁primi ng ▁or ▁using ▁to ▁treat ▁a ▁break through ▁pain ▁episode ▁) ▁ .
▁the ▁vi al ▁deliver s ▁1.2 ▁ml ▁( ▁150 ▁mg ▁) ▁of ▁xo la ir ▁ .
▁remove ▁the ▁empty ▁pen ▁from ▁the ▁skin ▁ .
▁con verse ly ▁ , ▁it ▁is ▁anticipat ed ▁that ▁pro kin e tic ▁substance s ▁such ▁as ▁ci sa pri de ▁may ▁decrease ▁the ▁bio ava il ability ▁of ▁thi azi de - type ▁di ure tics ▁ .
▁there ▁is ▁no ▁relevant ▁use ▁of ▁bon vi va ▁in ▁children ▁below ▁18 ▁years ▁ , ▁and ▁bon vi va ▁was ▁not ▁studie d ▁in ▁this ▁population ▁( ▁see ▁section ▁5.1 ▁and ▁5.2 ▁) ▁ .
▁in ▁another ▁open - label ▁ pharma cok ine tic ▁study ▁ , ▁19 ▁hi v - infect ed ▁pregnant ▁women ▁received ▁lo pina vir ▁/ ▁rito na vir ▁400 ▁/ ▁100 ▁mg ▁twice ▁daily ▁as ▁part ▁of ▁combination ▁anti ret rovi ral ▁ therapy ▁during ▁pre gna ncy ▁from ▁before ▁conception ▁ .
▁chronic ▁hepatitis ▁b ▁- ▁adult ▁patients
▁the ▁usual ▁dose ▁is ▁between ▁0.5 ▁and ▁1.0 ▁u ▁per ▁kilogram ▁body ▁weight ▁per ▁day ▁ .
▁over dos e ▁with ▁hydro ch lor o thi azi de ▁is ▁associated ▁with ▁electro ly te ▁de ple tion ▁( ▁hypo kala emia ▁ , ▁hypo ch lor a emia ▁ , ▁hypo na tra emia ▁) ▁and ▁de hydrat ion ▁result ing ▁from ▁excessive ▁di ures is ▁ .
▁om e pra zole ▁40 ▁mg ▁q d
▁what ▁benefits ▁of ▁stri bild ▁have ▁been ▁shown ▁in ▁studies ▁?
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁me man tine ▁mer z
▁typical ▁advers e ▁drug ▁reaction s ▁of ▁ nsa ids ▁such ▁as ▁loss ▁of ▁appetit e ▁ , ▁vom i ting ▁ , ▁di ar r ho e a ▁ , ▁fa e cal ▁occ ult ▁blood ▁and ▁a pathy ▁have ▁occasion ally ▁been ▁reported ▁ .
▁as ▁it ▁cannot ▁be ▁exclu ded ▁that ▁the ▁change ▁in ▁c max ▁is ▁clinic ally ▁significant ▁ , ▁temo zo lom ide ▁teva ▁should ▁be ▁ad minister ed ▁without ▁food ▁ .
▁19 ▁patients ▁were ▁en roll ed ▁and ▁18 ▁patients ▁are ▁on - go ing ▁in ▁the ▁study ▁ .
▁what ▁mim para ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁the ▁dose ▁is ▁2. 125 ▁mg ▁ tyl valo sin ▁per ▁kg ▁body weight ▁per ▁day ▁in - feed ▁for ▁7 ▁consecutiv e ▁days ▁ .
▁war ning ▁of ▁the ▁difference ▁of ▁both ▁pos ology ▁and ▁concentration ▁between ▁novo thir teen ▁and ▁other ▁fx i ii ▁contain ing ▁products ▁( ▁the ▁recommended ▁dose ▁of ▁novo thir teen ▁is ▁35 ▁iu ▁/ ▁kg ▁body ▁weight ▁( ▁bw ▁) ▁once ▁monthly ▁ , ▁ad minister ed ▁as ▁an ▁intra ven ous ▁bol us ▁inject ion ▁ .
▁it ▁must ▁not ▁be ▁used ▁in ▁patients ▁who ▁have ▁had ▁a ▁gastro inte stin al ▁cancer ▁( ▁cancer ▁of ▁the ▁stomach ▁ , ▁gut ▁or ▁ liver ▁) ▁in ▁the ▁last ▁five ▁years ▁ .
▁use ▁within ▁one ▁hour ▁after ▁recon stitu tion ▁ .
▁the ▁hl st m 01 ▁study ▁en roll ed ▁a ▁total ▁of ▁seven ▁patients ▁( ▁ 6.7 ▁% ▁of ▁the ▁study ▁population ▁) ▁with ▁an ▁age ▁at ▁base line ▁of ▁65 ▁years ▁or ▁above ▁ , ▁and ▁seven ▁additional ▁patients ▁( ▁24. 1 ▁% ▁) ▁were ▁included ▁in ▁hl st m 02 ▁ .
▁when ▁applied ▁to ▁a ▁mois t ▁surface ▁ , ▁the ▁ thro mbin ▁is ▁activa ted ▁and ▁cu ts ▁fi brin ogen ▁up ▁into ▁smaller ▁unit s ▁called ▁fi brin ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁tres iba ▁contain s
▁special ▁war nings ▁and ▁precau tions ▁for ▁use
▁iba ndro nic ▁acid ▁teva ▁150 ▁mg ▁: ▁medicinal ▁product ▁subject ▁to ▁medical ▁pre scription ▁ .
▁date ▁of ▁first ▁author isation ▁: ▁16 ▁januar y ▁2009 ▁date ▁of ▁latest ▁rene wal ▁: ▁16 ▁januar y ▁2014
▁op di vo ▁contain s ▁the ▁active ▁substance ▁nivo lum ab ▁ .
▁detailed ▁information ▁on ▁this ▁medicine ▁is ▁available ▁on ▁the ▁european ▁medicine s ▁agency ▁web ▁site ▁: ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁and ▁on ▁each ▁bli ster ▁after ▁' ▁exp ▁' ▁ .
▁depression ▁ , ▁hal lucina tion ▁ , ▁anxiety ▁ , ▁ insomni a ▁ , ▁agita tion ▁ , ▁confusion al ▁state
▁na x cel ▁200 ▁mg ▁/ ▁ml ▁suspens ion ▁for ▁inject ion ▁for ▁ca ttle
▁this ▁will ▁allow ▁quick ▁ identification ▁of ▁new ▁safety ▁information ▁ .
▁any ▁remain ing ▁half ▁tablet ▁should ▁be ▁placed ▁back ▁in ▁the ▁opened ▁bli ster ▁and ▁store d ▁( ▁for ▁a ▁maximum ▁of ▁1 ▁day ▁) ▁in ▁the ▁original ▁card board ▁carton ▁out ▁of ▁the ▁sight ▁and ▁reach ▁of ▁children ▁ .
▁to ▁emphasis e ▁the ▁need ▁for ▁effective ▁contra ception ▁during ▁treatment ▁with ▁teri flu nom ide ▁to ▁stop ▁treatment ▁with ▁teri flu nom ide ▁immediately ▁if ▁they ▁suspect ▁they ▁might ▁be ▁pregnant ▁and ▁also ▁to ▁contact ▁their ▁doctor ▁immediately
▁however ▁ , ▁you ▁and ▁your ▁doctor ▁may ▁decide ▁that ▁you ▁may ▁inject ▁si mpon i ▁yourself ▁ .
▁other ▁ ≥ ▁grade ▁3 dex a met has one - related ▁advers e ▁events
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁e per zan ▁contain s
▁by ▁expand ing ▁these ▁blood ▁ves sels ▁ , ▁the ▁blood ▁pressure ▁is ▁reduce d ▁and ▁symptoms ▁are ▁improve d ▁ .
▁it ▁is ▁used ▁to ▁prevent ▁bone ▁complica tions ▁in ▁adults ▁with ▁advanced ▁cancer ▁that ▁is ▁affect ing ▁the ▁bone ▁ .
▁the ▁vaccin e ▁is ▁given ▁as ▁a ▁single ▁inject ion ▁into ▁a ▁muscle ▁ , ▁prefer ably ▁the ▁ne ck ▁muscle ▁behind ▁the ▁ear ▁ .
▁if ▁you ▁receive ▁two ▁dos es ▁in ▁one ▁inject ion ▁site ▁by ▁mistake ▁this ▁might ▁lead ▁to ▁more ▁local ▁reaction ▁such ▁as ▁bru ising ▁or ▁ sensitiv ity ▁ .
▁evaluation ▁of ▁experimental ▁animal ▁studies ▁has ▁shown ▁reproduc tive ▁ toxic ity ▁ , ▁i . e . ▁effects ▁on ▁the ▁development ▁of ▁the ▁em bry o ▁or ▁the ▁fo etus ▁ .
▁na use a ▁and ▁vom i ting ▁are ▁very ▁common ▁advers e ▁reaction s ▁in ▁children ▁and ▁adolescents ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁the ▁vi als ▁that ▁is ▁not ▁being ▁used ▁is ▁to ▁be ▁store d ▁in ▁a ▁refrigera tor ▁( ▁2 ▁° ▁c ▁- ▁8 ▁° ▁c ▁) ▁ .
▁primary ▁hyper ch olesterol a emia ▁is ▁when ▁the ▁levels ▁of ▁cholesterol ▁in ▁the ▁blood ▁are ▁high ▁ .
▁rever sible ▁neutro p enia ▁ , ▁ thro mbo cy top enia ▁ , ▁or ▁ana emia ▁developed ▁in ▁a ▁few ▁dog s ▁treated ▁with ▁8 ▁or ▁10 ▁mg ▁/ ▁kg ▁/ ▁day ▁( ▁total ▁olan za pine ▁exposure ▁[ ▁au c ▁] ▁is ▁12- ▁to ▁15- fold ▁greater ▁than ▁that ▁of ▁a ▁man ▁given ▁a ▁12- mg ▁dose ▁) ▁ .
▁ava mys ▁was ▁more ▁effective ▁than ▁place bo ▁at ▁ reducing ▁symptoms ▁of ▁allergi c ▁r hin itis ▁in ▁patients ▁a ged ▁six ▁years ▁and ▁over ▁ .
▁solve nt ▁: ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁ .
▁such ▁infection s ▁may ▁have ▁been ▁" ▁silent ▁" ▁and ▁not ▁detect ed ▁by ▁the ▁we ak ▁immun e ▁system ▁before ▁treatment ▁was ▁started ▁ .
▁patients ▁with ▁base line ▁h ba 1 c ▁> ▁10 ▁% ▁to ▁ ≤ ▁12 ▁%
▁rare ▁white ▁blood ▁cell ▁count ▁decrease d
▁in ▁80- 85 ▁% ▁of ▁all ▁patients ▁treated ▁with ▁either ▁dose ▁ , ▁rep atha ▁demonstrat ed ▁a ▁ ≥ ▁50 ▁% ▁re duction ▁in ▁l dl - c ▁at ▁the ▁mean ▁of ▁weeks ▁10 ▁and ▁12 ▁ .
▁it ▁is ▁available ▁as ▁a ▁powder ▁and ▁solve nt ▁used ▁to ▁make ▁a ▁solution ▁for ▁inject ion ▁ .
▁a ▁short ▁lived ▁swe lling ▁at ▁the ▁inject ion ▁site ▁may ▁occur ▁( ▁max . ▁diameter ▁5 ▁cm ▁) ▁which ▁decrease s ▁within ▁4 ▁days ▁ .
▁plasma ▁clear ance ▁ , ▁volume ▁of ▁distribution ▁and ▁half - ▁life ▁are ▁independent ▁of ▁dose ▁ .
▁talk ▁to ▁your ▁doctor ▁about ▁how ▁to ▁take ▁appropriate ▁measure s ▁to ▁avoid ▁becoming ▁pregnant ▁during ▁your ▁treatment ▁with ▁jak avi ▁ .
▁note ▁: ▁50 1 ▁( ▁2 ▁° ▁g ▁my co phen ola te ▁mo fe til ▁daily ▁) ▁ , ▁ 289 ▁( ▁3 ▁° ▁g ▁my co phen ola te ▁mo fe til ▁daily ▁) ▁and ▁27 7 ▁( ▁2 ▁° ▁g ▁intra ven ous ▁/ ▁3 ▁° ▁g ▁oral ▁my co phen ola te ▁mo fe til ▁daily ▁) ▁patients ▁were ▁treated ▁in ▁phase ▁i ii ▁studies ▁for ▁the ▁pre vention ▁of ▁ reje ction ▁in ▁renal ▁ , ▁cardiac ▁and ▁he pati c ▁transplant ation ▁ , ▁respective ly ▁ .
▁pec fen t ▁contain s ▁fent an yl ▁ , ▁which ▁is ▁a ▁strong ▁pain - re lie ving ▁medicine ▁known ▁as ▁an ▁op io id ▁pain ▁ki ller ▁ .
▁additional ▁side ▁effects ▁in ▁children ▁and ▁adolescents
▁to ▁help ▁you ▁sleep ▁or ▁for ▁anxiety
▁each ▁a trip la ▁film - co ated ▁tablet ▁contain s ▁600 ▁mg ▁of ▁efa vir enz ▁ , ▁200 ▁mg ▁of ▁em trici ta bine ▁and ▁245 ▁mg ▁of ▁te no fo vir ▁di so prox il ▁( ▁as ▁fumar ate ▁) ▁ .
▁ingredients ▁of ▁the ▁capsule ▁ shell ▁: ▁gelatin ▁ , ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁and ▁so dium ▁la ur yl ▁sul pha te ▁ .
▁if ▁you ▁have ▁a ▁severe ▁heart ▁or ▁ liver ▁problem ▁ .
▁stea dy - state ▁c max ▁for ▁sof os bu vir ▁ , ▁g s -33 100 7 ▁and ▁vel pata s vir ▁were ▁ 566 ▁ , ▁ 868 ▁and ▁25 9 ▁ng ▁/ ▁ml ▁ , ▁respective ly ▁ .
▁any ▁in fusion - related ▁advers e ▁events ▁should ▁be ▁treated ▁by ▁lower ing ▁the ▁in fusion ▁rate ▁or ▁by ▁stop ping ▁the ▁in fusion ▁ .
▁tic lo pidi ne ▁ , ▁other ▁anti plate let ▁agent ▁ .
▁the ▁ch mp ▁not ed ▁that ▁there ▁was ▁a ▁need ▁for ▁new ▁cop d ▁treatment s ▁and ▁that ▁the ▁main ▁studies ▁showed ▁a ▁modest ▁benefit ▁of ▁da xas ▁in ▁patients ▁with ▁severe ▁cop d ▁ .
▁aluminium ▁foi l ▁laminat ed ▁sa chet ▁contain ing ▁40 ▁g ▁ , ▁160 ▁g ▁or ▁400 ▁g ▁of ▁granul es ▁ .
▁qui xi dar ▁does ▁not ▁contain ▁any ▁animal ▁products ▁ .
▁how ▁pande mic ▁influenza ▁vaccin e ▁h 5 n 1 ▁med im mu ne ▁works
▁detailed ▁instructions ▁for ▁use ▁are ▁provided ▁in ▁the ▁section ▁below ▁ .
▁the ▁treatment - free ▁period ▁ , ▁however ▁ , ▁should ▁take ▁into ▁account ▁the ▁ pharma cok ine tic ▁properties ▁of ▁the ▁products ▁used ▁previously ▁ .
▁the ▁full ▁e par ▁for ▁panto loc ▁control ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁a cute ▁general ised ▁ex an thema to us ▁pus tulo sis
▁studies ▁in ▁rabbi ts ▁demonstrat ed ▁that ▁the ▁top ically ▁ad minister ed ▁nepa fen ac ▁is ▁distribu ted ▁local ly ▁from ▁the ▁front ▁of ▁the ▁eye ▁to ▁the ▁posterior ▁segment s ▁of ▁the ▁eye ▁( ▁retin a ▁and ▁cho roid ▁) ▁ .
▁dog s ▁should ▁be ▁carefully ▁observe d ▁following ▁administration ▁to ▁ensure ▁that ▁each ▁tablet ▁is ▁swa llow ed ▁ .
▁sustain ed ▁re duction ▁of ▁dis ability ▁( ▁s rd ▁)
▁horse s ▁: ▁me at ▁and ▁of fal ▁: ▁5 ▁days ▁ .
▁ arth ral gia ▁and ▁back ▁pain
▁the ▁mean ▁stea dy ▁state ▁apparent ▁volume ▁of ▁distribution ▁( ▁v ds s ▁) ▁is ▁approximately ▁500 ▁l ▁ .
▁luce ntis ▁is ▁suppli ed ▁as ▁a ▁pack ▁contain ing ▁one ▁glass ▁vi al ▁of ▁ rani biz um ab ▁with ▁chlor o but yl ▁rub ber ▁stopper ▁ .
▁the ▁solution ▁should ▁not ▁be ▁too ▁cold ▁when ▁it ▁is ▁ad minister ed ▁ .
▁blue vac ▁b tv 8 ▁suspens ion ▁for ▁inject ion ▁for ▁ca ttle ▁and ▁she ep
▁detailed ▁information ▁on ▁this ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁( ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁/ ▁) ▁ .
▁15 ▁ml ▁twice ▁daily
▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁or ▁your ▁family ▁/ ▁care r ▁notice s ▁you ▁are ▁developing ▁urge s ▁or ▁ cra ving s ▁to ▁be have ▁in ▁ways ▁that ▁are ▁unusual ▁for ▁you ▁or ▁you ▁cannot ▁resist ▁the ▁impuls e ▁ , ▁drive ▁or ▁temp tation ▁to ▁carry ▁out ▁certain ▁activities ▁that ▁could ▁har m ▁you ▁or ▁others ▁ .
▁available ▁data ▁suggest ▁that ▁no ▁dose ▁adjust ment ▁is ▁necessary ▁in ▁patients ▁with ▁mild ▁to ▁moderat e ▁renal ▁im pair ment ▁ .
▁spin al ▁or ▁regional ▁ana es the sia ▁is ▁advise d ▁prior ▁to ▁intra mus cular ▁administration ▁ , ▁due ▁to ▁the ▁number ▁of ▁inject ions ▁required ▁ .
▁signifo r ▁20 ▁mg ▁powder ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion ▁signifo r ▁40 ▁mg ▁powder ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion ▁signifo r ▁60 ▁mg ▁powder ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion ▁pas ireo ti de
▁hypo gly ca emia ▁is ▁the ▁most ▁frequent ▁unde sir able ▁effect ▁of ▁insulin ▁ therapy ▁that ▁a ▁patient ▁with ▁diabetes ▁may ▁suffer ▁ .
▁10 ▁million ▁iu ▁/ ▁ml ▁powder ▁and ▁solve nt ▁for ▁solution ▁for ▁inject ion
▁dose ▁absorb ed ▁per ▁activity ▁ad minister ed ▁( ▁μ gy ▁/ ▁mb q ▁)
▁then ▁ , ▁the ▁recommended ▁dose ▁is ▁one ▁75 - mg ▁tablet ▁of ▁clo pido gre l ▁zen tiva ▁per ▁day ▁as ▁described ▁above ▁ .
▁the ▁survival ▁for ▁vor ico na zole ▁was ▁significantly ▁greater ▁than ▁that ▁for ▁am pho teri cin ▁b ▁ .
▁in ▁place bo - control led ▁trial s ▁ , ▁the ▁incide nce ▁of ▁aka th isia ▁in ▁bi po lar ▁patients ▁was ▁12. 1 ▁% ▁with ▁ar ipi pra zole ▁and ▁3.2 ▁% ▁with ▁place bo ▁ .
▁after ▁the ▁boost er ▁dose ▁a ▁lower ▁percentage ▁of ▁subject s ▁with ▁op a ▁titre s ▁8 ▁was ▁observe d ▁in ▁the ▁2- dos e ▁schedule ▁for ▁ser o type s ▁5 ▁( ▁8 7.2 ▁% ▁versus ▁9 7.5 ▁% ▁for ▁the ▁3- dos e ▁prime d ▁subject s ▁) ▁and ▁6 b ▁( ▁8 1.1 ▁% ▁versus ▁90 . 3 ▁% ▁) ▁ , ▁all ▁other ▁response s ▁were ▁comparable ▁ .
▁what ▁is ▁op atan ol ▁used ▁for ▁?
▁studies ▁la sted ▁for ▁six ▁months ▁or ▁one ▁year ▁ .
▁prior ▁treatment ▁with ▁high ▁dose ▁di ure tics ▁may ▁result ▁in ▁volume ▁de ple tion ▁and ▁a ▁risk ▁of ▁hypo tension ▁when ▁initiat ing ▁ therapy ▁with ▁ir besar tan ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁inhibi tion ▁of ▁the ▁m tor c 1 ▁signal ling ▁path way ▁interfere s ▁with ▁the ▁translation ▁and ▁synth es is ▁of ▁protein s ▁by ▁ reducing ▁the ▁activity ▁of ▁s 6 ▁ribo som al ▁protein ▁kina se ▁( ▁s 6 k 1 ▁) ▁and ▁eu kar yo tic ▁e long ation ▁factor ▁4 e - binding ▁protein ▁( ▁4 eb p -1 ▁) ▁that ▁regula te ▁protein s ▁involved ▁in ▁the ▁cell ▁cycle ▁ , ▁ang io gene sis ▁and ▁gly col ysis ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁150 ▁mg ▁of ▁la mi vu dine ▁and ▁300 ▁mg ▁of ▁ra lte grav ir ▁( ▁as ▁po tas s ium ▁) ▁ .
▁other ▁information ▁about ▁le flu nom ide ▁teva
▁bron chi tol ▁is ▁in hal ed ▁using ▁the ▁in hal er ▁device ▁provided ▁ .
▁in ▁a ▁study ▁reflect ing ▁clinic al ▁practice ▁ , ▁the ▁con com i tant ▁anti ep ile ptic ▁medication ▁could ▁be ▁withdraw n ▁in ▁a ▁limited ▁number ▁of ▁patients ▁who ▁responde d ▁to ▁leve ti race tam ▁ad ju nc tive ▁ therapy ▁( ▁36 ▁adult ▁patients ▁out ▁of ▁69 ▁) ▁ .
▁the ▁mean ▁stea dy ▁state ▁volume ▁of ▁distribution ▁( ▁v d ▁) ▁for ▁sil den a fil ▁is ▁105 ▁l ▁ , ▁indicat ing ▁distribution ▁into ▁the ▁tissu es ▁ .
▁for ▁the ▁full ▁list ▁of ▁restriction s ▁and ▁side ▁effects ▁with ▁revol ade ▁ , ▁see ▁the ▁package ▁le a flet ▁ .
▁co - administration ▁of ▁ sime pre vir ▁with ▁efa vir enz ▁is ▁not ▁recommended ▁ .
▁er lo tin ib ▁( ▁used ▁to ▁treat ▁cancer ▁)
▁tram etin ib ▁in ▁combination ▁with ▁da bra fen ib ▁in ▁patients ▁with ▁brain ▁metas tas es
▁cancel ▁the ▁fresh ▁em bry o ▁transfer ▁and ▁cry o pre serve ▁em bry os ▁; ▁avoid ▁administration ▁of ▁h c g ▁for ▁lu te al ▁phase ▁support ▁ .
▁insulin ▁human ▁win thro p ▁com b ▁50 ▁: ▁50 ▁% ▁solu ble ▁insulin ▁and ▁50 ▁% ▁crystal line ▁pro tamine ▁insulin ▁ .
▁before ▁starting ▁mab ther a ▁sub cuta ne ous ▁inject ions ▁ , ▁all ▁patients ▁must ▁always ▁receive ▁before hand ▁ , ▁a ▁full ▁dose ▁of ▁mab ther a ▁by ▁intra ven ous ▁in fusion ▁ , ▁using ▁mab ther a ▁intra ven ous ▁formula tion ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁ratio gra s tim ▁48 ▁mi u ▁/ ▁ 0.8 ▁ml ▁solution ▁for ▁inject ion ▁or ▁in fusion ▁fil gra s tim
▁why ▁is ▁z yka dia ▁approved ▁?
▁allergi c ▁and ▁ana phy la ctic ▁reaction s ▁- ▁the ▁sign s ▁can ▁include ▁a ▁ rash ▁that ▁may ▁be ▁it chy ▁or ▁bli s tering ▁ , ▁swe lling ▁of ▁the ▁eyes ▁and ▁face ▁ , ▁difficult y ▁in ▁breath ing ▁or ▁s w allowing ▁ , ▁a ▁sud den ▁drop ▁in ▁blood ▁pressure ▁and ▁loss ▁of ▁ conscious ness ▁ .
▁a ▁significant ▁effect ▁was ▁observe d ▁on ▁the ▁primary ▁com posit e ▁end point ▁in ▁the ▁overall ▁group ▁of ▁patients ▁receiving ▁beta ▁block er ▁ therapy ▁( ▁hazard ▁ratio ▁: ▁0 . 85 ▁ , ▁95 ▁% ▁ci ▁[ ▁0 . 76 ▁; ▁0 . 94 ▁] ▁) ▁ .
▁store ▁and ▁transport ▁refrigera ted ▁( ▁2 ▁° ▁c -8 ▁° ▁c ▁) ▁do ▁not ▁free ze
▁most ▁inject ion ▁site ▁reaction s ▁were ▁trans ient ▁and ▁of ▁mild ▁intens ity ▁ .
▁other ▁side ▁effects ▁that ▁have ▁been ▁reported
▁following ▁transfer ▁from ▁an ▁animal ▁insulin ▁to ▁human ▁insulin ▁ , ▁dose ▁regime n ▁re duction ▁may ▁be ▁required ▁in ▁particular ▁in ▁patients ▁who
▁there ▁are ▁no ▁vir ologic ▁treatment ▁stop ping ▁rules ▁that ▁apply ▁to ▁the ▁combination ▁of ▁oly sio ▁with ▁sof os bu vir ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁20 ▁mg ▁ta dala fil ▁ .
▁similar ly ▁ , ▁dar una vir ▁use ▁in ▁ob t ▁in ▁dar una vir - na ï ve ▁patients ▁was ▁count ed ▁as ▁one ▁active ▁drug ▁in ▁ob t ▁ .
▁the ▁rate ▁of ▁progression ▁of ▁structura l ▁damage ▁in ▁year ▁2 ▁was ▁significantly ▁lower ▁than ▁that ▁in ▁year ▁1 ▁for ▁patients ▁random ized ▁to ▁a bata cept ▁( ▁p ▁< ▁0.0 001 ▁) ▁ .
▁hyper sensitiv ity ▁( ▁grade ▁4 ▁) ▁to ▁the ▁active ▁substance ▁or ▁to ▁any ▁of ▁the ▁ex cip ient s ▁listed ▁in ▁section ▁6.1 ▁of ▁the ▁sm pc ▁ .
▁medicine s ▁to ▁treat ▁fun gal ▁infection s ▁ , ▁such ▁as ▁keto con a zole ▁ , ▁i trac ona zole ▁ , ▁vor ico na zole ▁and ▁posa con a zole
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁le vitra ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁you ▁should ▁expect ▁to ▁be ▁monitor ed ▁more ▁carefully ▁for ▁problems ▁with ▁low ▁levels ▁of ▁vitamin s ▁a ▁ , ▁d ▁ , ▁e ▁ , ▁k ▁and ▁foli c ▁acid ▁ .
▁use ▁in ▁patients ▁with ▁renal ▁im pair ment
▁then ▁ , ▁if ▁an c ▁remain s ▁> ▁1.0 ▁x ▁109 ▁/ ▁l ▁for ▁3 ▁more ▁consecutiv e ▁days
▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁ 008 ▁14 ▁film - co ated ▁tablets ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁ 009 ▁28 ▁film - co ated ▁tablets ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁ 010 ▁30 x 1 ▁film - co ated ▁tablet ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁ 011 ▁50 x 1 ▁film - co ated ▁tablet ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁01 2 ▁84 ▁film - co ated ▁tablets ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁01 3 ▁90 x 1 ▁film - co ated ▁tablet ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁6 23 ▁/ ▁0 14 ▁100 x 1 ▁film - co ated ▁tablet
▁14 ▁x ▁1 ▁tablet ▁( ▁unit ▁dose ▁)
▁following ▁initiat ion ▁of ▁ therapy ▁ , ▁se rum ▁creati nine ▁should ▁be ▁measure d ▁prior ▁to ▁each ▁dose ▁of ▁zo le dro nic ▁acid ▁teva ▁and ▁treatment ▁should ▁be ▁with held ▁if ▁renal ▁function ▁has ▁deteriora ted ▁ .
▁patients ▁with ▁non - val vu lar ▁at rial ▁fi bril lation a ▁)
▁the ▁active ▁substance ▁in ▁bet miga ▁ , ▁mira beg ron ▁ , ▁is ▁a ▁beta -3 - ad r energi c - recept or ▁ago nist ▁ .
▁after ▁first ▁opening ▁ , ▁the ▁medicine ▁can ▁be ▁store d ▁for ▁a ▁single ▁period ▁of ▁2 ▁months ▁at ▁a ▁temperature ▁not ▁above ▁25 ▁° ▁c ▁ , ▁after ▁which ▁it ▁must ▁be ▁disc ard ed ▁ .
▁experience ▁with ▁su tent ▁as ▁first - line ▁treatment ▁is ▁limited ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁inject ing ▁the ▁product ▁at ▁refrigera ted ▁temperature ▁may ▁reduce ▁pain ▁at ▁inject ion ▁ .
▁powder ▁for ▁concentrat e ▁and ▁dilu ent ▁for ▁solution ▁for ▁in fusion
▁in ▁order ▁to ▁improve ▁the ▁trace ability ▁of ▁bi ological ▁medicinal ▁products ▁ , ▁the ▁trade mark ▁and ▁the ▁bat ch ▁number ▁of ▁the ▁ad minister ed ▁product ▁should ▁be ▁clearly ▁record ed ▁( ▁or ▁state d ▁) ▁in ▁the ▁patient ▁file ▁ .
▁previous ▁treatment ▁with ▁insulin ▁g lar gine
▁the ▁drug ▁does ▁not ▁cross ▁the ▁blood ▁brain ▁barrier ▁in ▁patients ▁unless ▁the ▁mening es ▁are ▁infla med ▁ , ▁when ▁the ▁concentration ▁of ▁para - ami nos ali cy lic ▁acid ▁in ▁cerebro spin al ▁fluid ▁is ▁about ▁10 ▁to ▁50 ▁% ▁of ▁the ▁plasma ▁ .
▁however ▁ , ▁due ▁to ▁their ▁trans ient ▁nature ▁ , ▁the ▁incide nce ▁of ▁anti bo dies ▁detect ed ▁at ▁each ▁assessment ▁point ▁was ▁typically ▁less ▁than ▁7 ▁% ▁in ▁rhe um ato id ▁ar thri tis ▁subject s ▁and ▁psoriasis ▁subject s ▁ .
▁while ▁keeping ▁the ▁sy ringe ▁plu nger ▁presse d ▁ , ▁turn ▁the ▁system ▁up side ▁down ▁and ▁draw ▁the ▁solution ▁into ▁the ▁sy ringe ▁by ▁pull ing ▁the ▁plu nger ▁back ▁slowly ▁ .
▁ha e modi al ysis ▁reduce d ▁the ▁exposure ▁to ▁hydro xy car bam ide ▁by ▁33 ▁% ▁( ▁see ▁section s ▁4.2 ▁and ▁4.4 ▁) ▁ .
▁for ▁more ▁information ▁about ▁treatment ▁with ▁cet rot ide ▁ , ▁read ▁the ▁package ▁le a flet ▁( ▁also ▁part ▁of ▁the ▁e par ▁) ▁or ▁contact ▁your ▁doctor ▁or ▁ pharma ci st ▁..
▁because ▁the ▁solution ▁contain s ▁no ▁preserva tive ▁ , ▁privi gen ▁should ▁be ▁inf used ▁as ▁soon ▁as ▁possible ▁ .
▁in ▁the ▁off spring ▁of ▁rat s ▁given ▁olan za pine ▁ , ▁de lay s ▁in ▁fo et all ▁development ▁and ▁trans ient ▁decrease s ▁in ▁off spring ▁activity ▁levels ▁were ▁seen ▁ .
▁hydro ch lor ic ▁acid ▁concentrat ed ▁( ▁e 507 ▁) ▁( ▁ph ▁adjust ment ▁) ▁tro meta mol ▁( ▁ph ▁adjust ment ▁)
▁between ▁46 ▁% ▁and ▁55 ▁% ▁of ▁subject s ▁received ▁treatment ▁for ▁go ut ▁fl ares ▁from ▁week ▁8 ▁and ▁week ▁28 ▁ .
▁ tori sel ▁is ▁given ▁as ▁an ▁in fusion ▁ lasting ▁30 ▁to ▁60 ▁minutes ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁single ▁and ▁repeat ed ▁dose ▁ toxic ity ▁and ▁geno toxic ity ▁additional ▁to ▁that ▁already ▁state d ▁in ▁other ▁section s ▁of ▁this ▁sm pc ▁ .
▁the ▁overall ▁objective ▁response ▁rates ▁( ▁investiga tor ▁assessment ▁) ▁were ▁20 ▁% ▁( ▁first ▁trial ▁) ▁and ▁25 ▁% ▁( ▁second ▁trial ▁) ▁ .
▁a ▁graduate d ▁oral ▁sy ringe ▁is ▁also ▁included ▁ .
▁each ▁hard ▁capsule ▁contain s ▁ri va stig mine ▁hydro gen ▁tart rate ▁equivalent ▁to ▁4.5 ▁mg ▁ri va stig mine ▁ .
▁per i pher al ▁neuro pathi es ▁ , ▁di zzi ness ▁ , ▁tre mor
▁decrease d ▁number ▁of ▁blood ▁plate let s ▁ , ▁decrease d ▁number ▁of ▁white ▁blood ▁cell s ▁;
▁both ▁men ▁and ▁women ▁should ▁be ▁advise d ▁to ▁se ek ▁advice ▁and ▁consider ▁fertil ity ▁preserva tion ▁before ▁treatment ▁ .
▁the ▁pack ▁contain s ▁3 ▁inner ▁carton s ▁ .
▁reproduc tion ▁is ▁author ised ▁provided ▁the ▁source ▁is ▁acknowledge d . ▁animals ▁are ▁expose d ▁to ▁er y si pel oth rix ▁r hus io pathi a e ▁bacteria ▁ , ▁the ▁immun e ▁system ▁will ▁be ▁able ▁to ▁respond ▁more ▁quickly ▁ .
▁she lf ▁life ▁of ▁the ▁veterinar y ▁medicinal ▁product ▁as ▁package d ▁for ▁sale ▁: ▁3 ▁years ▁ .
▁ps oria tic ▁ar thri tis ▁( ▁ inflammation ▁of ▁the ▁joint s ▁which ▁occur s ▁in ▁some ▁patients ▁with ▁psoriasis ▁) ▁in ▁adults ▁who ▁have ▁not ▁responde d ▁adequat ely ▁to ▁other ▁treatment s ▁;
▁it ▁is ▁important ▁to ▁remain ▁under ▁your ▁health care ▁provider ▁' s ▁care ▁while ▁using ▁ro acte m ra ▁ .
▁while ▁bio ava il ability ▁of ▁ri va stig mine ▁is ▁greater ▁in ▁el der ly ▁than ▁in ▁young ▁healthy ▁volunteer s ▁ , ▁studies ▁in ▁al z heim er ▁patients ▁a ged ▁between ▁50 ▁and ▁92 ▁years ▁showed ▁no ▁change ▁in ▁bio ava il ability ▁with ▁age ▁ .
▁if ▁a ▁severe ▁allergi c ▁reaction ▁occur s ▁during ▁treatment ▁with ▁di fic lir ▁ , ▁the ▁medicinal ▁product ▁should ▁be ▁dis continu ed ▁and ▁appropriate ▁measure s ▁taken ▁ .
▁each ▁ml ▁of ▁oral ▁suspens ion ▁contain s ▁175 ▁mg ▁sor bit ol ▁( ▁e 420 ▁) ▁ .
▁patients ▁treated ▁with ▁vil dag lip tin ▁reported ▁significantly ▁lower ▁incide nce s ▁of ▁gastro inte stin al ▁advers e ▁reaction s ▁versus ▁those ▁treated ▁with ▁met form in ▁ .
▁your ▁blood ▁sugar ▁levels ▁are ▁almost ▁normal ▁or ▁are ▁uns table ▁ .
▁most ▁of ▁the ▁values ▁had ▁decrease d ▁to ▁grade ▁1 ▁or ▁resolve d ▁by ▁day ▁14 -15 ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁the ▁need le ▁will ▁insert ▁with ▁an ▁audi ble ▁click ▁ , ▁after ▁which ▁you ▁will ▁hear ▁the ▁sound ▁of ▁the ▁motor ▁running ▁ .
▁in ▁addition ▁ , ▁patients ▁were ▁instru cted ▁to ▁perform ▁pen ile ▁model ing ▁at ▁home ▁for ▁six ▁weeks ▁after ▁each ▁treatment ▁cycle ▁ .
▁st ▁joh n ▁' s ▁ wort ▁( ▁hyper icum ▁perfor atum ▁) ▁( ▁a ▁medicine ▁to ▁treat ▁depression ▁) ▁ .
▁due ▁to ▁potential ▁har m ful ▁effects ▁ , ▁the ▁tablets ▁must ▁be ▁kept ▁out ▁of ▁the ▁sight ▁and ▁reach ▁of ▁children ▁ .
▁patients ▁over ▁65 ▁years ▁of ▁age ▁and ▁patients ▁who ▁have ▁problems ▁with ▁their ▁ liver ▁or ▁ki dne ys ▁may ▁need ▁a ▁lower ▁starting ▁dose ▁of ▁5 ▁mg ▁per ▁day ▁ .
▁rap tiva ▁has ▁been ▁used ▁in ▁combination ▁with ▁topic al ▁corti co steroid s ▁in ▁psoriasis ▁patients ▁without ▁any ▁un to ward ▁effects ▁nor ▁with ▁any ▁observa ble ▁significant ▁beneficia l ▁effect ▁of ▁the ▁combination ▁ therapy ▁above ▁mono therapy ▁with ▁efa liz um ab ▁ .
▁for ▁practical ▁information ▁about ▁using ▁pre gabal in ▁my lan ▁ pharma ▁ , ▁patients ▁should ▁read ▁the ▁package ▁le a flet ▁or ▁contact ▁their ▁doctor ▁or ▁ pharma ci st ▁ .
▁in ▁clinic al ▁trial s ▁in ▁mild ▁to ▁severe ▁dem entia ▁ , ▁in vol ving ▁1,7 84 ▁patients ▁treated ▁with ▁me man tine ▁and ▁1,5 95 ▁patients ▁treated ▁with ▁place bo ▁ , ▁the ▁overall ▁incide nce ▁rate ▁of ▁advers e ▁reaction s ▁with ▁me man tine ▁did ▁not ▁differ ▁from ▁those ▁with ▁place bo ▁; ▁the ▁advers e ▁reaction s ▁were ▁usually ▁mild ▁to ▁moderat e ▁in ▁sever ity ▁ .
▁common ▁che st ▁pain ▁ , ▁fatigue
▁the ▁length ▁of ▁combination ▁anti ret rovi ral ▁ therapy ▁ , ▁corti co steroid ▁use ▁ , ▁alcohol ▁consum p tion ▁ , ▁severe ▁immun os up pression ▁ , ▁higher ▁body ▁mass ▁index ▁ , ▁among ▁others ▁ , ▁may ▁be ▁some ▁of ▁the ▁many ▁risk ▁factors ▁for ▁developing ▁this ▁disease ▁ .
▁these ▁include ▁serious ▁allergi c ▁reaction s ▁( ▁such ▁as ▁ana phy la xis ▁ , ▁ang io e od ema ▁) ▁ , ▁fe ver ▁ , ▁feeling ▁very ▁tired ▁ , ▁difficult y ▁sleeping ▁ , ▁pain s ▁( ▁such ▁as ▁stomach ▁ , ▁che st ▁ , ▁joint ▁or ▁muscle ▁ , ▁pain ▁on ▁pas sing ▁urin e ▁) ▁ , ▁head ache ▁ , ▁flu ▁symptoms ▁and ▁swe lling ▁ .
▁clinic ally ▁significant ▁interaction ▁un like ly ▁ .
▁these ▁decrease s ▁occur red ▁without ▁associated ▁ble ed ing ▁events ▁ .
▁following ▁repeat ed ▁sub cuta ne ous ▁administration ▁to ▁pregnant ▁mi ce ▁in ▁the ▁ therapeut ic ▁dose ▁range ▁( ▁> ▁0.5 ▁mg ▁/ ▁kg ▁) ▁ , ▁as fo tase ▁alfa ▁levels ▁were ▁quanti fi able ▁in ▁fet uses ▁at ▁all ▁dos es ▁test ed ▁ , ▁suggest ing ▁cross - place n tal ▁transport ▁of ▁as fo tase ▁alfa ▁ .
▁taking ▁three ▁separate ▁1 ▁mg ▁bli sters ▁deliver s ▁more ▁insulin ▁to ▁your ▁lung s ▁than ▁a ▁single ▁3 ▁mg ▁bli ster ▁does ▁ .
▁it ▁is ▁given ▁in ▁combination ▁with ▁either ▁aspirin ▁or ▁ , ▁where ▁appropriate ▁ , ▁with ▁clo pido gre l ▁ .
▁brit tle ▁and ▁loo se ▁na ils
▁like ▁all ▁medicine s ▁ , ▁this ▁medicine ▁can ▁cause ▁side ▁effects ▁ , ▁although ▁not ▁everybody ▁gets ▁them ▁ .
▁stoc rin ▁must ▁always ▁be ▁taken ▁in ▁combination ▁with ▁other ▁anti - hi v ▁medicine s ▁ .
▁treatment ▁should ▁be ▁initiat ed ▁at ▁a ▁daily ▁dose ▁of ▁400 ▁mg ▁ .
▁safety ▁ , ▁ef fica cy ▁and ▁ pharma cok ine tic ▁profile s ▁of ▁the ▁two ▁dose ▁regime ns ▁were ▁assess ed ▁after ▁3 ▁weeks ▁of ▁ therapy ▁in ▁each ▁patient ▁ .
▁the ▁" ▁ir besar tan ▁diabet ic ▁nep hro pathy ▁trial ▁( ▁id nt ▁) ▁" ▁shows ▁that ▁ir besar tan ▁decrease s ▁the ▁progression ▁of ▁renal ▁disease ▁in ▁patients ▁with ▁chronic ▁renal ▁insu ffi cie ncy ▁and ▁over t ▁protein uria ▁ .
▁the ▁other ▁ingredients ▁are ▁: ▁poly sor bate ▁80 ▁ , ▁octo xy nol ▁10 ▁ , ▁thi om er sal ▁ , ▁so dium ▁chlor ide ▁ , ▁di so dium ▁hydro gen ▁ phos pha te ▁ , ▁po tas s ium ▁di hydro gen ▁ phos pha te ▁ , ▁po tas s ium ▁chlor ide ▁ , ▁magnesium ▁chlor ide ▁ , ▁water ▁for ▁inject ions
▁in ▁this ▁ref i lling ▁procedure ▁the ▁remain ing ▁insulin ▁must ▁be ▁removed ▁from ▁the ▁pump ▁and ▁the ▁pump ▁ref ille d ▁with ▁new ▁insulin ▁ .
▁possible ▁interaction s ▁with ▁other ▁ha e mato po ie tic ▁growth ▁factors ▁and ▁cy tok ines ▁have ▁not ▁yet ▁been ▁investiga ted ▁in ▁clinic al ▁trial s ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁olan za pine ▁gl en mark ▁ europe ▁do ▁not ▁take ▁olan za pine ▁gl en mark ▁ europe
▁un com mon ▁side ▁effects ▁- may ▁affect ▁up ▁to ▁1 ▁in ▁100 ▁people ▁) ▁:
▁ham p shire ▁ rg 24 ▁9 nl ▁unit ed ▁king dom
▁you ▁should ▁have ▁a ▁pre gna ncy ▁test ▁before ▁initiat ion ▁of ▁op sumi t ▁and ▁every ▁month ▁during ▁treatment ▁even ▁if ▁you ▁think ▁that ▁you ▁are ▁not ▁pregnant ▁ .
▁of ev ▁must ▁not ▁be ▁used ▁in ▁patients ▁who ▁are ▁hyper sensitiv e ▁( ▁allergi c ▁) ▁to ▁ni nte dan ib ▁ , ▁pea nut ▁or ▁so ya ▁ , ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁ .
▁for ▁the ▁full ▁list ▁of ▁ex cip ient s ▁ , ▁see ▁section ▁6.1 ▁ .
▁plate let ▁ aggregat ion ▁induc ed ▁by ▁ago nist s ▁other ▁than ▁ad p ▁is ▁also ▁inhibi ted ▁by ▁block ing ▁the ▁amplifica tion ▁of ▁plate let ▁activa tion ▁by ▁released ▁ad p ▁ .
▁population s ▁with ▁limited ▁data
▁ir besar tan ▁hydro ch lor o thi azi de ▁b ms ▁is ▁used ▁in ▁adults ▁who ▁have ▁essential ▁hyper tension ▁( ▁high ▁blood ▁pressure ▁) ▁that ▁is ▁not ▁adequat ely ▁control led ▁on ▁ir besar tan ▁or ▁hydro ch lor o thi azi de ▁alone ▁ . ▁' ▁essential ▁' ▁means ▁that ▁the ▁hyper tension ▁has ▁no ▁obvious ▁cause ▁ .
▁one ▁dose ▁( ▁0.5 ▁ml ▁of ▁the ▁recon stitu ted ▁vaccin e ▁) ▁contain s ▁: ▁the ▁active ▁substance s ▁are ▁:
▁the ▁degree ▁of ▁accumula tion ▁of ▁des lor ata dine ▁was ▁consistent ▁with ▁its ▁half - life ▁( ▁approximately ▁27 ▁hours ▁) ▁and ▁a ▁once ▁daily ▁dos ing ▁fre que ncy ▁ .
▁since ▁con s tip ation ▁may ▁be ▁an ▁early ▁symptom ▁of ▁a ▁block age ▁in ▁your ▁inte s tine ▁ , ▁please ▁inform ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁experience ▁it ▁ .
▁what ▁measure s ▁are ▁being ▁taken ▁to ▁ensure ▁the ▁safe ▁and ▁effective ▁use ▁of ▁ra xon e ▁?
▁if ▁more ▁than ▁one ▁topic al ▁op h thal mic ▁medicinal ▁product ▁is ▁being ▁used ▁ , ▁the ▁medicinal ▁products ▁must ▁be ▁ad minister ed ▁at ▁least ▁5 ▁minutes ▁apart ▁ .
▁for ▁all ▁subsequent ▁cycle ▁start s ▁and ▁rein iti ation ▁( ▁e . g . ▁if ▁treatment ▁is ▁interrupt ed ▁for ▁4 ▁or ▁more ▁hours ▁) ▁ , ▁super vision ▁by ▁a ▁health care ▁professional ▁or ▁hospital isation ▁is ▁recommended ▁ .
▁treatment ▁of ▁invasi ve ▁a sper gil los is
▁apro vel ▁was ▁used ▁for ▁two ▁years ▁or ▁more ▁ .
▁available ▁reproduc tive ▁data ▁in ▁animals ▁have ▁shown ▁ex cre tion ▁of ▁el os ul fase ▁alfa ▁in ▁milk ▁ .
▁fre que ncies ▁are ▁define d ▁as ▁: ▁very ▁common ▁( ▁1 ▁/ ▁10 ▁) ▁ , ▁common ▁( ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁un com mon ▁( ▁1 ▁/ ▁1,000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁ , ▁rare ▁( ▁1 ▁/ ▁10,000 ▁to ▁< ▁1 ▁/ ▁1,000 ▁) ▁and ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁including ▁isola ted ▁reports ▁ .
▁fa bly n ▁may ▁be ▁ad minister ed ▁any ▁time ▁of ▁day ▁without ▁regard ▁to ▁food ▁or ▁be ver age ▁in take ▁ .
▁a ▁case ▁of ▁cho le static ▁hepatitis ▁has ▁been ▁reported ▁ .
▁fer ta vid ▁900 ▁iu ▁/ ▁1. 08 ▁ml ▁solution ▁for ▁inject ion ▁fol li trop in ▁beta
▁if ▁you ▁have ▁the ▁impression ▁that ▁the ▁effect ▁of ▁pri tor ▁is ▁too ▁strong ▁or ▁too ▁we ak ▁ , ▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁ .
▁cau tion ▁should ▁be ▁taken ▁if ▁medicinal ▁products ▁associated ▁with ▁r hab dom yol ysis ▁( ▁e . g . ▁stati ns ▁) ▁ , ▁are ▁ad minister ed ▁con com i tant ly ▁with ▁tra be cted in ▁ , ▁since ▁the ▁risk ▁of ▁r hab dom yol ysis ▁may ▁be ▁increased
▁clear ▁glass ▁( ▁type ▁i ▁) ▁vi al ▁with ▁fluor o tec ▁plus ▁( ▁et hy lene ▁te tra flu oro e thy lene ▁film ▁) ▁rub ber ▁stopper ▁and ▁aluminium ▁seal ▁and ▁an ▁orang e ▁flip - off ▁cap ▁ , ▁contain ing ▁1 ▁ml ▁of ▁concentrat e ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁xo fi go ▁contain s
▁as ▁observe d ▁for ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁ , ▁tel mis ar tan ▁and ▁the ▁other ▁ang io ten sin ▁i i ▁receptor ▁anta gon ists ▁are ▁apparently ▁less ▁effective ▁in ▁lower ing ▁blood ▁pressure ▁in ▁black ▁people ▁than ▁in ▁non - black s ▁ , ▁possibly ▁because ▁of ▁higher ▁prevale nce ▁of ▁low - re nin ▁states ▁in ▁the ▁black ▁hyper tensi ve ▁population ▁ .
▁if ▁there ▁are ▁air ▁bu bble s ▁present ▁ , ▁gent ly ▁tap ▁the ▁sy ringe ▁with ▁your ▁finger s ▁until ▁the ▁air ▁bu bble s ▁ rise ▁to ▁the ▁top ▁of ▁the ▁sy ringe ▁ .
▁it ▁may ▁be ▁taken ▁with ▁or ▁without ▁food ▁ .
▁ana phy la ctic ▁reaction ▁severe ▁allergi c ▁reaction
▁close ▁monitoring ▁is ▁required ▁during ▁the ▁in fusion ▁and ▁for ▁at ▁least ▁1 ▁hour ▁after ▁the ▁end ▁of ▁the ▁in fusion ▁ .
▁the ▁amount ▁of ▁imati ni b ▁act avis ▁given ▁will ▁depend ▁on ▁your ▁child ▁' s ▁condition ▁ , ▁body ▁weight ▁and ▁height ▁ .
▁ lon surf ▁has ▁been ▁shown ▁to ▁prolong ▁overall ▁survival ▁of ▁patients ▁with ▁meta static ▁colore c tal ▁cancer ▁who ▁previously ▁received ▁other ▁treatment s ▁ .
▁talk ▁to ▁your ▁doctor ▁before ▁taking ▁vim pat ▁if ▁you ▁suffer ▁from ▁a ▁condition ▁that ▁is ▁associated ▁with ▁im pair ed ▁electric ▁con duction ▁across ▁the ▁heart ▁( ▁av ▁block ▁ , ▁at rial ▁fi bril lation ▁and ▁at rial ▁flutt er ▁) ▁or ▁from ▁severe ▁heart ▁disease ▁such ▁as ▁ , ▁heart ▁failure ▁or ▁heart ▁attack ▁ .
▁co - administration ▁of ▁keto con a zole ▁ , ▁a ▁strong ▁cy p 3 a 4 ▁inhibi tor ▁ , ▁in ▁18 ▁fast ed ▁healthy ▁subject s ▁ , ▁increased ▁exposure ▁( ▁c max ▁and ▁au c ▁) ▁of ▁i bru tin ib ▁by ▁29- ▁and ▁24- fold ▁ , ▁respective ly ▁ .
▁what ▁benefit ▁has ▁ir besar tan ▁zen tiva ▁shown ▁during ▁the ▁studies ▁?
▁serious ▁arterial ▁cardiovascular ▁ , ▁cerebro vas cular ▁ , ▁and ▁per i pher al ▁vas cular ▁oc clusi ve ▁advers e ▁reaction s ▁( ▁treatment - em er gent ▁fre que ncies ▁) ▁occur red ▁in ▁ 6.7 ▁% ▁ , ▁ 5.6 ▁% ▁ , ▁and ▁5.1 ▁% ▁of ▁i clusi g ▁treated ▁patients ▁ , ▁respective ly ▁ .
▁regular ▁in take ▁of ▁io a ▁is ▁then ▁resume d ▁after ▁the ▁yellow ▁place bo ▁tablets ▁have ▁been ▁taken ▁of ▁the ▁second ▁pack ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁wa i ved ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁su tent ▁in ▁all ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁for ▁treatment ▁of ▁ki dne y ▁and ▁renal ▁pel vis ▁car cino ma ▁( ▁exclu ding ▁nep hro blas toma ▁ , ▁nep hro blas tomat osis ▁ , ▁clear ▁cell ▁sar com a ▁ , ▁mes obla stic ▁ne ph roma ▁ , ▁renal ▁med ulla ry ▁car cino ma ▁and ▁r hab do id ▁tum our ▁of ▁the ▁ki dne y ▁) ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁use ▁of ▁n altre xon e ▁/ ▁bu propi on ▁with ▁other ▁o ct 2 ▁substrat es ▁( ▁e . g . ▁ , ▁met form in ▁) ▁in ▁clinic al ▁trial s ▁did ▁not ▁indicate ▁the ▁need ▁for ▁dose ▁adjust ment ▁or ▁other ▁precau tions ▁ .
▁effects ▁of ▁other ▁medicinal ▁products ▁on ▁cele co x ib
▁however ▁ , ▁post - ▁hoc ▁analysis ▁of ▁data ▁from ▁the ▁two ▁phase ▁3 ▁clinic al ▁trial s ▁showed ▁that ▁the ▁ pharma cok ine tics ▁of ▁re gade no son ▁were ▁not ▁affected ▁in ▁a ▁small ▁sub set ▁of ▁patients ▁with ▁laborator y ▁values ▁suggest ive ▁of ▁im pair ed ▁he pati c ▁function ▁( ▁2.5 - fold ▁trans amin ase ▁eleva tion ▁or ▁1.5 - fold ▁eleva tion ▁of ▁se rum ▁bilir u bin ▁or ▁pro thro mbin ▁time ▁) ▁ .
▁total ▁system ic ▁exposure ▁( ▁au c ▁) ▁is ▁proportion al ▁to ▁dose ▁at ▁single - dos e ▁conditions ▁ .
▁all ▁patients ▁also ▁received ▁standard ▁anti plate let ▁medicine s ▁ .
▁in ▁patients ▁with ▁severe ▁heart ▁failure ▁whose ▁renal ▁function ▁may ▁depend ▁on ▁the ▁activity ▁of ▁the ▁re nin - angi oten sin - al do ster one ▁system ▁ , ▁treatment ▁with ▁a ce ▁inhibi tors ▁and ▁ang io ten sin ▁receptor ▁anta gon ists ▁has ▁been ▁associated ▁with ▁oli guri a ▁and ▁/ ▁or ▁progressive ▁az ota emia ▁and ▁( ▁rare ly ▁) ▁with ▁a cute ▁renal ▁failure ▁and ▁/ ▁or ▁death ▁ .
▁un com mon ▁: ▁inter stiti al ▁lung ▁disease ▁( ▁including ▁pneu moni tis ▁and ▁pulmonar y ▁fibro sis ▁) ▁*
▁how ▁to ▁store ▁ huma log ▁kwi k pen
▁what ▁measure s ▁are ▁being ▁taken ▁to ▁ensure ▁the ▁safe ▁and ▁effective ▁use ▁of ▁viza my l ▁?
▁novom ix ▁30 ▁ flex pen ▁100 ▁unit s ▁/ ▁ml ▁suspens ion ▁for ▁inject ion
▁detailed ▁information ▁on ▁this ▁medicine ▁is ▁available ▁on ▁the ▁european ▁medicine s ▁agency ▁web ▁site ▁: ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁novo e ight ▁on ▁13 ▁november ▁2013 ▁ .
▁osa tero ne ▁ac etate ▁inhibi ts ▁the ▁effects ▁of ▁an ▁excess ▁of ▁male ▁hormone ▁( ▁testosteron e ▁) ▁through ▁various ▁mechanism s ▁ .
▁the ▁mah ▁should ▁further ▁investiga te ▁the ▁ef fica cy ▁and ▁safety ▁of ▁bron chi tol ▁in ▁children ▁and ▁adolescents ▁with ▁cyst ic ▁fibro sis ▁ .
▁at ▁this ▁dose ▁ , ▁severe ▁li mb ▁anomali es ▁were ▁seen ▁as ▁well ▁as ▁a ▁significant ▁decrease ▁in ▁the ▁mean ▁fo e tal ▁weight ▁ .
▁general ▁disorder s ▁and ▁administration ▁site ▁conditions ▁un com mon ▁: ▁as th enia
▁not ▁known ▁ana phy la ctic ▁reaction ▁*
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁pri alt ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁women ▁must ▁use ▁effective ▁contra ception ▁during ▁treatment ▁with ▁pe metre x ed ▁li lly ▁ .
▁vim pat ▁treatment ▁initiat ion ▁pack ▁contain s ▁4 ▁different ▁package s ▁( ▁one ▁for ▁each ▁tablet ▁strength ▁) ▁with ▁14 ▁tablets ▁each ▁ , ▁for ▁the ▁first ▁2 ▁to ▁4 ▁weeks ▁of ▁ therapy ▁de pending ▁on ▁the ▁patient ▁' s ▁response ▁and ▁to ler ability ▁ .
▁za vice fta ▁2 ▁g ▁/ ▁0.5 ▁g ▁powder ▁for ▁concentrat e ▁for ▁solution ▁for ▁in fusion
▁gra pe fru it ▁juice ▁has ▁been ▁class ified ▁as ▁a ▁ potent ▁cy p 3 a 4 ▁inhibi tor ▁when ▁consum ed ▁in ▁large ▁quanti ties ▁ .
▁store ▁in ▁a ▁refrigera tor ▁( ▁2 ▁c ▁- ▁8 ▁c ▁) ▁ .
▁↑ ▁in ▁plasma ▁concentration s ▁of ▁these ▁drugs ▁have ▁been ▁observe d
▁the ▁clinic al ▁data ▁are ▁limited ▁and ▁an ▁increased ▁risk ▁of ▁cu tane ous ▁reaction s ▁in ▁patients ▁with ▁a ▁history ▁of ▁n n rti - as soci ated ▁cu tane ous ▁reaction ▁cannot ▁be ▁exclu ded ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁de po cy te ▁( ▁n ▁= ▁9 29 ▁cycle s ▁)
▁after ▁accident al ▁in gestion ▁of ▁the ▁product ▁ , ▁trans ient ▁reaction s ▁such ▁as ▁sa liv ation ▁ , ▁ab normal ▁fa e ces ▁and ▁e mesi s ▁may ▁occur ▁ , ▁however ▁these ▁should ▁resolve ▁without ▁treatment ▁within ▁4 ▁hours ▁ .
▁no ▁clinic ally ▁significant ▁effect ▁on ▁efa vir enz ▁ pharma cok ine tics ▁ .
▁the ▁ch mp ▁decided ▁that ▁ef ient ▁' s ▁benefits ▁are ▁greater ▁than ▁its ▁risk s ▁ , ▁when ▁given ▁together ▁with ▁aspirin ▁ , ▁for ▁the ▁pre vention ▁of ▁at hero thro mbo tic ▁events ▁in ▁patients ▁with ▁a cute ▁corona ry ▁syndrome ▁under go ing ▁primary ▁or ▁de lay ed ▁per cuta ne ous ▁corona ry ▁intervention ▁ .
▁the ▁patch ▁needs ▁to ▁be ▁changed ▁twice ▁week ly ▁ .
▁qui no lone ▁antibiotic s ▁ , ▁including ▁quin s air ▁ , ▁may ▁cause ▁levels ▁of ▁gluco se ▁in ▁the ▁blood ▁to ▁be ▁either ▁too ▁high ▁or ▁too ▁low ▁ .
▁in ▁clinic al ▁trial s ▁of ▁up ▁to ▁two ▁years ▁du ration ▁ , ▁pi og lita zone ▁reduce d ▁total ▁plasma ▁tri gly ceri des ▁and ▁free ▁fa tty ▁acid s ▁ , ▁and ▁increased ▁hd l ▁cholesterol ▁levels ▁ , ▁compared ▁with ▁place bo ▁ , ▁met form in ▁or ▁gli c lazi de ▁ .
▁pre gabal in ▁my lan ▁may ▁cause ▁blu r ring ▁or ▁loss ▁of ▁vision ▁ , ▁or ▁other ▁changes ▁in ▁eyes ight ▁ , ▁many ▁of ▁which ▁are ▁temporar y ▁ .
▁sample s ▁in ▁which ▁em e das tine ▁was ▁quanti fi able ▁range d ▁from ▁0 . 30 ▁to ▁0 . 49 ▁ng ▁/ ▁ml ▁ .
▁epi the li al ▁cell ▁prolifera tion ▁was ▁assess ed ▁by ▁ki 67 ▁immun oh isto chem ical ▁sta ining ▁in ▁healthy ▁subject s ▁ .
▁following ▁oral ▁administration ▁of ▁a ▁100- mg ▁dose ▁to ▁healthy ▁subject s ▁ , ▁si tag lip tin ▁was ▁rapid ly ▁absorb ed ▁ , ▁with ▁pe ak ▁plasma ▁concentration s ▁( ▁media n ▁t max ▁) ▁occur ring ▁1 ▁to ▁4 ▁hours ▁post - dos e ▁ , ▁mean ▁plasma ▁au c ▁of ▁si tag lip tin ▁was ▁8. 52 ▁m ▁• ▁hr ▁ , ▁c max ▁was ▁950 ▁n m ▁ .
▁high ▁level ▁of ▁" ▁u ric ▁acid ▁" ▁in ▁the ▁blood ▁( ▁shown ▁in ▁blood ▁tests ▁) ▁ , ▁which ▁may ▁cause ▁go ut ▁ inflammation ▁within ▁the ▁lung s ▁that ▁may ▁lead ▁to ▁permanent ▁damage ▁ .
▁this ▁means ▁that ▁it ▁was ▁not ▁possible ▁to ▁obtain ▁complete ▁information ▁about ▁b tv pur ▁als ap ▁8 ▁at ▁the ▁time ▁of ▁the ▁initial ▁author isation ▁ .
▁observe d ▁post - marketing ▁with ▁pali peri done
▁administration ▁of ▁un con ju ga ted ▁pneu moc oc cal ▁poly s ac char ides ▁at ▁13 ▁months ▁following ▁the ▁primary ▁series ▁with ▁ preven ar ▁e licit ed ▁an ▁an am ne stic ▁anti body ▁response ▁for ▁the ▁7 ▁ser o type s ▁included ▁in ▁the ▁vaccin e ▁ , ▁indicat ing ▁that ▁primi ng ▁had ▁occur red ▁ .
▁z y delig ▁was ▁also ▁more ▁effective ▁than ▁place bo ▁in ▁the ▁sub group ▁of ▁patients ▁who ▁had ▁a ▁specific ▁genetic ▁mutation ▁in ▁their ▁cancer ▁cell s ▁that ▁makes ▁them ▁un suit able ▁for ▁certain ▁other ▁ therapie s ▁ .
▁major ▁molecular ▁response ▁criteri a ▁: ▁in ▁the ▁per i pher al ▁blood ▁re duction ▁of ▁ ≥ ▁3 ▁lo gar ith ms ▁in ▁the ▁amount ▁of ▁b cr - a bl ▁tran script s ▁( ▁measure d ▁by ▁real - time ▁quantitat ive ▁rever se ▁tran script ase ▁pc r ▁as say ▁) ▁over ▁a ▁standard ised ▁base line ▁ .
▁des ir udin ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁conditions ▁with ▁increased ▁risk s ▁of ▁ha e mor r hage ▁such ▁as ▁major ▁surgery ▁ , ▁bio psy ▁or ▁punct ure ▁of ▁a ▁non - com press ible ▁ves sel ▁within ▁the ▁last ▁month ▁; ▁a ▁history ▁of ▁ha e mor r hagi c ▁stroke ▁ , ▁in trac rani al ▁or ▁intra o cular ▁ble ed ing ▁including ▁diabet ic ▁( ▁ha e mor r hagi c ▁) ▁retin o pathy ▁; ▁a ▁cerebral ▁is cha e mic ▁attack ▁within ▁the ▁last ▁6 ▁months ▁ , ▁a ▁known ▁ha emo static ▁disorder ▁( ▁con geni tal ▁or ▁acquire d ▁ , ▁e . g . ▁ha emo phil ia ▁ , ▁ liver ▁disease ▁) ▁or ▁a ▁history ▁of ▁gastro inte stin al ▁or ▁pulmonar y ▁ble ed ing ▁within ▁the ▁past ▁3 ▁months ▁ .
▁very ▁rare ▁: ▁er y thema ▁multi forme ▁ , ▁ste ven s - joh n son ▁syndrome ▁and ▁ toxic ▁epi der mal ▁nec rol ysis
▁the ▁concentrat e ▁is ▁a ▁clear ▁pale ▁yellow ▁to ▁brown ish - ye llow ▁solution ▁ .
▁why ▁has ▁fer ri prox ▁been ▁approved ▁?
▁juvenil e ▁dog s ▁developed ▁per i pher al ▁and ▁spin al ▁nerv e ▁les ions ▁at ▁dos es ▁lower ▁than ▁those ▁associated ▁with ▁skelet al ▁muscle ▁ toxic ity ▁ .
▁each ▁tablet ▁contain s ▁approximately ▁214 ▁mg ▁la ctos e ▁mono hydrat e ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁one ▁50 ▁ml ▁vi al ▁with ▁a ▁gre y ▁but yl ▁stopper ▁ , ▁aluminium ▁seal ▁and ▁plastic ▁flip - off ▁cap ▁ .
▁do ▁not ▁use ▁p vc ▁in fusion ▁container s ▁or ▁poly ure than e ▁in fusion ▁set s ▁for ▁the ▁preparation ▁and ▁administration ▁of ▁ jev tana ▁ .
▁as ▁you ▁get ▁older ▁( ▁particularly ▁above ▁about ▁35 ▁years ▁) ▁; ▁if ▁you ▁gave ▁birth ▁less ▁than ▁a ▁few ▁weeks ▁ago ▁ .
▁se psis ▁* ▁( ▁often ▁called ▁" ▁blood ▁pois o ning ▁ , ▁" ▁is ▁a ▁severe ▁infection ▁with ▁whole - body ▁infla mma tory ▁response ▁which ▁can ▁lead ▁to ▁death ▁) ▁ , ▁increase ▁in ▁certain ▁white ▁blood ▁cell s ▁( ▁eos ino phil ia ▁) ▁ , ▁low ▁plate let ▁count ▁( ▁ thro mbo cy top enia ▁) ▁ , ▁severe ▁allergi c ▁reaction ▁( ▁ana phy la ctic ▁reaction ▁) ▁ , ▁allergi c ▁reaction ▁( ▁e . g . ▁ rash ▁ , ▁it ching ▁ , ▁difficult y ▁breath ing ▁ , ▁w hee zing ▁ , ▁swe lling ▁of ▁the ▁face ▁or ▁low ▁blood ▁pressure ▁) ▁ , ▁low ▁blood ▁sugar ▁levels ▁( ▁in ▁diabet ic ▁patients ▁) ▁ , ▁feeling ▁an xio us ▁ , ▁som nol ence ▁ , ▁im pair ed ▁vision ▁ , ▁fast ▁heart ▁beat ▁( ▁ta chy car dia ▁) ▁ , ▁dry ▁mouth ▁ , ▁up set ▁stomach ▁ , ▁taste ▁disturb ance ▁( ▁dys ge usia ▁) ▁ , ▁ab normal ▁ liver ▁function ▁( ▁japanese ▁patients ▁are ▁more ▁likely ▁to ▁experience ▁this ▁side ▁effect ▁) ▁ , ▁rapid ▁swe lling ▁of ▁the ▁skin ▁and ▁mu cosa ▁which ▁can ▁also ▁lead ▁to ▁death ▁( ▁ang io ede ma ▁also ▁with ▁fatal ▁outcome ▁) ▁ , ▁e cze ma ▁( ▁a ▁skin ▁disorder ▁) ▁ , ▁red ness ▁of ▁skin ▁ , ▁hi ves ▁( ▁ur tica ria ▁) ▁ , ▁severe ▁drug ▁ rash ▁ , ▁joint ▁pain ▁( ▁ arth ral gia ▁) ▁ , ▁pain ▁in ▁extrem ity ▁ , ▁tendo n ▁pain ▁ , ▁flu - ▁like - ill ness ▁ , ▁decrease d ▁ha emo glob in ▁( ▁a ▁blood ▁protein ▁) ▁ , ▁increased ▁levels ▁of ▁u ric ▁acid ▁ , ▁increased ▁he pati c ▁enzym es ▁or ▁creati ne ▁ phos pho kina se ▁in ▁the ▁blood ▁ .
▁this ▁is ▁thought ▁to ▁result ▁from ▁the ▁combine d ▁effects ▁of ▁ni tra tes ▁and ▁ avana fil ▁on ▁the ▁ni tric ▁oxid e ▁/ ▁c g mp ▁path way ▁ .
▁advers e ▁reaction s ▁from ▁clinic al ▁trial ▁in ▁children ▁( ▁6 ▁months ▁to ▁17 ▁years ▁old ▁) ▁( ▁study ▁v 87 p 6 ▁)
▁l t ▁to xo id ▁10. 9 ▁log 2 ▁ab ▁titre 1
▁pure va x ▁r cp ▁fel v ▁l yo phil isa te ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion
▁the ▁remain ing ▁two ▁dos es ▁will ▁be ▁given ▁one ▁month ▁ , ▁and ▁six ▁months ▁after ▁the ▁first ▁dose ▁ .
▁poly vin yl ▁ac etate ▁ph thala te ▁ propyl ene ▁gly col ▁( ▁e 15 20 ▁) ▁car mine ▁( ▁e 120 ▁)
▁there ▁are ▁no ▁data ▁from ▁the ▁use ▁of ▁evo ta z ▁in ▁pregnant ▁women ▁ .
▁rep so ▁10 ▁mg ▁film - co ated ▁tablets ▁are ▁white ▁ , ▁round ▁film - co ated ▁tablets ▁ , ▁en grave d ▁with ▁" ▁10 ▁" ▁on ▁one ▁side ▁and ▁" ▁l ▁" ▁on ▁the ▁other ▁ .
▁heart ▁ rhythm ▁problems ▁including ▁very ▁fast ▁heart beat ▁( ▁palp it ations ▁) ▁ , ▁ab normal ▁finding s ▁on ▁heart ▁tests ▁( ▁like ▁ec gs ▁that ▁show ▁heart ▁ rhythm ▁)
▁further more ▁the ▁committee ▁highlight ed ▁the ▁medical ▁need ▁for ▁new ▁agents ▁to ▁treat ▁multi - drug ▁resist ant ▁tubercul osis ▁ .
▁injury ▁ , ▁pois o ning ▁and ▁procedura l ▁complica tions
▁therefore ▁ , ▁co - administration ▁of ▁pit ol isant ▁with ▁ potent ▁cy p 3 a 4 ▁induc ers ▁( ▁e . g . ▁rif ampi cin ▁ , ▁ phen oba rbi tal ▁ , ▁carb amaz e pine ▁ , ▁ phen y to in ▁) ▁should ▁be ▁done ▁with ▁cau tion ▁ .
▁conditions ▁or ▁restriction s ▁with ▁regard ▁to ▁the ▁safe ▁and ▁effective ▁use ▁of ▁the ▁medicinal ▁product
▁the ▁full ▁e par ▁for ▁ri va stig mine ▁sand oz ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁approximately ▁82 ▁% ▁of ▁all ▁patients ▁in ▁the ▁trial ▁had ▁apa che ▁i i ▁( ▁a cute ▁physio log y ▁and ▁chronic ▁health ▁evaluation ▁i i ▁) ▁score s ▁of ▁< ▁10 ▁and ▁2.3 ▁% ▁had ▁bac tera emia ▁at ▁base line ▁ .
▁the ▁recommended ▁dose ▁range s ▁from ▁185 ▁mg ▁/ ▁m 2 ▁/ ▁day ▁( ▁5 ▁mg ▁/ ▁kg ▁/ ▁day ▁) ▁to ▁ 481 ▁mg ▁/ ▁m 2 ▁/ ▁day ▁( ▁13 ▁mg ▁/ ▁kg ▁/ ▁day ▁) ▁divide d ▁in ▁one ▁or ▁two ▁daily ▁in fusion s ▁ , ▁ad minister ed ▁from ▁1 ▁up ▁to ▁2 ▁consecutiv e ▁days ▁before ▁allo gene ic ▁hp ct ▁de pending ▁on ▁the ▁combination ▁with ▁other ▁che mo therapeut ic ▁medicinal ▁products ▁ , ▁without ▁exceed ing ▁the ▁total ▁maximum ▁cum ul ative ▁dose ▁of ▁555 ▁mg ▁/ ▁m 2 ▁( ▁15 ▁mg ▁/ ▁kg ▁) ▁ , ▁during ▁the ▁time ▁of ▁the ▁entire ▁condition ing ▁treatment ▁ .
▁py re xia ▁ , ▁che st ▁pain ▁ , ▁per i pher al ▁oed ema ▁ , ▁mala ise ▁ , ▁feeling ▁hot ▁ , ▁irrita bility ▁ , ▁pain
▁what ▁pan ret in ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁bone ▁problems ▁: ▁some ▁patients ▁taking ▁combination ▁anti ret rovi ral ▁ therapy ▁may ▁develop ▁a ▁bone ▁disease ▁called ▁osteo ne cro sis ▁( ▁death ▁of ▁bone ▁tissu e ▁caused ▁by ▁loss ▁of ▁blood ▁supply ▁to ▁the ▁bone ▁) ▁ .
▁carton s ▁of ▁84 x 1 ▁film - co ated ▁tablets ▁in ▁perfor ated ▁aluminium - alum ini um ▁bli sters
▁if ▁rapid ▁protection ▁against ▁hepatitis ▁b ▁is ▁required ▁ , ▁the ▁standard ▁three ▁dose ▁regime n ▁of ▁the ▁combine d ▁vaccin e ▁contain ing ▁360 ▁el isa ▁unit s ▁of ▁formal in ▁in activa ted ▁hepatitis ▁a ▁virus ▁and ▁10 ▁micro gram s ▁of ▁reco mbin ant ▁hepatitis ▁b ▁surface ▁anti gen ▁is ▁recommended ▁ .
▁c max ▁: ▁0 ▁64 ▁% ▁( ▁0 ▁57 ▁to ▁0 ▁69 ▁)
▁do ▁not ▁use ▁if ▁box ▁has ▁been ▁opened ▁ .
▁data ▁from ▁clinic al ▁studies ▁with ▁reta crit ▁are ▁in ▁line ▁with ▁the ▁safety ▁profile ▁of ▁other ▁author ized ▁er y thro po iet ins ▁ .
▁gly bera ▁ therapy ▁must ▁be ▁pre scribe d ▁by ▁and ▁ad minister ed ▁under ▁the ▁super vision ▁of ▁a ▁physician ▁with ▁expertise ▁in ▁treat ing ▁l pl d ▁patients ▁and ▁in ▁gene ▁ therapy ▁administration ▁ , ▁in ▁full ▁consultation ▁with ▁the ▁patient ▁ .
▁breast - feed ing ▁must ▁be ▁dis continu ed ▁during ▁pe metre x ed ▁treatment ▁ .
▁skin ▁ , ▁hair ▁ , ▁eye ▁ , ▁general ▁: ▁convuls ion ▁ , ▁ inflammation ▁of ▁the ▁op tic ▁nerv e ▁that ▁may ▁cause ▁a ▁complete ▁or ▁parti al ▁loss ▁of ▁vision ▁ , ▁blue - pur ple ▁mot t ling ▁of ▁the ▁skin ▁ , ▁ab normal ly ▁high ▁thy roid ▁function ▁ , ▁ inflammation ▁of ▁the ▁thy roid ▁g land ▁ , ▁ata xia ▁( ▁a ▁condition ▁associated ▁with ▁lack ▁of ▁muscular ▁coordina tion ▁) ▁ , ▁difficult y ▁walking ▁ , ▁mis car ria ge ▁ , ▁ inflammation ▁of ▁the ▁skin ▁blood ▁ves sels ▁ , ▁skin ▁fibro sis
▁because ▁of ▁this ▁risk ▁ , ▁do ▁not ▁drive ▁or ▁operate ▁machine ry ▁for ▁the ▁remain der ▁of ▁the ▁day ▁after ▁each ▁inject ion ▁ .
▁life ▁threat en ing ▁hyper sensitiv ity ▁( ▁ana phy la ctic ▁reaction ▁) ▁to ▁the ▁active ▁substance ▁or ▁to ▁any ▁of ▁the ▁ex cip ient s ▁listed ▁in ▁section ▁6.1 ▁ , ▁when ▁rec hallen ge ▁was ▁un succes s ful ▁( ▁see ▁section s ▁4.4 ▁and ▁4. 8 ▁) ▁ .
▁therefore ▁ , ▁the ▁same ▁problems ▁may ▁be ▁seen ▁if ▁tru vada ▁is ▁ad minister ed ▁with ▁a ▁third ▁nucleo side ▁analog ue ▁ .
▁in ▁ pharma co dynamic ▁studies ▁in ▁healthy ▁volunteer s ▁of ▁p leri xa for ▁alone ▁ , ▁pe ak ▁mobil isation ▁of ▁cd 34 ▁+ ▁cell s ▁was ▁observe d ▁from ▁6 ▁to ▁9 ▁hours ▁after ▁administration ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁wa i ved ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁troba lt ▁in ▁pa e dia tric ▁patients ▁a ged ▁0 ▁to ▁below ▁2 ▁years ▁with ▁len no x ▁ga sta ut ▁syndrome ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁the ▁decision ▁to ▁treat ▁patients ▁with ▁bone ▁metas tas es ▁for ▁the ▁pre vention ▁of ▁skelet al ▁related ▁events ▁should ▁consider ▁that ▁the ▁ons et ▁of ▁treatment ▁effect ▁is ▁2-3 ▁months ▁ .
▁there ▁are ▁no ▁or ▁limited ▁amount ▁of ▁data ▁( ▁less ▁than ▁300 ▁pre gna ncy ▁outcome s ▁) ▁from ▁the ▁use ▁of ▁the ▁combination ▁of ▁des lor ata dine ▁and ▁pseudo ep hed rine ▁sul pha te ▁in ▁pregnant ▁women ▁ .
▁no ▁accumula tion ▁of ▁ime pito in ▁in ▁plasma ▁occur s ▁after ▁repeat ed ▁administration ▁ , ▁once ▁stea dy ▁state ▁is ▁reached ▁ .
▁ava stin ▁may ▁increase ▁the ▁risk ▁of ▁developing ▁serious ▁infection s ▁of ▁the ▁skin ▁or ▁deep er ▁layer s ▁under ▁the ▁skin ▁ , ▁especially ▁if ▁you ▁had ▁hole s ▁in ▁the ▁gut ▁wall ▁or ▁problems ▁with ▁wo und ▁hea ling ▁ .
▁1 ▁in ▁the ▁context ▁of ▁a ▁procedure ▁under ▁article ▁20 ▁of ▁regula tion ▁( ▁ec ▁) ▁no ▁7 26 ▁/ ▁2004 ▁ .
▁if ▁you ▁take ▁more ▁rey ata z ▁than ▁you ▁should
▁in ▁vi tro ▁la mi vu dine ▁inhibi ts ▁the ▁intra cel lular ▁ phos phor y lation ▁of ▁cla dri bine ▁leading ▁to ▁a ▁potential ▁risk ▁of ▁cla dri bine ▁loss ▁of ▁ef fica cy ▁in ▁case ▁of ▁combination ▁in ▁the ▁clinic al ▁setting ▁ .
▁although ▁not ▁studie d ▁clinic ally ▁ , ▁vor ico na zole ▁is ▁likely ▁to ▁increase ▁the ▁plasma ▁concentration s ▁of ▁stati ns ▁that ▁are ▁metabol ised ▁by ▁cy p 3 a 4 ▁and ▁could ▁lead ▁to ▁r hab dom yol ysis ▁ .
▁26 ▁rue ▁de ▁la ▁chap elle ▁68 330 ▁hun ingu e ▁franc e
▁do ▁not ▁use ▁a ▁double ▁dose ▁to ▁make ▁up ▁for ▁a ▁forgotten ▁dose ▁ .
▁the ▁active ▁substance ▁is ▁li xis en ati de ▁ .
▁in ▁a ▁study ▁of ▁fertil ity ▁ , ▁in ▁male ▁rat s ▁dos ed ▁for ▁70 ▁days ▁prior ▁to ▁ma ting ▁ , ▁testi cular ▁and ▁e pidi dy mal ▁weight s ▁and ▁percent ▁mot ile ▁sperm ▁were ▁decrease d ▁at ▁60 ▁mg ▁/ ▁kg ▁ , ▁approximately ▁equal ▁to ▁the ▁maximum ▁clinic al ▁dose ▁of ▁800 ▁mg ▁/ ▁day ▁ , ▁based ▁on ▁body ▁surface ▁area ▁ .
▁wait ▁until ▁the ▁click ing ▁stop s ▁and ▁the ▁green ▁ti ck ▁mark s ▁appear ▁ .
▁per am panel ▁did ▁not ▁prolong ▁the ▁q t c ▁interval ▁when ▁ad minister ed ▁in ▁daily ▁dos es ▁up ▁to ▁12 ▁mg ▁/ ▁day ▁ , ▁and ▁did ▁not ▁have ▁a ▁dose - related ▁or ▁clinic ally ▁important ▁effect ▁on ▁q rs ▁du ration ▁ .
▁however ▁ , ▁there ▁are ▁no ▁known ▁clinic ally ▁significant ▁interaction s ▁with ▁other ▁medicinal ▁products ▁or ▁laborator y ▁tests ▁ .
▁what ▁benefit ▁has ▁spr y cel ▁shown ▁during ▁the ▁studies ▁?
▁dose - related ▁reduc tions ▁in ▁leuk o cy tes ▁and ▁plate let s ▁appear ▁to ▁be ▁sensitive ▁indicator s ▁of ▁ toxic ity ▁ .
▁the ▁tablets ▁contain ▁100 ▁ , ▁200 ▁ , ▁400 ▁ , ▁600 ▁or ▁800 ▁micro gram s ▁of ▁fent an yl ▁ .
▁there ▁is ▁increased ▁risk ▁of ▁la ctic ▁acid osis ▁in ▁a cute ▁alcohol ▁in toxic ation ▁( ▁particularly ▁in ▁the ▁case ▁of ▁fast ing ▁ , ▁mal nutri tion ▁or ▁he pati c ▁insu ffi cie ncy ▁) ▁due ▁to ▁the ▁met form in ▁active ▁substance ▁of ▁glu bra va ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁detailed ▁information ▁of ▁this ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁ .
▁14 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 3 ▁- ▁white ▁28 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 4 ▁- ▁white ▁30 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 5 ▁- ▁white ▁49 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 6 ▁- ▁white ▁56 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 7 ▁- ▁white ▁98 ▁prolong ed - release ▁tablets ▁- ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 395 ▁/ ▁08 8 ▁- ▁white
▁the ▁degree ▁of ▁cy to gene tic ▁response ▁and ▁molecular ▁response ▁had ▁a ▁clear ▁effect ▁on ▁long - term ▁outcome s ▁in ▁patients ▁on ▁imati ni b ▁ .
▁the ▁sign s ▁ , ▁symptoms ▁ , ▁and ▁sever ity ▁will ▁var y ▁according ▁to ▁the ▁location ▁and ▁degree ▁or ▁extent ▁of ▁the ▁ble ed ing ▁( ▁see ▁section s ▁4.4 ▁and ▁5.1 ▁) ▁ .
▁el der ly ▁( ▁above ▁65 ▁years ▁)
▁a ▁dominant ▁le thal ▁as say ▁in ▁rat s ▁was ▁negative ▁ , ▁indicat ing ▁that ▁if ▁mutation s ▁occur red ▁in ▁rat s ▁they ▁were ▁not ▁transmit ted ▁through ▁male ▁game tes ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁when ▁em trici ta bine ▁is ▁co - ad minister ed ▁with ▁medicinal ▁products ▁that ▁are ▁elimina ted ▁by ▁active ▁tub ular ▁secret ion ▁as ▁such ▁co - administration ▁may ▁lead ▁to ▁an ▁increase ▁in ▁se rum ▁concentration s ▁of ▁either ▁em trici ta bine ▁or ▁a ▁co - ad minister ed ▁medicinal ▁product ▁ , ▁due ▁to ▁competition ▁for ▁this ▁elimina tion ▁path way ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁mean ▁stea dy - state ▁tro ugh ▁plasma ▁concentration s ▁of ▁between ▁0.0 4 ▁and ▁0.0 7 ▁mg ▁/ ▁l ▁are ▁reached ▁within ▁3 ▁to ▁4 ▁days ▁with ▁once - daily ▁dos ing ▁of ▁te li thro my cin ▁800 ▁mg ▁ .
▁local ▁skin ▁infection ▁regardless ▁of ▁specific ▁a eti ology ▁including ▁but ▁not ▁limited ▁to ▁:
▁once ▁a ▁sy ringe ▁has ▁been ▁removed ▁from ▁the ▁refrigera tor ▁and ▁has ▁reached ▁room ▁temperature ▁( ▁not ▁above ▁30 ▁c ▁) ▁it ▁must ▁either ▁be ▁used ▁within ▁3 ▁days ▁or ▁dispose d ▁of ▁ .
▁in ▁female ▁versus ▁male ▁subject s ▁ad minister ed ▁oral ▁olan za pine ▁the ▁mean ▁elimina tion ▁half ▁life ▁was ▁somewhat ▁prolong ed ▁( ▁3 6.7 ▁versus ▁3 2.3 ▁hr s ▁) ▁and ▁the ▁clear ance ▁was ▁reduce d ▁( ▁18. 9 ▁versus ▁27. 3 ▁l ▁/ ▁hr ▁) ▁ .
▁pho sal ▁50 ▁p g ▁( ▁ phos pha tid yl cho line ▁ , ▁ propyl ene ▁gly col ▁ , ▁mono - and ▁dig ly ceri des ▁ , ▁et han ol ▁ , ▁so ya ▁fa tty ▁acid s ▁and ▁as cor byl ▁palm itate ▁) ▁ .
▁in ▁non - ende mic ▁areas ▁there ▁should ▁be ▁no ▁risk ▁of ▁cat s ▁having ▁heart worm ▁ .
▁keep ▁out ▁of ▁reach ▁of ▁children ▁ .
▁what ▁ad va graf ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁the ▁effective ness ▁of ▁bra vec to ▁against ▁fle as ▁and ▁ti cks ▁was ▁investiga ted ▁in ▁both ▁laborator y ▁and ▁field ▁studies ▁ .
▁please ▁refer ▁to ▁the ▁patient ▁information ▁le a flet s ▁of ▁the ▁other ▁anti ret rovi ral s ▁for ▁guidance ▁on ▁how ▁to ▁take ▁those ▁medicine s ▁ .
▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁0 26 ▁4 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁device ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁0 27 ▁6 ▁pre - fill ed ▁sy ring es
▁if ▁you ▁have ▁any ▁further ▁questions ▁on ▁the ▁use ▁of ▁this ▁product ▁ , ▁ask ▁your ▁doctor ▁or ▁hospital ▁ pharma ci st ▁or ▁nurse ▁ .
▁immun e ▁re activa tion ▁syndrome ▁: ▁in ▁hi v - infect ed ▁patients ▁with ▁severe ▁immun e ▁de fici en cy ▁at ▁the ▁time ▁of ▁institution ▁of ▁combination ▁anti ret rovi ral ▁ therapy ▁( ▁cart ▁) ▁ , ▁an ▁infla mma tory ▁reaction ▁to ▁as ym pto matic ▁or ▁residu al ▁opportun istic ▁path ogen s ▁may ▁a rise ▁and ▁cause ▁serious ▁clinic al ▁conditions ▁ , ▁or ▁ag grav ation ▁of ▁symptoms ▁ .
▁doce ta xel ▁ pharma cok ine tics ▁in ▁the ▁presence ▁of ▁pred nis one ▁was ▁studie d ▁in ▁patients ▁with ▁me static ▁prostat e ▁cancer ▁ .
▁replace ment ▁ therapy ▁in ▁seconda ry ▁immun o de fici en cy
▁although ▁not ▁specifically ▁studie d ▁with ▁the ▁coa prove l ▁ , ▁re bound ▁hyper tension ▁has ▁not ▁been ▁seen ▁with ▁either ▁ir besar tan ▁or ▁hydro ch lor o thi azi de ▁ .
▁the ▁tablets ▁should ▁be ▁taken ▁by ▁mouth ▁ , ▁every ▁12 ▁hours ▁ , ▁at ▁the ▁same ▁time ▁of ▁the ▁day ▁each ▁day ▁( ▁e . g . ▁in ▁the ▁morning ▁and ▁evening ▁) ▁ .
▁each ▁vi al ▁contain s ▁10 ▁ml ▁of ▁solution ▁ .
▁if ▁this ▁happens ▁do ▁not ▁drive ▁or ▁use ▁any ▁tools ▁or ▁machines ▁ .
▁a ▁coa g ulation ▁test ▁helps ▁to ▁identify ▁patients ▁with ▁an ▁increased ▁ble ed ing ▁risk ▁due ▁to ▁increased ▁da biga tran ▁exposure ▁ .
▁administration ▁of ▁the lin ▁to ▁female ▁rat s ▁from ▁late - pre gna ncy ▁through ▁lac tation ▁reduce d ▁pup ▁survival ▁ , ▁and ▁caused ▁testi s ▁tub ular ▁a plas ia ▁and ▁de lay ed ▁vaginal ▁opening ▁at ▁the ▁lo west ▁exposure ▁test ed ▁( ▁17 -45 ▁times ▁the ▁human ▁exposure ▁) ▁ .
▁in ▁the ▁case ▁of ▁treatment - related ▁advers e ▁events ▁ , ▁dis continu ation ▁of ▁vor ico na zole ▁and ▁use ▁of ▁alternative ▁anti fung al ▁agents ▁must ▁be ▁considered ▁( ▁see ▁section ▁4.4 ▁and ▁4. 8 ▁)
▁improvement s ▁were ▁seen ▁in ▁up dr s ▁parts ▁i ▁- ▁i v ▁score s ▁ .
▁the ▁powder ▁in ▁the ▁capsule s ▁must ▁only ▁be ▁in hal ed ▁using ▁the ▁in hal er ▁included ▁in ▁the ▁pack ▁ .
▁the ▁most ▁frequent ▁renal - related ▁advers e ▁reaction ▁was ▁blood ▁creati nine ▁increased ▁( ▁4.3 ▁% ▁with ▁zu ram pic ▁200 ▁mg ▁and ▁ 7.8 ▁% ▁with ▁zu ram pic ▁400 ▁mg ▁compared ▁to ▁2.3 ▁% ▁with ▁place bo ▁) ▁ .
▁the ▁primary ▁end point ▁was ▁the ▁or r ▁define d ▁as ▁the ▁proportion ▁of ▁subject s ▁who ▁achieve d ▁a ▁cr ▁or ▁pr ▁( ▁based ▁on ▁the ▁revi sed ▁response ▁criteri a ▁for ▁malign ant ▁lymph oma ▁[ ▁che son ▁] ▁) ▁ , ▁and ▁ , ▁for ▁subject s ▁with ▁wal den ström ▁macro glob ul ina emia ▁ , ▁a ▁minor ▁response ▁( ▁mr ▁) ▁( ▁based ▁on ▁the ▁response ▁assessment ▁for ▁wal den ström ▁macro glob ul ina emia ▁[ ▁o wen ▁] ▁) ▁ .
▁a baca vir ▁is ▁not ▁recommended ▁in ▁patients ▁with ▁moderat e ▁or ▁severe ▁he pati c ▁im pair ment ▁ .
▁slightly ▁increased ▁incide nce ▁of ▁testi cular ▁tub ular ▁a trop hy ▁was ▁observe d ▁in ▁rat s ▁given ▁bo sent an ▁oral ly ▁at ▁dos es ▁as ▁low ▁as ▁125 ▁mg ▁/ ▁kg ▁/ ▁day ▁( ▁about ▁4 ▁times ▁the ▁maximum ▁recommended ▁human ▁dose ▁[ ▁mr hd ▁] ▁and ▁the ▁lo west ▁dos es ▁test ed ▁) ▁for ▁two ▁years ▁but ▁not ▁at ▁dos es ▁as ▁high ▁as ▁1500 ▁mg ▁/ ▁kg ▁/ ▁day ▁( ▁about ▁50 ▁times ▁the ▁mr hd ▁) ▁for ▁6 ▁months ▁ .
▁intro na ▁may ▁be ▁ad minister ed ▁using ▁either ▁glass ▁or ▁plastic ▁disposa ble ▁inject ion ▁sy ring es ▁ .
▁seven ty - th re e ▁percent ▁of ▁nucleo side - exp erien ced ▁and ▁69 ▁% ▁of ▁nucleo side - na ï ve ▁patients ▁achieve d ▁complete ▁response ▁to ▁treatment ▁; ▁90 ▁% ▁of ▁nucleo side - exp erien ced ▁and ▁88 ▁% ▁of ▁nucleo side - na ï ve ▁patients ▁achieve d ▁ hb v ▁d na ▁sup pression ▁< ▁400 ▁copie s ▁/ ▁ml ▁ .
▁do ▁not ▁mix ▁zo meta ▁recon stitu ted ▁solution ▁with ▁calci um - conta ining ▁or ▁other ▁di valent ▁ cation - conta ining ▁solutions ▁such ▁as ▁la cta ted ▁ ringer ▁' s ▁solution ▁ .
▁the ▁mah ▁shall ▁perform ▁the ▁required ▁ pharma co vigil ance ▁activities ▁and ▁intervention s ▁detailed ▁in ▁the ▁agreed ▁r mp ▁presente d ▁in ▁module ▁1. 8.2 ▁of ▁the ▁marketing ▁author isation ▁and ▁any ▁subsequent ▁updates ▁of ▁the ▁r mp ▁ .
▁co - administration ▁of ▁desco vy ▁with ▁other ▁medicinal ▁products ▁that ▁inhibi t ▁p - gp ▁( ▁e . g . ▁ , ▁co bici stat ▁ , ▁rito na vir ▁ , ▁ciclo spor in ▁) ▁are ▁expected ▁to ▁increase ▁the ▁ab sor p tion ▁and ▁plasma ▁concentration ▁of ▁te no fo vir ▁ala fen ami de ▁ .
▁30 ▁to ▁49 ▁ml ▁/ ▁min
▁i clusi g ▁should ▁be ▁used ▁during ▁pre gna ncy ▁only ▁when ▁clearly ▁necessary ▁ .
▁for ▁detailed ▁results ▁see ▁table ▁4 ▁ .
▁60 ▁x ▁1 ▁tablet
▁push ▁up ▁the ▁plu nger ▁slowly ▁back ▁to ▁the ▁correct ▁dose ▁ .
▁these ▁are ▁considered ▁to ▁be ▁related ▁to ▁art ▁or ▁subsequent ▁pre gna ncy ▁ .
▁when ▁your ▁supply ▁of ▁a trip la ▁start s ▁to ▁run ▁low ▁ , ▁get ▁more ▁from ▁your ▁doctor ▁or ▁ pharma ci st ▁ .
▁you ▁should ▁take ▁ammo nap s ▁in ▁equal ly ▁divide d ▁dos es ▁by ▁mouth ▁ , ▁through ▁a ▁gastro sto my ▁( ▁tube ▁that ▁goes ▁through ▁the ▁ab dom en ▁to ▁the ▁stomach ▁) ▁or ▁through ▁a ▁na so gas tric ▁tube ▁( ▁tube ▁that ▁goes ▁through ▁the ▁nos e ▁to ▁the ▁stomach ▁) ▁ .
▁for ▁men ▁taking ▁rev limi d
▁additional ▁information ▁on ▁individual ▁component s ▁: ▁in ▁addition ▁to ▁the ▁advers e ▁reaction s ▁listed ▁above ▁for ▁the ▁combination ▁product ▁ , ▁other ▁advers e ▁reaction s ▁previously ▁reported ▁with ▁one ▁of ▁the ▁individual ▁component s ▁may ▁be ▁potential ▁advers e ▁reaction s ▁with ▁ir besar tan ▁hydro ch lor o thi azi de ▁b ms ▁ .
▁reduce d ▁number ▁of ▁blood ▁cell s ▁( ▁neutro p enia ▁ , ▁ thro mbo cy top enia ▁ , ▁lymph op enia ▁ , ▁leuk op enia ▁)
▁the ▁most ▁common ▁side ▁effects ▁with ▁fer ri prox ▁( ▁seen ▁in ▁more ▁than ▁1 ▁patient ▁in ▁10 ▁) ▁are ▁redd ish - brow n ▁urin e ▁( ▁showing ▁that ▁ir on ▁is ▁being ▁elimina ted ▁) ▁ , ▁na use a ▁( ▁feeling ▁sick ▁) ▁ , ▁abdominal ▁pain ▁( ▁stomach ▁a che ▁) ▁and ▁vom i ting ▁ .
▁also ▁contain s ▁: ▁meta cre sol ▁ , ▁so dium ▁chlor ide ▁( ▁see ▁le a flet ▁for ▁further ▁information ▁) ▁ , ▁tro meta mol ▁ , ▁poly sor bate ▁20 ▁ , ▁concentrat ed ▁hydro ch lor ic ▁acid ▁ , ▁so dium ▁hydro xi de ▁( ▁see ▁le a flet ▁for ▁further ▁information ▁) ▁ , ▁water ▁for ▁inject ions ▁ .
▁for ▁patients ▁in adequa tely ▁control led ▁on ▁gli me piri de ▁mono therapy ▁( ▁typically ▁4 ▁mg ▁) ▁ .
▁before ▁using ▁ , ▁inspect ▁the ▁vi al ▁content s ▁ .
▁ ≥ ▁600 ▁μ mol ▁/ ▁l ▁ , ▁4 1.9 ▁% ▁( ▁13 ▁/ ▁31 ▁) ▁of ▁those ▁treated ▁with ▁sa prop ter in ▁and ▁13. 2 ▁% ▁( ▁5 ▁/ ▁38 ▁) ▁of ▁those ▁treated ▁with ▁place bo ▁had ▁blood ▁ phen yla lan ine ▁levels ▁< ▁600 ▁μ mol ▁/ ▁l ▁at ▁the ▁end ▁of ▁the ▁6- week ▁study ▁period ▁( ▁p ▁= ▁0.0 12 ▁) ▁ .
▁rien so ▁is ▁a ▁collo i dal ▁ir on - car bo hydrat e ▁complex ▁ .
▁key ▁data ▁are ▁summa ris ed ▁in ▁table ▁2 ▁:
▁a ▁war ning ▁message ▁for ▁h cp s ▁treat ing ▁the ▁patient ▁at ▁any ▁time ▁ , ▁including ▁in ▁conditions ▁of ▁emergency ▁ , ▁that ▁the ▁patient ▁has ▁been ▁treated ▁with ▁le m tra da
▁the ▁active ▁substance ▁is ▁de fi bro ti de ▁ .
▁the ▁mean ▁a au cm bs ▁( ▁log 10 ▁c ▁/ ▁ml ▁) ▁in ▁the ▁itt ▁( ▁e ▁) ▁population ▁( ▁observe d ▁analysis ▁) ▁at ▁48 ▁weeks ▁( ▁primary ▁end - point ▁) ▁and ▁other ▁ef fica cy ▁outcome s ▁by ▁sub group ▁are ▁described ▁in ▁the ▁table s ▁below ▁:
▁con com i tant ▁use ▁of ▁gin k go ▁bilo ba ▁extract s ▁is ▁not ▁recommended ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁it ▁is ▁available ▁as ▁a ▁powder ▁and ▁solve nt ▁that ▁are ▁mix ed ▁together ▁to ▁make ▁a ▁prolong ed - release ▁suspens ion ▁for ▁inject ion ▁that ▁provides ▁2 ▁mg ▁of ▁ex en ati de ▁ .
▁if ▁you ▁exercise ▁more ▁than ▁usual
▁how ▁has ▁des lor ata dine ▁ratio ph arm ▁been ▁studie d ▁?
▁id nt ▁was ▁a ▁double ▁blind ▁ , ▁control led ▁ , ▁morbi d ity ▁and ▁mortal ity ▁trial ▁compar ing ▁ir besar tan ▁ , ▁am lo di pine ▁and ▁place bo ▁ .
▁gaz y varo ▁is ▁a ▁cancer ▁medicine ▁used ▁to ▁treat ▁adult ▁patients ▁with ▁:
▁during ▁ha e modi al ysis ▁ , ▁patients ▁treated ▁with ▁dy ne po ▁may ▁require ▁increased ▁antico ag ulation ▁treatment ▁to ▁prevent ▁clo tting ▁of ▁the ▁arteri o - ven ous ▁shu nt ▁ .
▁in ▁patients ▁with ▁a ▁pred is pos ing ▁risk ▁due ▁to ▁previous ▁prolong ed ▁ , ▁system ic ▁amino gly co side ▁ therapy ▁it ▁may ▁be ▁necessary ▁to ▁consider ▁renal ▁and ▁audi ological ▁assessment ▁before ▁initiat ing ▁to bi ▁pod hal er ▁ therapy ▁ .
▁if ▁you ▁have ▁been ▁told ▁by ▁your ▁doctor ▁that ▁you ▁have ▁an ▁in tolerance ▁to ▁some ▁sugar s ▁ , ▁contact ▁your ▁doctor ▁before ▁taking ▁this ▁medicinal ▁product ▁ .
▁keep ▁the ▁container ▁in ▁the ▁out er ▁carton ▁in ▁order ▁to ▁protect ▁from ▁light ▁ .
▁the ▁label ▁on ▁the ▁insulin ▁vi al ▁should ▁be ▁check ed ▁before ▁use ▁to ▁make ▁sure ▁this ▁is ▁the ▁correct ▁insulin ▁for ▁the ▁intended ▁route ▁of ▁administration ▁ .
▁be ▁very ▁care ful ▁if ▁you ▁do ▁change ▁insulin ▁ .
▁the ▁media n ▁dose ▁per ▁pro phy la ctic ▁in fusion ▁was ▁3 7.8 ▁iu ▁/ ▁kg ▁ .
▁studies ▁in ▁animals ▁have ▁shown ▁reproduc tive ▁ toxic ity ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁kom bog ly ze ▁is ▁used ▁in ▁adults ▁with ▁type ▁2 ▁diabetes ▁to ▁improve ▁the ▁control ▁of ▁blood ▁gluco se ▁( ▁sugar ▁) ▁levels ▁ .
▁what ▁pande mic ▁influenza ▁vaccin e ▁h 5 n 1 ▁med im mu ne ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁you ▁should ▁not ▁take ▁viagra ▁if ▁you ▁are ▁taking ▁medicine s ▁called ▁ni tra tes ▁ , ▁as ▁the ▁combination ▁of ▁these ▁medicine s ▁may ▁lead ▁to ▁a ▁dangerous ▁fall ▁in ▁your ▁blood ▁pressure ▁ .
▁common ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁:
▁cat ▁vaccin ation ▁during ▁and ▁after ▁vir ba gen ▁omega ▁treatment ▁is ▁contra - indica ted ▁as ▁both ▁fel v ▁and ▁fi v ▁infection s ▁are ▁known ▁to ▁be ▁immun os up press ive ▁ .
▁a ce tyl sali cy lic ▁acid ▁and ▁ nsa ids ▁in ▁a ▁two - year ▁study ▁in ▁post meno paus al ▁women ▁with ▁osteo por osis ▁( ▁b m ▁16 549 ▁) ▁ , ▁the ▁incide nce ▁of ▁upp er ▁gastro inte stin al ▁events ▁in ▁patients ▁con com i tant ly ▁taking ▁a ce tyl sali cy lic ▁acid ▁or ▁ nsa ids ▁was ▁similar ▁in ▁patients ▁taking ▁iba ndro nic ▁acid ▁2.5 ▁mg ▁daily ▁or ▁150 ▁mg ▁once ▁monthly ▁after ▁one ▁and ▁two ▁years ▁ .
▁two ▁pack - size s ▁of ▁of ev ▁150 ▁mg ▁capsule s ▁are ▁available ▁:
▁brin a ves s ▁is ▁to ▁be ▁used ▁for ▁fi bril lation ▁that ▁has ▁started ▁within ▁the ▁last ▁seven ▁days ▁ , ▁or ▁within ▁the ▁last ▁three ▁days ▁if ▁the ▁patient ▁had ▁recently ▁had ▁heart ▁surgery ▁ .
▁animal ▁studies ▁have ▁shown ▁ex cre tion ▁of ▁i dur sul fase ▁in ▁breast ▁milk ▁ .
▁clo pido gre l ▁teva ▁75 ▁mg ▁film - co ated ▁tablets
▁spin os ad ▁could ▁therefore ▁interact ▁with ▁other ▁p gp - sub strate s ▁( ▁for ▁example ▁ , ▁digo xin ▁ , ▁do xor ubi cin ▁) ▁and ▁possibly ▁enhance ▁advers e ▁reaction s ▁from ▁such ▁mole cules ▁or ▁compromis e ▁ef fica cy ▁ .
▁if ▁you ▁have ▁hearing ▁problem ▁ , ▁count ▁15 ▁seconds ▁from ▁the ▁time ▁you ▁first ▁press ▁the ▁button ▁and ▁then ▁lift ▁the ▁pre - fill ed ▁pen ▁from ▁the ▁inject ion ▁site ▁ .
▁er y thema ▁multi form 1 ▁ , ▁ste ven s - joh n son ▁syndrome 1 ▁ , ▁ toxic ▁epi der mal ▁nec rol ysis 1
▁in ▁the ▁presence ▁of ▁renal ▁im pair ment ▁ , ▁mean ▁pe ak ▁plasma ▁levels ▁and ▁au c ▁values ▁of ▁hydro ch lor o thi azi de ▁are ▁increased ▁and ▁the ▁urin ary ▁ex cre tion ▁rate ▁is ▁reduce d ▁ .
▁pigment ation ▁disorder ▁ , ▁dermatit is ▁a topic ▁ , ▁skin ▁ex folia tion
▁this ▁medicine ▁is ▁an ▁anti tum our ▁agent ▁ .
▁in ▁horse s ▁ , ▁after ▁intra ven ous ▁inject ion ▁melo xi cam ▁is ▁elimina ted ▁with ▁a ▁terminal ▁half - life ▁of ▁ 8.5 ▁hours ▁ .
▁contact ▁your ▁doctor ▁and ▁dentist ▁immediately ▁if ▁you ▁experience ▁any ▁problems ▁with ▁your ▁mouth ▁or ▁te eth ▁such ▁as ▁loo se ▁te eth ▁ , ▁pain ▁or ▁swe lling ▁ , ▁non - hea ling ▁of ▁so res ▁or ▁dis charge ▁ , ▁as ▁these ▁could ▁be ▁sign s ▁of ▁osteo ne cro sis ▁of ▁the ▁ja w ▁ .
▁the ▁side ▁effects ▁listed ▁below ▁have ▁happened ▁with ▁h 1 n 1 ▁as 03 - conta ining ▁vaccin es ▁ .
▁9 ▁in ▁active ▁compara tor ▁control led ▁trial s ▁mean ▁weight ▁increase ▁with ▁pi og lita zone ▁given ▁as ▁mono therapy ▁was ▁2 ▁- ▁3 ▁kg ▁over ▁one ▁year ▁ .
▁the ▁child ▁is ▁to ▁drink ▁the ▁entire ▁residu al ▁mix ture ▁ .
▁it ▁may ▁contain ▁trace ▁amount s ▁of ▁clear ▁to ▁white ▁parti cles ▁ .
▁drink ing ▁alcohol ▁and ▁taking ▁novom ix ▁50
▁12 ▁ , ▁rue ▁and ré ▁hu et ▁51 100 ▁rei ms
▁if ▁you ▁have ▁type ▁1 ▁diabetes ▁ .
▁the ▁head ▁of ▁the ▁cat ▁should ▁be ▁held ▁with ▁its ▁nos e ▁point ing ▁up ward ▁and ▁its ▁mouth ▁closed ▁ , ▁so ▁that ▁it ▁is ▁forced ▁to ▁breath e ▁through ▁its ▁nostri ls ▁ .
▁other ▁information ▁about ▁tres iba
▁acquire d ▁hypo thy roid ism ▁was ▁not ed ▁in ▁6.2 ▁% ▁of ▁gi st ▁patients ▁on ▁sun itin ib ▁versus ▁1 ▁% ▁on ▁place bo ▁ .
▁in ▁clinic al ▁trial s ▁ , ▁there ▁was ▁an ▁increased ▁incide nce ▁of ▁these ▁events ▁in ▁older ▁people ▁and ▁those ▁with ▁a ▁prior ▁history ▁of ▁cardiac ▁disease ▁ .
▁in fusion ▁related ▁reaction ▁events ▁in ▁p jia ▁patients ▁included ▁but ▁were ▁not ▁limited ▁to ▁head ache ▁ , ▁na use a ▁and ▁hypo tension
▁the ▁active ▁substance ▁is ▁clo pido gre l ▁ .
▁the ▁mean ▁( ▁% ▁cv ▁) ▁em trici ta bine ▁drug ▁exposure ▁increased ▁from ▁12 ▁( ▁25 ▁% ▁) ▁μ g ▁• ▁h ▁/ ▁ml ▁in ▁subject s ▁with ▁normal ▁renal ▁function ▁ , ▁to ▁20 ▁( ▁6 ▁% ▁) ▁μ g ▁• ▁h ▁/ ▁ml ▁ , ▁25 ▁( ▁23 ▁% ▁) ▁μ g ▁• ▁h ▁/ ▁ml ▁and ▁34 ▁( ▁6 ▁% ▁) ▁μ g ▁• ▁h ▁/ ▁ml ▁ , ▁in ▁subject s ▁with ▁mild ▁ , ▁moderat e ▁and ▁severe ▁renal ▁im pair ment ▁ , ▁respective ly ▁ .
▁> ▁8 ▁x ▁ul n ▁: ▁treatment ▁must ▁be ▁stopped ▁and ▁rein tro duction ▁of ▁the lin ▁is ▁not ▁to ▁be ▁considered ▁ .
▁administration ▁: ▁when ▁recon stitu tion ▁and ▁dilu tion ▁are ▁perform ed ▁under ▁a se ptic ▁conditions ▁or encia ▁in fusion ▁solution ▁can ▁be ▁used ▁immediately ▁or ▁within ▁24 ▁hours ▁if ▁store d ▁refrigera ted ▁at ▁2 ▁° ▁c ▁to ▁8 ▁° ▁c . ▁however ▁ , ▁for ▁micro bi ological ▁reasons ▁ , ▁it ▁is ▁to ▁be ▁used ▁immediately ▁ .
▁use ▁of ▁firma gon ▁has ▁not ▁been ▁investiga ted ▁in ▁patients ▁with ▁severe ▁ki dne y ▁disease ▁ .
▁in ▁situations ▁where ▁the ▁veni punct ure ▁set ▁provided ▁cannot ▁be ▁used ▁( ▁e . g . ▁when ▁in fus ing ▁into ▁a ▁per i pher al ▁or ▁central ▁line ▁) ▁ , ▁a ▁separate ▁filter ▁compatible ▁with ▁ko gen ate ▁bay er ▁should ▁be ▁used ▁ .
▁how ▁has ▁clo pido gre l ▁b gr ▁been ▁studie d ▁?
▁in ▁the ▁two - year ▁place bo - control led ▁study ▁ , ▁hyper tension ▁was ▁reported ▁as ▁an ▁advers e ▁event ▁in ▁6.5 ▁% ▁of ▁patients ▁on ▁fin go li mod ▁0.5 ▁mg ▁and ▁in ▁3.3 ▁% ▁of ▁patients ▁on ▁place bo ▁ .
▁conditions ▁with ▁increased ▁potential ▁for ▁gastro inte stin al ▁perfor ation
▁following ▁administration ▁ , ▁ovi tre lle ▁may ▁interfere ▁for ▁up ▁to ▁ten ▁days ▁with ▁the ▁immun ological ▁determina tion ▁of ▁se rum ▁or ▁urin ary ▁h c g ▁ , ▁potential ly ▁leading ▁to ▁a ▁false ▁positive ▁pre gna ncy ▁test ▁ .
▁ari claim ▁has ▁been ▁studie d ▁in ▁two ▁12- week ▁studies ▁in ▁8 09 ▁diabet ic ▁adults ▁who ▁had ▁had ▁pain ▁every ▁day ▁for ▁at ▁least ▁six ▁months ▁ .
▁for ▁more ▁information ▁about ▁treatment ▁with ▁a iv los in ▁animal ▁owners ▁or ▁keep ers ▁should ▁read ▁the ▁package ▁le a flet ▁or ▁contact ▁their ▁veterinar ian ▁or ▁ pharma ci st ▁ .
▁pack ▁size ▁of ▁1 ▁vi al ▁ .
▁therefore ▁garda sil ▁can ▁be ▁used ▁during ▁breast - feed ing ▁ .
▁if ▁you ▁are ▁pregnant ▁ , ▁you ▁should ▁take ▁sus tiva ▁only ▁if ▁you ▁and ▁your ▁doctor ▁decide ▁it ▁is ▁clearly ▁needed ▁ .
▁as ▁the ▁half - life ▁of ▁met ho tre xa te ▁can ▁be ▁prolong ed ▁to ▁4 ▁times ▁the ▁normal ▁length ▁in ▁patients ▁who ▁possess ▁a ▁third ▁distribution ▁space ▁dose ▁re duction ▁ , ▁in ▁some ▁cases ▁ , ▁dis continu ation ▁of ▁met ho tre xa te ▁administration ▁may ▁be ▁required ▁( ▁see ▁section s ▁5.2 ▁and ▁4.4 ▁) ▁ .
▁mal form ations ▁of ▁the ▁reproduc tive ▁organ s ▁incomp ati ble ▁with ▁pre gna ncy ▁ .
▁the ▁main ▁function ▁of ▁ser pin s ▁is ▁to ▁regula te ▁the ▁activity ▁of ▁ser ine ▁prote as es ▁ .
▁anti vir al ▁activity ▁in ▁cell ▁culture
▁tell ▁your ▁doctor ▁immediately ▁if ▁you ▁get ▁either ▁of ▁these ▁symptoms ▁ .
▁kad cy la ▁160 mg ▁: ▁using ▁a ▁steril e ▁sy ringe ▁ , ▁slowly ▁inject ▁8 ▁ml ▁of ▁steril e ▁water ▁for ▁inject ion ▁into ▁the ▁160 ▁mg ▁tras tuz um ab ▁em tan sine ▁vi al ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁ , ▁for ▁versi can ▁plus ▁l 4 ▁on ▁31 ▁jul y ▁2014 ▁ .
▁maximum ▁number ▁of ▁piercing s ▁is ▁14 ▁for ▁the ▁20 ▁ml ▁ , ▁50 ▁ml ▁and ▁100 ▁ml ▁stopper s ▁and ▁20 ▁for ▁the ▁250 ▁ml ▁stopper ▁ .
▁cart ridge ▁( ▁glass ▁) ▁in ▁pre - fill ed ▁pen ▁( ▁opt iset ▁) ▁cart ridge
▁in ▁patients ▁treated ▁for ▁pre vention ▁of ▁stroke ▁and ▁system ic ▁e mbol ism ▁ , ▁ble ed ing ▁of ▁any ▁type ▁or ▁sever ity ▁was ▁reported ▁with ▁an ▁event ▁rate ▁of ▁28 ▁per ▁100 ▁patient ▁years ▁ , ▁and ▁ana emia ▁with ▁an ▁event ▁rate ▁of ▁2.5 ▁per ▁100 ▁patient ▁years ▁ .
▁administration ▁of ▁de fit elio ▁to ▁patients ▁who ▁have ▁ha emo dynamic ▁in st ability ▁ , ▁define d ▁as ▁in ability ▁to ▁maintain ▁mean ▁arterial ▁pressure ▁with ▁single ▁presso r ▁support ▁ , ▁is ▁not ▁recommended ▁ .
▁check ▁that ▁you ▁have ▁the ▁correct ▁product ▁and ▁the ▁correct ▁dose ▁( ▁gre y ▁plu nger ▁for ▁150 ▁mg ▁/ ▁ml ▁) ▁ .
▁ liver ▁transplant ▁recipient s ▁- ▁study ▁01 26
▁complete ▁symptom a tic ▁response ▁is ▁define d ▁as ▁a ▁100 ▁% ▁re duction ▁in ▁the ▁base line ▁m cd ▁overall ▁symptom ▁score ▁sustain ed ▁for ▁at ▁least ▁18 ▁weeks ▁prior ▁to ▁treatment ▁failure
▁following ▁con com i tant ▁administration ▁of ▁a ▁single ▁dose ▁of ▁le flu nom ide ▁to ▁subject s ▁receiving ▁multiple ▁dos es ▁of ▁rif ampi cin ▁( ▁non - specific ▁cy to ch rom e ▁p 450 ▁induc er ▁) ▁a 77 17 26 ▁pe ak ▁levels ▁were ▁increased ▁by ▁approximately ▁40 ▁% ▁ , ▁where as ▁the ▁au c ▁was ▁not ▁significantly ▁changed ▁ .
▁1 ▁advers e ▁reaction ▁observe d ▁with ▁ul ti bro ▁bre ezh a ler ▁ , ▁but ▁not ▁with ▁the ▁individual ▁component s ▁ .
▁se vela mer ▁carbon ate ▁zen tiva ▁800 ▁mg ▁film - co ated ▁tablets ▁se vela mer ▁carbon ate
▁ 0.8 62 ▁( ▁0 . 676 ▁to ▁1. 100 ▁)
▁tru licit y ▁0 . 75 ▁mg ▁solution ▁for ▁inject ion ▁in ▁pre - fill ed ▁pen ▁du la glut ide
▁the ▁full ▁e par ▁for ▁re bet ol ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁the ▁extent ▁of ▁this ▁effect ▁was ▁dependent ▁on ▁the ▁absolute ▁degree ▁of ▁hyper ho mo cy stein emia ▁ , ▁being ▁higher ▁in ▁severe ▁hyper ho mo cy stein emia ▁ .
▁the ▁clinic al ▁ef fica cy ▁and ▁safety ▁of ▁ lon surf ▁were ▁evaluat ed ▁in ▁an ▁international ▁ , ▁random ised ▁ , ▁double - ▁blind ▁ , ▁place bo - control led ▁phase ▁i ii ▁study ▁( ▁recours e ▁) ▁in ▁patients ▁with ▁previously ▁treated ▁meta static ▁colore c tal ▁cancer ▁ .
▁difficult y ▁breath ing ▁with ▁w hee zing ▁or ▁co ugh ing ▁ .
▁once ▁opened ▁use ▁within ▁24 ▁hours ▁( ▁store ▁at ▁2 ▁c ▁- ▁8 ▁c ▁) ▁ .
▁safety ▁and ▁ef fica cy ▁in ▁children ▁a ged ▁under ▁18 ▁years ▁have ▁not ▁been ▁established ▁ .
▁most ▁effects ▁occur red ▁close ▁to ▁the ▁intended ▁human ▁exposure s ▁ .
▁statement ▁of ▁the ▁active ▁and ▁other ▁substance s
▁you ▁can ▁also ▁report ▁side ▁effects ▁directly ▁via ▁the ▁national ▁report ing ▁system ▁listed ▁in ▁appen di x ▁v . ▁by ▁report ing ▁side ▁effects ▁you ▁can ▁help ▁provide ▁more ▁information ▁on ▁the ▁safety ▁of ▁this ▁medicine ▁ .
▁sleep ines s ▁or ▁los ing ▁ conscious ness
▁after ▁having ▁been ▁treated ▁for ▁an ▁a cute ▁episode ▁for ▁6 ▁weeks ▁and ▁stabili sed ▁for ▁an ▁additional ▁8 ▁weeks ▁with ▁in vega ▁( ▁dos es ▁rang ing ▁from ▁3 ▁to ▁15 ▁mg ▁once ▁daily ▁) ▁patients ▁were ▁then ▁random ised ▁in ▁a ▁double - blind ▁manner ▁to ▁either ▁continue ▁on ▁in vega ▁or ▁on ▁place bo ▁until ▁they ▁experienced ▁a ▁re lapse ▁in ▁schi zo ph r enia ▁symptoms ▁ .
▁during ▁treatment ▁ , ▁your ▁doctor ▁will ▁check ▁you ▁for ▁sign s ▁of ▁sco li osis ▁ , ▁a ▁type ▁of ▁spin al ▁de form ity ▁ .
▁it ▁is ▁used ▁in ▁patients ▁who ▁have ▁had ▁problems ▁due ▁to ▁blood ▁clo ts ▁in ▁the ▁past ▁( ▁such ▁as ▁heart ▁disease ▁ , ▁a ▁stroke ▁or ▁arter y ▁disease ▁) ▁or ▁who ▁have ▁type ▁2 ▁diabetes ▁that ▁has ▁damage d ▁an ▁organ ▁( ▁such ▁as ▁the ▁eyes ▁ , ▁heart ▁or ▁ki dne ys ▁) ▁ .
▁this ▁is ▁because ▁some ▁medicine s ▁can ▁we ak en ▁or ▁streng h ten ▁the ▁effect ▁of ▁glu bra va ▁on ▁the ▁level ▁of ▁sugar ▁in ▁your ▁blood ▁ .
▁vaccin ation ▁may ▁result ▁in ▁moderat e ▁swe lling ▁of ▁the ▁breast ▁tissu e ▁which ▁will ▁resolve ▁within ▁30 ▁days ▁ .
▁for ▁renal ▁function ▁approach ing ▁moderat e ▁renal ▁im pair ment ▁ , ▁at ▁least ▁2 ▁to ▁4 ▁times ▁per ▁year ▁ .
▁your ▁doctor ▁will ▁conduct ▁regular ▁medical ▁check - ▁up s ▁if ▁you ▁have ▁high ▁blood ▁pressure ▁ , ▁diabetes ▁ , ▁have ▁taken ▁hormone ▁replace ment ▁ therapy ▁or ▁if ▁you ▁are ▁obes e ▁( ▁b mi ▁over ▁30 ▁) ▁ .
▁ho spira ▁uk ▁limited ▁ , ▁ horizon ▁ , ▁honey ▁la ne ▁ , ▁hur ley ▁ , ▁mai den head ▁ , ▁sl 6 ▁6 r j ▁ , ▁uk
▁dos ing ▁is ▁based ▁on ▁baby ▁' s ▁weight ▁ .
▁the ▁most ▁common ly ▁reported ▁advers e ▁drug ▁reaction s ▁( ▁reported ▁in ▁> ▁1 ▁/ ▁10 ▁patients ▁) ▁are ▁reaction s ▁consistent ▁with ▁the ▁ pharma c ologic ▁action ▁of ▁ke pi vance ▁on ▁skin ▁and ▁oral ▁epi the lium ▁ , ▁e . g . ▁oed ema ▁ , ▁including ▁per i pher al ▁oed ema ▁ , ▁and ▁hyper trop hia ▁of ▁oral ▁structure s ▁ .
▁pack s ▁of ▁1 ▁ , ▁2 ▁ , ▁4 ▁and ▁5 ▁vi als ▁are ▁available ▁ .
▁after ▁a ▁single ▁oral ▁dose ▁of ▁75 ▁mg ▁ , ▁clo pido gre l ▁has ▁a ▁half - life ▁of ▁approximately ▁6 ▁hours ▁ .
▁1 ▁dos ing ▁sy ringe ▁( ▁5 ▁ml ▁)
▁particular s ▁to ▁appear ▁on ▁the ▁out er ▁packaging
▁based ▁on ▁the ▁results ▁of ▁this ▁study ▁ , ▁the ▁use ▁of ▁je t rea ▁as ▁an ▁ad jun ct ▁to ▁vit r ecto my ▁in ▁children ▁ , ▁to ▁facilita te ▁vi tre ous ▁separa tion ▁and ▁remo val ▁ , ▁is ▁not ▁recommended ▁ .
▁by ▁att ach ing ▁to ▁cd 20 ▁ , ▁of atum um ab ▁stimula tes ▁the ▁body ▁' s ▁immun e ▁system ▁to ▁attack ▁the ▁cancer ous ▁cell s ▁ , ▁helping ▁to ▁control ▁the ▁disease ▁ .
▁fe v 1 ▁should ▁be ▁measure d ▁before ▁and ▁after ▁in hal ation ▁of ▁to bi ▁pod hal er ▁ .
▁although ▁ , ▁the ▁majority ▁of ▁them ▁could ▁be ▁managed ▁by ▁dose ▁re duction ▁ , ▁close ▁monitoring ▁of ▁ha e mat ological ▁parameter s ▁should ▁be ▁under tak en ▁in ▁this ▁population ▁of ▁patients ▁( ▁see ▁section ▁4.2 ▁and ▁below ▁" ▁laborator y ▁tests ▁" ▁and ▁section ▁4. 8 ▁) ▁ .
▁act g 50 95 ▁was ▁a ▁random ised ▁( ▁1 ▁: ▁1 ▁: ▁1 ▁) ▁ , ▁double - blind ▁ , ▁place bo - control led ▁trial ▁perform ed ▁in ▁11 47 ▁anti ret rovi ral ▁na ï ve ▁hi v -1 ▁infect ed ▁adults ▁ , ▁compar ing ▁3 ▁regime ns ▁: ▁zid ovu dine ▁( ▁z dv ▁) ▁ , ▁la mi vu dine ▁( ▁3 t c ▁) ▁ , ▁a baca vir ▁( ▁ab c ▁) ▁ , ▁efa vir enz ▁( ▁ef v ▁) ▁vs ▁z dv ▁/ ▁3 t c ▁/ ▁ef v ▁vs ▁z dv ▁/ ▁3 t c ▁/ ▁ab c ▁ .
▁some ▁medicinal ▁products ▁should ▁not ▁be ▁co - ad minister ed ▁with ▁gen vo ya ▁( ▁see ▁section s ▁4.3 ▁and ▁4.5 ▁) ▁ .
▁general ▁side ▁effects ▁: ▁decrease d ▁blood ▁pressure ▁ , ▁che st ▁pain ▁ , ▁irregular ▁heart beat ▁ , ▁slow ▁or ▁fast ▁heart ▁rate ▁ , ▁palp it ations ▁ , ▁difficult y ▁sleeping ▁( ▁ insomni a ▁) ▁ , ▁night mar es ▁ , ▁depression ▁ , ▁general ised ▁we ak ness ▁ , ▁head ache ▁ , ▁di zzi ness ▁ , ▁ner vous ness ▁ , ▁irrita bility ▁ , ▁general ▁feeling ▁of ▁being ▁un well ▁ , ▁memory ▁loss ▁ , ▁short ness ▁of ▁breath ▁ , ▁as th ma ▁ , ▁nos e ▁ble ed s ▁ , ▁cold ▁symptoms ▁ , ▁dry ▁nos e ▁or ▁ thro at ▁ , ▁sore ▁ thro at ▁ , ▁ thro at ▁irrita tion ▁ , ▁co ugh ▁ , ▁run ny ▁nos e ▁ , ▁stuff y ▁nos e ▁ , ▁sne ez ing ▁ , ▁sinus ▁infection ▁ , ▁che st ▁con gestion ▁ , ▁ring ing ▁in ▁ear ▁ , ▁indi gestion ▁ , ▁intestinal ▁gas ▁or ▁stomach ▁a che ▁ , ▁na use a ▁ , ▁di ar r ho e a ▁ , ▁vom i ting ▁ , ▁ab normal ▁sensation ▁in ▁mouth ▁ , ▁increased ▁allergi c ▁symptoms ▁on ▁skin ▁ , ▁ rash ▁ , ▁ab normal ▁skin ▁sensation ▁ , ▁hair ▁loss ▁ , ▁general ised ▁it ching ▁ , ▁increased ▁blood ▁chlor ine ▁levels ▁ , ▁or ▁decrease d ▁red ▁blood ▁cell ▁count ▁as ▁seen ▁in ▁a ▁blood ▁test ▁ , ▁pain ▁ , ▁back ▁pain ▁ , ▁muscle ▁pain ▁or ▁spas m ▁ , ▁ki dne y ▁pain ▁such ▁as ▁lower ▁back ▁pain ▁ , ▁decrease d ▁libido ▁ , ▁male ▁sexual ▁difficult y ▁ .
▁keep ▁the ▁vi al ▁in ▁the ▁out er ▁carton ▁in ▁order ▁to ▁protect ▁from ▁light
▁a ▁risk ▁to ▁the ▁new born ▁/ ▁infants ▁cannot ▁be ▁exclu ded ▁ .
▁the ▁causa l ▁relationship ▁of ▁il aris ▁to ▁these ▁events ▁cannot ▁be ▁exclu ded ▁ .
▁con com i tant ▁administration ▁of ▁prezi sta ▁with ▁low ▁dose ▁rito na vir ▁with ▁ tica gre lor ▁is ▁contra indica ted ▁ .
▁insu man ▁led ▁to ▁a ▁decrease ▁in ▁the ▁level ▁of ▁h ba 1 c ▁ , ▁indicat ing ▁that ▁blood ▁gluco se ▁levels ▁had ▁been ▁control led ▁to ▁a ▁similar ▁level ▁to ▁that ▁seen ▁with ▁semi - syn the tic ▁human ▁insulin ▁ .
▁in ▁a ▁re lapse ▁pre vention ▁study ▁ , ▁patients ▁respond ing ▁to ▁12- week s ▁of ▁a cute ▁treatment ▁with ▁open - label ▁du lo xe tine ▁60 ▁mg ▁once ▁daily ▁were ▁random ised ▁to ▁either ▁du lo xe tine ▁60 ▁mg ▁once ▁daily ▁or ▁place bo ▁for ▁a ▁further ▁6- mont h s ▁ .
▁tell ▁your ▁doctor ▁if ▁you ▁are ▁taking ▁either ▁of ▁the ▁following ▁medicine s ▁ , ▁as ▁treatment ▁with ▁vor ico na zole ▁ho spira ▁at ▁the ▁same ▁time ▁should ▁be ▁avoid ed ▁if ▁possible ▁ , ▁and ▁a ▁dose ▁adjust ment ▁of ▁vor ico na zole ▁may ▁be ▁required ▁:
▁finally ▁ , ▁in ▁2 ▁studies ▁of ▁patients ▁with ▁suspect ed ▁fun gal ▁infection ▁who ▁were ▁treated ▁em pir ically ▁ , ▁can cidas ▁was ▁as ▁effective ▁as ▁am pho teri cin ▁b . ▁in ▁one ▁of ▁studies ▁in vol ving ▁around ▁1,000 ▁adults ▁ , ▁34 ▁% ▁of ▁patients ▁had ▁a ▁f avour able ▁response ▁with ▁either ▁can cidas ▁or ▁am pho teri cin ▁b ▁similar ▁results ▁were ▁seen ▁in ▁the ▁second ▁study ▁ , ▁which ▁involved ▁82 ▁children ▁a ged ▁between ▁two ▁and ▁17 ▁years ▁ .
▁if ▁you ▁are ▁being ▁treated ▁for ▁granul omat osis ▁with ▁poly angi itis ▁or ▁micro sco pic ▁poly angi itis
▁children ▁a ged ▁less ▁than ▁6 ▁months ▁:
▁no ▁effects ▁on ▁ability ▁to ▁drive ▁or ▁use ▁machines ▁have ▁been ▁observe d ▁ .
▁introduce ▁the ▁sy ringe ▁need le ▁through ▁the ▁vi al ▁ closure ▁and ▁inject ▁10 ▁ml ▁of ▁steril e ▁water ▁for ▁inject ions ▁ .
▁the ▁combination ▁with ▁dia com it ▁should ▁be ▁avoid ed ▁as ▁it ▁may ▁increase ▁their ▁blood ▁levels ▁ , ▁leading ▁to ▁digestiv e ▁disorder s ▁ , ▁rac ing ▁heart ▁and ▁ insomni a ▁ .
▁she lf ▁life ▁of ▁the ▁veterinar y ▁medicinal ▁product ▁as ▁package d ▁for ▁sale ▁: ▁30 ▁months ▁ .
▁it ▁is ▁important ▁to ▁note ▁that ▁the ▁scale s ▁used ▁in ▁this ▁indica tion ▁var y ▁and ▁direct ▁comparison s ▁of ▁results ▁for ▁different ▁ therapeut ic ▁agents ▁are ▁not ▁valid ▁ .
▁neutro p enia ▁ , ▁ thro mbo cy top enia ▁and ▁palma r - plan tar ▁er y thro dys aeth esia ▁syndrome ▁were ▁observe d ▁more ▁frequently ▁in ▁patients ▁of ▁e ast ▁asian ▁des cent ▁ .
▁ci ▁- ▁confidence ▁interval ▁ .
▁the ▁full ▁e par ▁for ▁ir besar tan ▁zen tiva ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁intr in sic ▁clear ance ▁is ▁therefore ▁reduce d ▁ , ▁couple d ▁with ▁a ▁higher ▁un bound ▁ fraction ▁of ▁pi og lita zone ▁ .
▁if ▁a ▁patient ▁is ▁hyper sensitiv e ▁to ▁so ya ▁ , ▁amb ris en tan ▁must ▁not ▁be ▁used ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁patients ▁received ▁an ▁initial ▁dose ▁of ▁80 ▁mg ▁hum ira ▁followed ▁by ▁40 ▁mg ▁every ▁other ▁week ▁( ▁starting ▁one ▁week ▁after ▁the ▁initial ▁dose ▁) ▁or ▁place bo ▁for ▁16 ▁weeks ▁ .
▁detailed ▁information ▁on ▁this ▁medicinal ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁/ ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁du ores p ▁spir o max ▁on ▁28 ▁april ▁2014 ▁ .
▁conditions ▁or ▁restriction s ▁regarding ▁supply ▁and ▁use
▁in hi xa ▁must ▁not ▁be ▁used ▁in ▁patients ▁with ▁existing ▁major ▁ble ed ing ▁ , ▁severe ▁disorder s ▁of ▁blood ▁clo tting ▁ , ▁or ▁with ▁conditions ▁that ▁increase ▁the ▁risk ▁of ▁ , ▁or ▁from ▁ , ▁ble ed ing ▁ , ▁such ▁as ▁stomach ▁ul cer s ▁or ▁stroke ▁ .
▁multi pack ▁: ▁168 ▁( ▁4 ▁x ▁42 ▁) ▁am po ules ▁with ▁1 ▁ml ▁ .
▁what ▁benefit ▁has ▁pure va x ▁fel v ▁shown ▁during ▁the ▁studies ▁?
▁what ▁is ▁the ▁risk ▁associated ▁with ▁li pro log ▁?
▁fil gra s tim ▁he xal ▁contain s ▁sor bit ol
▁before ▁taking ▁kis ply x ▁ , ▁your ▁doctor ▁may ▁carry ▁out ▁some ▁blood ▁tests ▁ , ▁for ▁example ▁to ▁check ▁your ▁blood ▁pressure ▁and ▁your ▁ liver ▁or ▁ki dne y ▁function ▁and ▁to ▁see ▁if ▁you ▁have ▁low ▁levels ▁of ▁salt ▁and ▁high ▁levels ▁of ▁thy roid ▁stimula ting ▁hormone ▁in ▁your ▁blood ▁ .
▁mean ▁absolute ▁lymph o cy te ▁count s ▁remain ed ▁stable ▁with ▁daily ▁dos ing ▁up ▁to ▁102 ▁weeks ▁in ▁du ration ▁ .
▁other ▁ liver - related ▁changes ▁in ▁repeat - dos e ▁ toxic ity ▁studies ▁in ▁rat s ▁and ▁dog s ▁included ▁increased ▁se rum ▁amino transfer as es ▁ , ▁sub a cute ▁ inflammation ▁( ▁rat s ▁only ▁) ▁ , ▁and ▁single - cell ▁nec rosi s ▁ .
▁this ▁app lies ▁especially ▁to ▁the ▁medicine s ▁listed ▁below ▁taken ▁at ▁the ▁same ▁time ▁with ▁kin zal kom b ▁:
▁where ▁at ▁the ▁6- ho ur ▁time ▁point ▁:
▁the ▁anti body ▁media tes ▁the ▁lys is ▁of ▁lymph o cy tes ▁via ▁complement ▁fixa tion ▁and ▁anti body - dependent ▁cell ▁media ted ▁cy to toxic ity ▁ .
▁i pili mum ab ▁has ▁been ▁designed ▁to ▁att ach ▁to ▁and ▁block ▁the ▁activity ▁of ▁a ▁protein ▁called ▁ct la -4 ▁that ▁is ▁found ▁on ▁the ▁surface ▁of ▁t ▁cell s ▁ , ▁a ▁type ▁of ▁white ▁blood ▁cell ▁ .
▁this ▁medicinal ▁product ▁must ▁not ▁be ▁mix ed ▁with ▁other ▁medicinal ▁products ▁except ▁those ▁mentioned ▁in ▁section ▁ 6.6 ▁ .
▁each ▁pen ▁should ▁be ▁used ▁by ▁one ▁person ▁only ▁and ▁is ▁for ▁single ▁use ▁ .
▁patients ▁with ▁prior ▁is cha e mic ▁stroke
▁1.9 ▁months ▁ , ▁hazard ▁ratio ▁= ▁0 . 65 ▁ , ▁ci ▁= ▁0.3 9 ▁ , ▁1. 10 ▁ , ▁p ▁= ▁0.0 6 18 ▁) ▁ .
▁the ▁brain ▁contain s ▁so - call ed ▁n - met hyl - d - as parta te ▁( ▁n mda ▁) ▁- recept ors ▁that ▁are ▁involved ▁in ▁transmit ting ▁nerv e ▁signal s ▁important ▁in ▁learning ▁and ▁memory ▁ .
▁the ▁prac ▁recommend s ▁that ▁patients ▁should ▁be ▁evaluat ed ▁for ▁sign s ▁and ▁symptoms ▁of ▁under ly ing ▁cardio pul mon ary ▁disease ▁prior ▁to ▁initiat ing ▁and ▁during ▁tha li domi de ▁ therapy ▁ .
▁ thro mbin ▁then ▁convert s ▁fi brin ogen ▁into ▁fi brin ▁and ▁a ▁clo t ▁can ▁be ▁for med ▁ .
▁via ▁its ▁ binding ▁to ▁a ▁specific ▁cy to plas mic ▁immun o phil in ▁( ▁f k b p 12 ▁) ▁ , ▁tac rol imus ▁inhibi ts ▁calci um - ▁dependent ▁signal ▁trans duction ▁path ways ▁in ▁t ▁cell s ▁ , ▁there by ▁prevent ing ▁the ▁tran scription ▁and ▁synth es is ▁of ▁il -2 ▁ , ▁il -3 ▁ , ▁il -4 ▁ , ▁il -5 ▁and ▁other ▁cy tok ines ▁such ▁as ▁g m - cs f ▁ , ▁t n f - α ▁and ▁if n - γ ▁ .
▁if ▁you ▁stop ▁use ▁of ▁rev atio
▁what ▁benefit ▁has ▁ratio gra s tim ▁shown ▁during ▁the ▁studies ▁?
▁both ▁ , ▁the ▁primary ▁( ▁p ▁= ▁0 . 92 ▁) ▁and ▁seconda ry ▁end point s ▁showed ▁no ▁statistic ally ▁significant ▁difference s ▁between ▁efa vir enz ▁and ▁vir am une ▁200 ▁mg ▁twice ▁daily ▁ .
▁one ▁dose ▁of ▁0.5 ▁ml ▁at ▁an ▁ele cted ▁date ▁ .
▁the ▁media n ▁time ▁to ▁ons et ▁in ▁len vati ni b - tre ated ▁patients ▁was ▁16 ▁days ▁ .
▁patients ▁receiving ▁du la glut ide ▁in ▁combination ▁with ▁sul phon y lu rea ▁or ▁insulin ▁may ▁have ▁an ▁increased ▁risk ▁of ▁hypo gly ca emia ▁ .
▁difference ▁from ▁gli pi zi de ▁+ ▁met form inc ▁( ▁95 ▁% ▁ci ▁)
▁the ▁active ▁substance ▁in ▁ion sys ▁is ▁fent an yl ▁hydro ch lor ide ▁ .
▁each ▁vi al ▁contain s ▁100 ▁mg ▁of ▁pe metre x ed ▁( ▁as ▁pe metre x ed ▁dia cid ▁) ▁ .
▁increased ▁or ▁decrease d ▁urin e ▁production ▁( ▁due ▁to ▁ki dne y ▁damage ▁) ▁ , ▁pain ful ▁pas sing ▁of ▁urin e ▁or ▁blood ▁/ ▁protein s ▁in ▁the ▁urin e ▁ , ▁fluid ▁re tention
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁of ▁the ▁bi ological ▁active ▁substance
▁in ▁a ▁seconda ry ▁analysis ▁ , ▁which ▁ut ilised ▁dr c ▁assessment s ▁at ▁the ▁latest ▁ evalua ble ▁time ▁point ▁( ▁e ot ▁ , ▁or ▁2 ▁ , ▁6 ▁ , ▁or ▁12 ▁weeks ▁after ▁e ot ▁) ▁vor ico na zole ▁and ▁the ▁regime n ▁of ▁am pho teri cin ▁b ▁followed ▁by ▁flu con a zole ▁had ▁successful ▁response ▁rates ▁of ▁65 ▁% ▁and ▁71 ▁% ▁ , ▁respective ly ▁ .
▁lu veri s ▁treatment ▁sel dom ▁causes ▁severe ▁oh s s ▁ .
▁hyper sensitiv ity ▁to ▁chi nese ▁ham ster ▁ova ry ▁( ▁cho ▁) ▁cell ▁products ▁or ▁other ▁reco mbin ant ▁human ▁or ▁human ised ▁anti bo dies ▁ .
▁ex cip ient s ▁: ▁suc rose ▁ , ▁l - h isti dine ▁ , ▁l - h isti dine ▁mono hydro ch lor ide ▁mono hydrat e ▁ , ▁poly sor bate ▁80 ▁ , ▁water ▁for ▁inject ions ▁ .
▁a ▁study ▁in ▁animals ▁has ▁shown ▁an ▁increased ▁risk ▁of ▁spontane ous ▁abort ion ▁/ ▁em bry o - fo e tal ▁death ▁at ▁a ▁high ▁dose ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁if ▁you ▁have ▁an ▁infection ▁in ▁or ▁around ▁your ▁eye ▁ .
▁if ▁you ▁have ▁taken ▁more ▁tablets ▁than ▁you ▁should ▁and ▁experience ▁any ▁side ▁effects ▁( ▁see ▁section ▁4 ▁) ▁ , ▁please ▁contact ▁your ▁doctor ▁ .
▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁ 008 ▁10 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁ 009 ▁20 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁ 010 ▁30 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁ 011 ▁60 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁01 2 ▁90 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁01 3 ▁200 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁0 17 ▁50 ▁prolong ed - release ▁tablets ▁eu ▁/ ▁1 ▁/ ▁12 ▁/ ▁8 09 ▁/ ▁ 018 ▁100 ▁prolong ed - release ▁tablets
▁pede a ▁should ▁not ▁be ▁given ▁in ▁the ▁first ▁6 ▁hours ▁of ▁life ▁ .
▁take ▁care ▁not ▁to ▁block ▁the ▁air ▁vent s ▁ .
▁all ▁contra indica tions ▁associated ▁with ▁auto logo us ▁blood ▁pred on ation ▁programme s ▁should ▁be ▁respect ed ▁in ▁patients ▁being ▁supplement ed ▁with ▁ab se a med ▁ .
▁if ▁you ▁have ▁loss ▁of ▁appetit e ▁ , ▁fatigue ▁ , ▁feeling ▁sick ▁( ▁na use a ▁) ▁ , ▁repeat ed ▁vom i ting ▁ , ▁especially ▁if ▁you ▁notice ▁wide spre ad ▁it ching ▁ , ▁yellow ing ▁of ▁the ▁skin ▁or ▁of ▁the ▁white s ▁of ▁the ▁eyes ▁ , ▁or ▁easy ▁bru ising ▁ .
▁as ▁hypo gly ca emia ▁in ▁this ▁study ▁was ▁avoid ed ▁through ▁increased ▁calorie ▁in take ▁ , ▁a ▁relative ▁over dos e ▁may ▁result ▁in ▁an ▁ex a gger ated ▁gluco se - lo wering ▁effect ▁with ▁development ▁of ▁hypo gly ca e mic ▁symptoms ▁( ▁di zzi ness ▁ , ▁sweat ing ▁ , ▁tre mor ▁ , ▁head ache ▁etc ▁ . ▁) ▁ .
▁if ▁possible ▁take ▁your ▁medicine ▁and ▁this ▁le a flet ▁with ▁you ▁ .
▁high ▁levels ▁of ▁so dium ▁ , ▁po tas s ium ▁ , ▁creati nine ▁ , ▁u ric ▁acid ▁and ▁blood ▁sugar
▁date ▁of ▁first ▁author isation ▁: ▁25 ▁march ▁2004 ▁date ▁of ▁latest ▁rene wal ▁: ▁4 ▁march ▁2009
▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁ .
▁additional ly ▁ , ▁riba vir in ▁or ▁pe ga sys ▁plus ▁riba vir in ▁combination ▁ therapy ▁can ▁be ▁dis continu ed ▁ .
▁store ▁in ▁the ▁original ▁package ▁in ▁order ▁to ▁protect ▁from ▁light ▁and ▁mois ture ▁ .
▁approximately ▁half ▁the ▁cases ▁were ▁lymph om as ▁ .
▁in ▁art ▁ , ▁fol li trop in ▁alfa ▁at ▁a ▁lower ▁total ▁dose ▁and ▁short er ▁treatment ▁period ▁than ▁urin ary ▁f sh ▁ , ▁result ed ▁in ▁a ▁higher ▁number ▁of ▁oo cy tes ▁re trie ved ▁when ▁compared ▁to ▁urin ary ▁f sh ▁ .
▁how ▁does ▁ir besar tan ▁b ms ▁work ▁?
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁des lor ata dine ▁teva ▁on ▁24 ▁november ▁2011 ▁ .
▁pre gabal in ▁my lan ▁ pharma ▁contain s ▁the ▁active ▁substance ▁pre gabal in ▁which ▁be long s ▁to ▁a ▁group ▁of ▁medicine s ▁used ▁to ▁treat ▁epi le psy ▁ , ▁neuro pathi c ▁pain ▁and ▁general ised ▁anxiety ▁disorder ▁( ▁ gad ▁) ▁in ▁adults ▁ .
▁in dina vir ▁is ▁associated ▁with ▁indirect ▁un con ju ga ted ▁hyper bili ru bina emia ▁due ▁to ▁inhibi tion ▁of ▁u gt ▁ .
▁equi lis ▁te ▁equi lis ▁te ▁equi lis ▁te ▁equi lis ▁te
▁edib le ▁white ▁in k ▁: ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁ , ▁ propyl ene ▁gly col ▁ , ▁ shell ac ▁ , ▁po vido ne ▁ .
▁amb ris en tan ▁is ▁contra indica ted ▁in ▁pre gna ncy ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁they ▁may ▁also ▁have ▁temporar y ▁swe lling s ▁at ▁the ▁inject ion ▁that ▁may ▁last ▁for ▁over ▁two ▁weeks ▁ .
▁you ▁may ▁need ▁to ▁stop ▁taking ▁vo kana met ▁for ▁a ▁couple ▁of ▁days ▁before ▁and ▁after ▁the ▁operation . ▁an ▁x - ray ▁where ▁you ▁will ▁be ▁inject ed ▁with ▁a ▁dy e ▁ .
▁therefore ▁ , ▁the ▁potential ▁exist s ▁for ▁interaction s ▁between ▁o at p ▁inhibi tors ▁and ▁ali ski ren ▁when ▁ad minister ed ▁con com i tant ly ▁( ▁see ▁interaction ▁with ▁gra pe fru it ▁juice ▁) ▁ .
▁this ▁means ▁that ▁e bil fum in ▁is ▁similar ▁to ▁a ▁' ▁reference ▁medicine ▁' ▁already ▁author ised ▁in ▁the ▁european ▁union ▁( ▁eu ▁) ▁called ▁tam i flu ▁ .
▁this ▁medicine ▁is ▁stable ▁for ▁2 ▁hours ▁at ▁25 oc ▁ .
▁children ▁taking ▁la mi vu dine ▁/ ▁zid ovu dine ▁teva ▁should ▁be ▁close ly ▁monitor ed ▁for ▁side ▁effects ▁ .
▁since ▁de pre oti de ▁also ▁bind s ▁to ▁som at osta tin ▁receptor s ▁ , ▁cau tion ▁should ▁be ▁exercise d ▁when ▁ad minister ing ▁this ▁medicinal ▁product ▁to ▁patients ▁with ▁insulin om as ▁or ▁diabetes ▁mell itus ▁ .
▁if ▁the ▁measure d ▁field ▁strength ▁in ▁the ▁location ▁in ▁which ▁the ▁administration ▁system ▁is ▁used ▁exceed s ▁the ▁applicable ▁ rf ▁compliance ▁level ▁above ▁ , ▁the ▁administration ▁system ▁should ▁be ▁observe d ▁to ▁ver ify ▁normal ▁operation ▁ .
▁content s ▁by ▁weight ▁ , ▁by ▁volume ▁or ▁by ▁unit
▁larger ▁groups ▁should ▁be ▁treated ▁with ▁medica ted ▁feed ing ▁stuff ▁contain ing ▁the ▁premi x ▁ .
▁total ▁bilir u bin ▁: ▁= ▁1.5 ▁ul n
▁mi card is ▁may ▁be ▁less ▁effective ▁in ▁lower ing ▁the ▁blood ▁pressure ▁in ▁black ▁patients ▁ .
▁detailed ▁information ▁on ▁this ▁medicinal ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁is cover ▁ .
▁bo val to ▁i bra x ion ▁can ▁be ▁used ▁during ▁pre gna ncy ▁and ▁lac tation ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁taking ▁re bi f ▁if ▁you ▁have ▁an ▁aller gy ▁( ▁hyper sensitiv ity ▁) ▁to ▁any ▁other ▁medicine s ▁ .
▁clinic al ▁relevan ce ▁of ▁this ▁observation ▁is ▁un know n ▁ .
▁package ▁contain ing ▁one ▁or ▁four ▁pre - fill ed ▁pens ▁of ▁a ▁60 ▁μ g ▁nespo ▁solution ▁for ▁inject ion ▁in ▁0.3 ▁ml ▁( ▁200 ▁μ g ▁/ ▁ml ▁) ▁ .
▁cell cept ▁500 ▁mg ▁powder ▁for ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁ .
▁the ▁following ▁table ▁cover s ▁advers e ▁drug ▁reaction s ▁from ▁the ▁poole d ▁studies ▁mentioned ▁above ▁in ▁patients ▁with ▁par kin son ▁' s ▁disease ▁ .
▁ang io ten sin - con ver ting - en zy me ▁( ▁a ce ▁) ▁inhibi tors ▁may ▁decrease ▁blood ▁gluco se ▁levels ▁ .
▁there ▁is ▁a ▁potential ▁for ▁increased ▁risk ▁of ▁con s tip ation ▁when ▁taking ▁el ux ado line ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁treatment ▁should ▁be ▁dis continu ed ▁after ▁10 ▁days ▁if ▁no ▁clinic al ▁improvement ▁is ▁apparent ▁ .
▁a ▁total ▁of ▁4 7.3 ▁% ▁of ▁patients ▁experienced ▁at ▁least ▁one ▁advers e ▁reaction ▁ .
▁a ▁dose ▁re duction ▁of ▁a baca vir ▁may ▁be ▁required ▁for ▁patients ▁with ▁mild ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁grade ▁a ▁) ▁ .
▁com tes s ▁is ▁a ▁medicine ▁that ▁contain s ▁the ▁active ▁substance ▁en ta ca pone ▁ .
▁the ▁recommended ▁dose ▁of ▁or encia ▁for ▁patients ▁6 ▁to ▁17 ▁years ▁of ▁age ▁with ▁juvenil e ▁ idio pathi c ▁ar thri tis ▁who ▁we igh ▁less ▁than ▁75 ▁kg ▁is ▁10 ▁mg ▁/ ▁kg ▁calcula ted ▁based ▁on ▁the ▁patient ▁' s ▁body ▁weight ▁at ▁each ▁administration ▁ .
▁not ▁known ▁( ▁fre que ncy ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁: ▁re curr ence ▁( ▁re activa tion ▁) ▁of ▁hepatitis ▁b ▁infection ▁when ▁you ▁have ▁had ▁hepatitis ▁b ▁in ▁the ▁past ▁( ▁a ▁ liver ▁infection ▁) ▁ .
▁most ▁patients ▁under ▁observation ▁recover ed ▁within ▁24 ▁hours ▁of ▁withdraw al ▁of ▁the ▁medicinal ▁product ▁ .
▁each ▁tablet ▁contain s ▁150 ▁mg ▁of ▁el vite grav ir ▁ , ▁150 ▁mg ▁of ▁co bici stat ▁ , ▁200 ▁mg ▁of ▁em trici ta bine ▁and ▁te no fo vir ▁ala fen ami de ▁fumar ate ▁equivalent ▁to ▁10 ▁mg ▁of ▁te no fo vir ▁ala fen ami de ▁ .
▁once ▁you ▁have ▁started ▁pe ga sys ▁treatment ▁ , ▁talk ▁to ▁your ▁doctor ▁ , ▁nurse ▁or ▁ pharma ci st ▁:
▁the ▁tablet ▁formula tion ▁is ▁not ▁adapt ed ▁for ▁use ▁in ▁infants ▁and ▁children ▁under ▁the ▁age ▁of ▁6 ▁years ▁ .
▁tho rina ne ▁is ▁indicate d ▁for ▁adults ▁for ▁:
▁insulin ▁human ▁win thro p ▁com b ▁25 ▁100 ▁iu ▁/ ▁ml ▁suspens ion ▁for ▁inject ion ▁in ▁a ▁vi al ▁insulin ▁human
▁in ▁the ▁event ▁of ▁over dos e ▁ , ▁symptom a tic ▁and ▁support ive ▁treatment ▁immediately ▁should ▁be ▁started ▁and ▁maintain ed ▁it ▁for ▁as ▁long ▁as ▁necessary ▁ .
▁do ▁not ▁use ▁ri va stig mine ▁he xal ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁ .
▁information ▁for ▁medical ▁and ▁health care ▁professionals ▁on ▁dose ▁calcula tion ▁ , ▁preparation ▁and ▁administration ▁of ▁nu loj ix ▁is ▁provided ▁at ▁the ▁end ▁of ▁the ▁le a flet ▁ .
▁if ▁the ▁use ▁of ▁duo pla vin ▁is ▁dis continu ed ▁ , ▁patients ▁may ▁benefit ▁with ▁continua tion ▁of ▁one ▁anti plate let ▁medicinal ▁product ▁ .
▁absolute ▁re duction ▁in ▁fra c ture ▁incide nce ▁% ▁( ▁ci ▁)
▁this ▁is ▁part ly ▁link ed ▁to ▁resto red ▁health ▁and ▁lifestyle ▁ , ▁and ▁in ▁the ▁case ▁of ▁blood ▁lipid s ▁sometimes ▁to ▁the ▁hi v ▁medicine s ▁themselves ▁ .
▁cases ▁of ▁osteo ne cro sis ▁have ▁been ▁reported ▁ , ▁particularly ▁in ▁patients ▁with ▁generally ▁acknowledge d ▁risk ▁factors ▁ , ▁advanced ▁hi v ▁disease ▁or ▁long - term ▁exposure ▁to ▁cart ▁ .
▁the ▁recon stitu ted ▁solution ▁should ▁not ▁be ▁ad minister ed ▁if ▁it ▁contain s ▁parti cles ▁or ▁is ▁not ▁clear ▁ .
▁ri va stig mine ▁1 ▁a ▁ pharma ▁oral ▁solution ▁should ▁be ▁used ▁within ▁1 ▁month ▁of ▁opening ▁the ▁bottle ▁ .
▁2 ▁these ▁are ▁medicinal ▁products ▁within ▁class ▁where ▁similar ▁interaction s ▁could ▁be ▁predict ed ▁ .
▁after ▁the ▁end ▁of ▁sir tur o ▁treatment ▁( ▁i . e . ▁after ▁week ▁24 ▁) ▁ , ▁q t cf ▁increase s ▁in ▁the ▁sir tur o ▁group ▁gradual ly ▁became ▁less ▁prono un ced ▁ .
▁as ▁such ▁ , ▁variation s ▁in ▁drug - meta boli sing ▁enzym es ▁are ▁not ▁expected ▁to ▁affect ▁the ▁elimina tion ▁of ▁dar atum um ab ▁ .
▁a ▁decrease ▁in ▁the ▁levels ▁of ▁ phos pha te ▁in ▁the ▁blood ▁ .
▁your ▁doctor ▁may ▁decide ▁not ▁to ▁pre scribe ▁ gile nya ▁if ▁you ▁are ▁taking ▁such ▁a ▁medicine ▁because ▁it ▁could ▁intensif y ▁the ▁effect ▁on ▁irregular ▁heart beat ▁ .
▁avoid ▁shak ing ▁or ▁rapid ▁movement ▁as ▁it ▁may ▁cause ▁fo am ing ▁ .
▁development al ▁ toxic ity ▁studies ▁have ▁been ▁perform ed ▁in ▁rat s ▁and ▁rabbi ts ▁at ▁daily ▁dos es ▁up ▁to ▁5 ▁times ▁the ▁human ▁daily ▁dose ▁and ▁have ▁reveal ed ▁no ▁evidence ▁of ▁har m ▁to ▁the ▁fo etus ▁due ▁to ▁i vac af tor ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁a ste mi zole ▁( ▁used ▁to ▁treat ▁allergi es ▁)
▁in ▁a ▁large ▁clinic al ▁trial ▁in ▁7 , 736 ▁patients ▁ , ▁osteo ne cro sis ▁of ▁the ▁ja w ▁has ▁been ▁reported ▁in ▁one ▁patient ▁treated ▁with ▁ac la sta ▁and ▁one ▁patient ▁treated ▁with ▁place bo ▁ .
▁meta cam ▁1 ▁mg ▁che w able ▁tablets ▁for ▁dog s ▁meta cam ▁2.5 ▁mg ▁che w able ▁tablets ▁for ▁dog s
▁do ▁not ▁use ▁in ▁pregnant ▁or ▁la cta ting ▁mare s
▁ging ival ▁hyper plas ia ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁col itis ▁including ▁cy to mega lo virus ▁col itis ▁ , ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁pan creati tis ▁ , ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁and ▁intestinal ▁vill ous ▁a trop hy ▁ .
▁in sufficient ▁safety ▁and ▁ef fica cy ▁data ▁are ▁available ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁to ▁provide ▁a ▁dose ▁adjust ment ▁recommend ation ▁ .
▁before ▁in it ▁i ation ▁of ▁le flu nom ide ▁ ,
▁when ▁ad minister ing ▁the ▁product ▁ , ▁try ▁to ▁avoid ▁we tting ▁the ▁fur ▁as ▁this ▁will ▁lead ▁to ▁a ▁stick y ▁and ▁tan gled ▁appearance ▁ .
▁prior ▁to ▁each ▁inject ion ▁a ▁safety ▁test ▁has ▁to ▁be ▁perform ed ▁to ▁ensure ▁that ▁pen ▁and ▁need le ▁work ▁properly ▁and ▁to ▁remove ▁air ▁bu bble s ▁ .
▁studies ▁perform ed ▁in ▁bacteria ▁to ▁determine ▁muta geni city ▁were ▁negative ▁for ▁ thro mbin ▁alone ▁ , ▁bi ological ▁active ▁component ▁( ▁contain ing ▁fi brin ogen ▁ , ▁cit rate ▁ , ▁gly cine ▁ , ▁tra ne xa mic ▁acid ▁ , ▁and ▁argi nine ▁hydro ch lor ide ▁) ▁ , ▁t n b p ▁alone ▁ , ▁and ▁tri ton ▁x -100 ▁alone ▁at ▁all ▁concentration s ▁test ed ▁ .
▁however ▁ , ▁in ▁a ▁pande mic ▁situation ▁ , ▁it ▁may ▁be ▁appropriate ▁to ▁give ▁the ▁vaccin e ▁ , ▁provided ▁that ▁facilities ▁for ▁res uscita tion ▁are ▁immediately ▁available ▁in ▁case ▁of ▁need . ▁see ▁section ▁4.4 ▁ .
▁repeat ed ▁occur r ence ▁of ▁malign ant ▁( ▁cancer ous ▁) ▁disease ▁ .
▁common ▁side ▁effects ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁are ▁:
▁tw elve ▁percent ▁( ▁12 ▁% ▁) ▁of ▁patients ▁were ▁diabet ic ▁ , ▁34 ▁% ▁were ▁hyper li pide mic ▁and ▁the ▁most ▁frequent ▁cardiovascular ▁condition ▁was ▁stable ▁ang ina ▁pec toris ▁in ▁3.5 ▁% ▁of ▁the ▁participants ▁ .
▁de si pra mine ▁ , ▁nor trip ty line ▁ , ▁paro xe tine ▁and ▁similar ▁medicine s ▁( ▁used ▁to ▁treat ▁depression ▁)
▁pro phy la ctic ▁hep arin ▁did ▁not ▁increase ▁the ▁risk ▁of ▁serious ▁ble ed ing ▁compared ▁to ▁place bo ▁( ▁ 3.9 ▁% ▁vs ▁5.2 ▁% ▁ , ▁respective ly ▁) ▁ , ▁including ▁c ns ▁ble ed ing ▁( ▁1.0 ▁% ▁vs ▁ 0.7 ▁% ▁ , ▁respective ly ▁) ▁ .
▁serious ▁skin ▁reaction s ▁( ▁fre que ncy ▁not ▁known ▁: ▁fre que ncy ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁: ▁ rash ▁with ▁swe lling ▁ , ▁bli s tering ▁or ▁peeling ▁of ▁the ▁skin ▁ , ▁los ing ▁skin ▁and ▁ble ed ing ▁around ▁eyes ▁ , ▁nos e ▁ , ▁mouth ▁or ▁genital s ▁and ▁rapid ▁deteriora tion ▁of ▁your ▁general ▁health ▁ , ▁or ▁ rash ▁when ▁expose d ▁to ▁the ▁sun ▁ .
▁do ▁not ▁use ▁it ▁if ▁any ▁damage ▁or ▁le ak age ▁is ▁seen ▁or ▁if ▁the ▁plu nger ▁has ▁been ▁draw n ▁above ▁the ▁white ▁label ▁band ▁( ▁picture ▁a ▁) ▁ .
▁table ▁2 ▁: ▁gala fold ▁( ▁mig ala stat ▁) ▁amen ability ▁table
▁when ▁rito na vir ▁is ▁used ▁in ▁combination ▁with ▁another ▁prote ase ▁inhibi tor ▁and ▁bu pren or phi ne ▁ , ▁the ▁sp c ▁of ▁the ▁co - ad minister ed ▁prote ase ▁inhibi tor ▁should ▁be ▁review ed ▁for ▁specific ▁dos ing ▁information ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁sy ringe ▁label ▁and ▁on ▁the ▁out er ▁carton ▁after ▁" ▁exp ▁ . ▁"
▁in ▁vi tro ▁and ▁in ▁vivo ▁studies ▁with ▁et ravi rine ▁reveal ed ▁no ▁evidence ▁of ▁a ▁mu tage nic ▁potential ▁ .
▁chemical ▁and ▁physical ▁in - use ▁stabilit y ▁has ▁been ▁demonstrat ed ▁for ▁24 ▁hours ▁at ▁2 ▁to ▁8 ▁c ▁and ▁25 ▁c ▁ .
▁in ▁the ▁case ▁of ▁ble ed ing ▁ , ▁please ▁contact ▁your ▁doctor ▁before ▁stop ping ▁the ▁in take ▁of ▁pra da xa ▁® ▁ .
▁the ▁incide nce ▁of ▁pneu monia ▁in ▁patients ▁with ▁as th ma ▁was ▁common ▁at ▁the ▁higher ▁dose ▁ .
▁however ▁ , ▁this ▁has ▁not ▁formal ly ▁been ▁studie d ▁in ▁patients ▁with ▁im pair ed ▁renal ▁or ▁he pati c ▁function ▁; ▁therefore ▁patients ▁with ▁severe ▁renal ▁or ▁he pati c ▁im pair ment ▁should ▁be ▁carefully ▁monitor ed ▁for ▁any ▁advers e ▁effects ▁ .
▁gastro inte stin al ▁and ▁abdominal ▁pain ▁ , ▁na use a ▁ , ▁vom i ting ▁ , ▁con s tip ation ▁ , ▁di ar r ho e a ▁ , ▁flat ul ence ▁ , ▁blo ating ▁and ▁dis tension
▁so dium ▁star ch ▁gly colla te ▁( ▁type ▁a ▁) ▁hy pro mel lose ▁micro c ry stal line ▁cell ul ose ▁la ctos e ▁mono hydrat e ▁magnesium ▁stea rate ▁ .
▁in ▁dog s ▁ , ▁renal ▁tub ular ▁di lation ▁and ▁a trop hy ▁were ▁observe d ▁ .
▁nefa zo done ▁( ▁used ▁to ▁treat ▁depression ▁) ▁ ,
▁10 ▁ , ▁32 ▁or ▁100 ▁ml ▁bottle ▁with ▁two ▁sy ring es ▁per ▁presentation ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁70 ▁mg ▁das atin ib ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁do ▁not ▁store ▁above ▁25 ▁c ▁ .
▁if ▁you ▁take ▁more ▁x y rem ▁than ▁you ▁were ▁told ▁to ▁take ▁ , ▁or ▁take ▁it ▁by ▁accident ▁ , ▁get ▁emergency ▁medical ▁help ▁right ▁away ▁ .
▁effects ▁of ▁intr insa ▁were ▁observe d ▁at ▁4 ▁weeks ▁after ▁initiat ion ▁of ▁ therapy ▁( ▁the ▁first ▁measure d ▁time ▁point ▁) ▁and ▁at ▁all ▁monthly ▁ef fica cy ▁time ▁points ▁there a fter ▁ .
▁10 ▁pre - fill ed ▁sy ring es ▁with ▁1 ▁separate ▁need le
▁how n ▁to ▁significantly ▁increase
▁events ▁such ▁as ▁ tors ades ▁de ▁point es ▁ , ▁ste ven s - joh n son ▁syndrome ▁ , ▁er y thema ▁multi forme ▁ , ▁inter stiti al ▁lung ▁disease ▁( ▁sometimes ▁fatal ▁) ▁and ▁pres ▁( ▁r pl s ▁) ▁have ▁occur red ▁in ▁patients ▁treated ▁with ▁vand etan ib ▁mono therapy ▁ .
▁you ▁should ▁consult ▁with ▁your ▁doctor ▁if ▁you ▁need ▁to ▁adjust ▁the ▁dose ▁of ▁your ▁other ▁medicine ▁while ▁taking ▁ac tel sar ▁h ct ▁ .
▁m t x ▁) ▁to ▁to cili zum ab ▁mono therapy ▁result ed ▁in ▁increased ▁fre que ncy ▁of ▁these ▁eleva tions ▁ .
▁each ▁carton ▁contain s ▁one ▁bottle ▁and ▁both ▁a ▁cali bra ted ▁poly propyl ene ▁me as uring ▁cup ▁and ▁a ▁cali bra ted ▁poly propyl ene ▁low - dens ity ▁poly e thy lene ▁drop per ▁ .
▁the ▁starting ▁dose ▁could ▁be ▁reduce d ▁to ▁200 ▁mg ▁in ▁patients ▁with ▁moderat e ▁renal ▁im pair ment ▁; ▁safety ▁and ▁ef fica cy ▁have ▁however ▁not ▁been ▁established ▁with ▁200 ▁mg ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁you ▁should ▁also ▁tell ▁your ▁doctor ▁if ▁a ▁close ▁relative ▁has ▁ , ▁or ▁ever ▁had ▁breast ▁cancer ▁( ▁see ▁section ▁2 ▁" ▁when ▁to ▁take ▁special ▁care ▁with ▁zo ely ▁" ▁) ▁ .
▁after ▁week ▁26 ▁ , ▁patients ▁remain ed ▁on ▁lo mita pide ▁to ▁determine ▁the ▁effects ▁of ▁longer - term ▁treatment ▁and ▁were ▁allowed ▁to ▁change ▁background ▁lipid - lo wering ▁ therapie s ▁ .
▁shu nt ▁ thro mbo ses ▁may ▁occur ▁ , ▁especially ▁in ▁patients ▁who ▁have ▁a ▁tende ncy ▁to ▁hypo tension ▁or ▁whose ▁arteri ove nous ▁fi stu la e ▁exhibi t ▁complica tions ▁( ▁e . g . ▁ste nos es ▁ , ▁an eur ys ms ▁ , ▁etc ▁ . ▁) ▁ .
▁if ▁any ▁component ▁of ▁the ▁package ▁is ▁opened ▁or ▁damage d ▁ , ▁do ▁not ▁use ▁this ▁component ▁ .
▁what ▁benefits ▁of ▁op sumi t ▁have ▁been ▁shown ▁in ▁studies ▁?
▁a ▁per i - ▁and ▁post - na tal ▁development ▁study ▁was ▁perform ed ▁in ▁rat s ▁with ▁leve ti race tam ▁dos es ▁of ▁70 ▁ , ▁350 ▁and ▁1 , 800 ▁mg ▁/ ▁kg ▁/ ▁day ▁ .
▁when ▁turning ▁the ▁dose ▁se lector ▁be ▁care ful ▁not ▁to ▁push ▁the ▁push - ▁button ▁as ▁insulin ▁will ▁come ▁out ▁ .
▁what ▁sa vene ▁looks ▁like ▁and ▁content s ▁of ▁the ▁emergency ▁kit
▁influenza ▁vaccin e ▁( ▁live ▁att en u ated ▁ , ▁na sal ▁)
▁the ▁overall ▁safety ▁profile ▁of ▁da cla tas vir ▁is ▁based ▁on ▁data ▁from ▁22 15 ▁patients ▁with ▁chronic ▁h c v ▁infection ▁who ▁received ▁da klin za ▁once ▁daily ▁either ▁in ▁combination ▁with ▁sof os bu vir ▁with ▁or ▁without ▁riba vir in ▁( ▁n ▁= ▁ 679 ▁ , ▁poole d ▁data ▁) ▁or ▁in ▁combination ▁with ▁pe g inter fer on ▁alfa ▁and ▁riba vir in ▁( ▁n ▁= ▁15 36 ▁ , ▁poole d ▁data ▁) ▁from ▁a ▁total ▁of ▁14 ▁clinic al ▁studies ▁ .
▁12 ▁weeks ▁t n ▁( ▁n ▁= ▁26 ▁)
▁other ▁conditions ▁and ▁requirements ▁of ▁the ▁marketing ▁author isation
▁the ▁active ▁substance ▁of ▁masiv et ▁can ▁cause ▁severe ▁eye - ir rit ation ▁and ▁serious ▁damage ▁to ▁the ▁eyes ▁ .
▁the ▁summary ▁of ▁the ▁opinion ▁of ▁the ▁committee ▁for ▁or phan ▁medicinal ▁products ▁for ▁da co gen ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁rare ▁disease ▁design ation ▁ .
▁di ar r ho e a ▁sto mati tis 2 ▁na use a ▁vom i ting
▁the ▁antibiotic ▁line zo lid ▁is ▁a ▁rever sible ▁non - sel ective ▁ma oi ▁and ▁should ▁not ▁be ▁given ▁to ▁patients ▁treated ▁with ▁cy mbal ta ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁your ▁doctor ▁may ▁also ▁tell ▁you ▁to ▁drink ▁plenty ▁of ▁fluid s ▁ .
▁maintenance ▁of ▁the ▁ef fica cy ▁of ▁macro cycli c ▁la cto nes ▁is ▁critical ▁for ▁di ro fil aria ▁im miti s ▁control ▁ , ▁therefore ▁ , ▁to ▁minimi se ▁the ▁risk ▁of ▁resist ance ▁selection ▁ , ▁it ▁is ▁recommended ▁that ▁dog s ▁should ▁be ▁check ed ▁for ▁both ▁circula ting ▁anti gens ▁and ▁blood ▁micro fil aria e ▁at ▁the ▁beginning ▁of ▁each ▁season ▁of ▁prevent ative ▁treatment ▁ .
▁bus il ve x ▁must ▁be ▁dilu ted ▁prior ▁to ▁use ▁with ▁either ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁or ▁gluco se ▁solution ▁for ▁inject ion ▁5 ▁% ▁ .
▁bio gra s tim ▁contain ing ▁r - met hug - cs f ▁( ▁fil gra s tim ▁) ▁causes ▁marked ▁increase s ▁in ▁per i pher al ▁blood ▁neutro phil ▁count s ▁within ▁24 ▁hours ▁ , ▁with ▁minor ▁increase s ▁in ▁mono cy tes ▁ .
▁this ▁will ▁avoid ▁ aggregat e ▁formation ▁( ▁see ▁section ▁6.2 ▁) ▁ .
▁tol ura ▁20 ▁mg ▁tablets
▁what ▁is ▁mix tar d ▁used ▁for ▁?
▁information ▁on ▁the ▁need ▁for ▁regular ▁monitoring ▁ , ▁and ▁when ▁it ▁should ▁be ▁carried ▁out ▁ , ▁of ▁se rum ▁creati nine ▁ , ▁creati nine ▁clear ance ▁ , ▁protein uria ▁ , ▁he pati c ▁enzym es ▁ , ▁fer rit in
▁do ▁not ▁use ▁a ▁double ▁dose ▁to ▁make ▁up ▁for ▁a ▁forgotten ▁dose ▁ .
▁stop ▁and ▁contact ▁your ▁health care ▁professional ▁ .
▁three ▁presentation s ▁are ▁available ▁:
▁eu ▁/ ▁1 ▁/ ▁98 ▁/ ▁09 2 ▁/ ▁02 3 ▁7 ▁trans der mal ▁patch es ▁eu ▁/ ▁1 ▁/ ▁98 ▁/ ▁09 2 ▁/ ▁0 24 ▁30 ▁trans der mal ▁patch es
▁tell ▁your ▁baby ▁' s ▁doctor ▁if ▁your ▁new born ▁is ▁taking ▁ , ▁have ▁recently ▁taken ▁or ▁might ▁take ▁any ▁other ▁medicine s ▁ .
▁in ▁patients ▁treated ▁with ▁t m z ▁ , ▁whether ▁used ▁in ▁combination ▁with ▁ rt ▁or ▁as ▁mono therapy ▁following ▁ rt ▁for ▁new ly - diagnos ed ▁gli obla s toma ▁multi forme ▁ , ▁or ▁as ▁mono therapy ▁in ▁patients ▁with ▁re current ▁or ▁progressive ▁gli oma ▁ , ▁the ▁reported ▁very ▁common ▁advers e ▁reaction s ▁were ▁similar ▁: ▁na use a ▁ , ▁vom i ting ▁ , ▁con s tip ation ▁ , ▁ano re xia ▁ , ▁head ache ▁and ▁fatigue ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁when ▁switch ing ▁patients ▁with ▁portal ▁hyper tension ▁from ▁a ▁che la ting ▁agent ▁to ▁wil zin ▁ , ▁when ▁such ▁patients ▁are ▁doing ▁well ▁and ▁the ▁treatment ▁is ▁to ler ated ▁ .
▁mild ▁hypo gly ca e mic ▁episode s ▁can ▁be ▁treated ▁by ▁oral ▁administration ▁of ▁gluco se ▁or ▁other ▁products ▁contain ing ▁sugar ▁ .
▁sv r ▁rates ▁for ▁patients ▁with ▁or ▁without ▁cir r ho sis
▁treatment ▁with ▁vir a cept ▁should ▁be ▁initiat ed ▁by ▁a ▁doctor ▁who ▁has ▁experience ▁in ▁the ▁treatment ▁of ▁hi v ▁infection ▁ .
▁advers e ▁effects ▁can ▁occur ▁if ▁mamma ls ▁are ▁expose d ▁to ▁excessive ▁levels ▁of ▁oxygen ▁for ▁long ▁period s ▁of ▁time ▁or ▁if ▁high ▁levels ▁of ▁oxygen ▁are ▁ad minister ed ▁under ▁hyper bar ic ▁conditions ▁ .
▁the ▁recommended ▁and ▁starting ▁dose ▁is ▁400 ▁mg ▁unless ▁your ▁doctor ▁decided ▁to ▁give ▁you ▁a ▁lower ▁starting ▁or ▁follow ▁up ▁dose ▁( ▁300 ▁mg ▁ , ▁200 ▁mg ▁or ▁160 ▁mg ▁) ▁ .
▁all ▁patients ▁met ▁rom e ▁i i ▁criteri a ▁for ▁i bs - c ▁and ▁were ▁required ▁to ▁report ▁a ▁mean ▁abdominal ▁pain ▁score ▁of ▁ ≥ ▁3 ▁on ▁a ▁0 - to -10- point ▁numeri c ▁rating ▁scale ▁( ▁criteri a ▁that ▁correspond ▁to ▁a ▁moderat e ▁to ▁severe ▁i bs ▁population ▁) ▁ , ▁< ▁3 ▁complete ▁spontane ous ▁bo wel ▁movement s ▁and ▁ ≤ ▁5 ▁s b ms ▁per ▁week ▁during ▁a ▁2- week ▁base line ▁period ▁ .
▁el ux ado line ▁has ▁very ▁low ▁oral ▁bio ava il ability ▁and ▁ex ert s ▁no ▁detect able ▁central ▁ner vous ▁system ▁( ▁c ns ▁) ▁- media ted ▁effects ▁when ▁ad minister ed ▁oral ly ▁to ▁animals ▁at ▁effective ▁dos es ▁ .
▁step ▁3 ▁- ▁3 ▁capsule s ▁( ▁120 ▁mg ▁)
▁in ▁this ▁study ▁ , ▁31 ▁% ▁of ▁patients ▁achieve d ▁a ▁ha e mat ological ▁response ▁( ▁36 ▁% ▁in ▁previously ▁un tre ated ▁patients ▁and ▁22 ▁% ▁in ▁previously ▁treated ▁patients ▁) ▁ .
▁in ▁the ▁control led ▁portion s ▁of ▁clinic al ▁trial s ▁of ▁t n f - anta gon ists ▁ , ▁more ▁cases ▁of ▁malign a ncies ▁including ▁lymph oma ▁have ▁been ▁observe d ▁among ▁patients ▁receiving ▁a ▁t n f - anta gon ist ▁compared ▁with ▁control ▁patients ▁ .
▁in ▁patients ▁with ▁some ▁remain ing ▁end ogen ous ▁corti sol ▁production ▁a ▁lower ▁dose ▁may ▁be ▁ sufficient ▁ .
▁the ▁un open ed ▁vi al ▁does ▁not ▁require ▁any ▁special ▁storage ▁conditions ▁ .
▁immediately ▁there a fter ▁ , ▁open ▁the ▁bottle ▁by ▁remo ving ▁the ▁child ▁resist ant ▁screw ▁cap ▁ .
▁if ▁you ▁have ▁been ▁taking ▁steroid ▁tablets ▁for ▁your ▁as th ma ▁or ▁cop d ▁ , ▁your ▁doctor ▁may ▁reduce ▁the ▁number ▁of ▁tablets ▁that ▁you ▁take ▁ , ▁once ▁you ▁start ▁to ▁use ▁bir es p ▁spir o max ▁ .
▁rim ona bant ▁has ▁not ▁been ▁studie d ▁in ▁patients ▁being ▁treated ▁for ▁epi le psy ▁ .
▁local ▁ana es the sia ▁may ▁be ▁applied ▁before ▁the ▁model ing ▁if ▁desire d ▁ .
▁not ▁known ▁( ▁fre que ncy ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁:
▁your ▁child ▁must ▁not ▁take ▁these ▁medicine s ▁: ▁carbon ic ▁an hyd rase ▁inhibi tors ▁( ▁like ▁to pira mate ▁and ▁ac eta zola mi de ▁) ▁ , ▁and ▁anti cho liner gi c ▁agents ▁( ▁like ▁clo mi pra mine ▁ , ▁hydro xy zi ne ▁ , ▁di phen hy dra mine ▁ , ▁hal o peri dol ▁ , ▁imi pra mine ▁and ▁ oxy but y nin ▁) ▁ .
▁as ▁concern s ▁the ▁patients ▁with ▁high ▁or ▁very ▁high ▁dr l ▁at ▁base line ▁ , ▁35 ▁% ▁of ▁patients ▁experienced ▁improvement ▁due ▁to ▁non - pharma c ological ▁effects ▁in ▁the ▁period ▁between ▁the ▁initial ▁visit ▁( ▁screening ▁) ▁and ▁random isation ▁ .
▁if ▁not ▁used ▁immediately ▁ , ▁in - use ▁storage ▁times ▁and ▁conditions ▁are ▁the ▁responsibility ▁of ▁the ▁user ▁and ▁must ▁normal ly ▁not ▁be ▁longer ▁than ▁24 ▁hours ▁at ▁2 ▁c ▁- ▁8 ▁c ▁followed ▁by ▁up ▁to ▁24 ▁hours ▁at ▁room ▁temperature ▁( ▁23 ▁c ▁- ▁27 ▁c ▁) ▁during ▁administration ▁ .
▁further ▁research ▁is ▁needed ▁to ▁establish ▁whether ▁serial ▁ liver ▁che mist ry ▁tests ▁or ▁prope pti de ▁of ▁type ▁i ii ▁collage n ▁can ▁detect ▁he pato toxic ity ▁ sufficient ly ▁ .
▁vi als ▁contain ▁either ▁1 ▁mg ▁or ▁4 ▁mg ▁of ▁to pote can ▁ .
▁key ▁sign s ▁and ▁symptoms ▁of ▁i vt ▁inject ion ▁related ▁advers e ▁events ▁including ▁increased ▁intra o cular ▁pressure ▁ , ▁traumat ic ▁ca tar act ▁and ▁en do ph thal miti s
▁ada lim um ab ▁bind s ▁to ▁a ▁specific ▁protein ▁( ▁tum our ▁nec rosi s ▁factor ▁or ▁t n f ▁) ▁ , ▁which ▁is ▁present ▁at ▁increased ▁levels ▁in ▁infla mma tory ▁disease s ▁such ▁as ▁rhe um ato id ▁ar thri tis ▁ , ▁poly arti cular ▁juvenil e ▁ idio pathi c ▁ar thri tis ▁ , ▁en the s itis - related ▁ar thri tis ▁ , ▁an ky los ing ▁ spon dy liti s ▁ , ▁a xi al ▁ spon dy lo ar thri tis ▁without ▁radio graphic ▁evidence ▁of ▁an ky los ing ▁ spon dy liti s ▁ , ▁ps oria tic ▁ar thri tis ▁ , ▁psoriasis ▁ , ▁hid raden itis ▁sup pura tiva ▁ , ▁cro h n ▁' s ▁disease ▁ , ▁ul cer ative ▁col itis ▁and ▁non - infect i ous ▁u ve itis ▁affect ing ▁the ▁back ▁of ▁the ▁eye ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁ , ▁for ▁versi can ▁plus ▁pi ▁on ▁4 ▁jul y ▁2014 ▁ .
▁in ▁a ▁clinic al ▁trial ▁of ▁patients ▁with ▁multiple ▁mye loma ▁that ▁compared ▁emp licit i ▁combine d ▁with ▁le nali domi de ▁and ▁de xa met has one ▁treatment ▁to ▁le nali domi de ▁and ▁de xa met has one ▁treatment ▁( ▁study ▁1 ▁) ▁ , ▁the ▁incide nce ▁of ▁sp ms ▁ , ▁and ▁specifically ▁of ▁solid ▁tu mo urs ▁and ▁non - mela noma ▁skin ▁cancer ▁ , ▁was ▁higher ▁in ▁patient ▁treated ▁with ▁emp licit i ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁the ▁local ▁advers e ▁reaction s ▁are ▁character istic ▁of ▁an ▁a cute ▁tissu e ▁infla mma tory ▁response ▁induc ed ▁by ▁photo activa tion ▁and ▁common ly ▁include ▁oed ema ▁and ▁pain ▁followed ▁by ▁nec rosi s ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁the ▁vaccin e ▁should ▁be ▁shake n ▁well ▁to ▁obtain ▁a ▁homo gene ous ▁white ▁suspens ion ▁prior ▁to ▁exp e lling ▁air ▁from ▁the ▁sy ringe ▁ , ▁and ▁should ▁be ▁inspect ed ▁visual ly ▁for ▁any ▁parti cula te ▁matter ▁and ▁/ ▁or ▁variation ▁of ▁physical ▁aspect ▁prior ▁to ▁administration ▁ .
▁method ▁and ▁route ▁of ▁administration
▁however ▁ , ▁if ▁you ▁take ▁more ▁ne oc lari tyn ▁oral ▁solution ▁than ▁you ▁were ▁told ▁to ▁ , ▁tell ▁your ▁doctor ▁ , ▁ pharma ci st ▁or ▁nurse ▁immediately ▁ .
▁re pag lini de ▁accord ▁is ▁used ▁to ▁control ▁type ▁2 ▁diabetes ▁in ▁adults ▁as ▁an ▁add - on ▁to ▁die t ▁and ▁exercise ▁: ▁treatment ▁is ▁usually ▁started ▁if ▁die t ▁ , ▁exercise ▁and ▁weight ▁re duction ▁alone ▁have ▁not ▁been ▁able ▁to ▁control ▁( ▁or ▁lower ▁) ▁your ▁blood ▁sugar ▁ .
▁pe metre x ed ▁accord ▁1000 ▁mg ▁:
▁these ▁character istic s ▁had ▁no ▁clinic ally ▁meaning ful ▁effect ▁on ▁the ▁ pharma cok ine tics ▁of ▁si tag lip tin ▁based ▁on ▁a ▁com posit e ▁analysis ▁of ▁phase ▁i ▁ pharma cok ine tic ▁data ▁and ▁on ▁a ▁population ▁ pharma cok ine tic ▁analysis ▁of ▁phase ▁i ▁and ▁phase ▁i i ▁data ▁ .
▁a ▁trans ient ▁increase ▁in ▁mean ▁q t c ▁was ▁observe d ▁for ▁both ▁dos es ▁during ▁period s ▁of ▁increasing ▁heart ▁rate ▁and ▁the ▁maximum ▁change ▁in ▁mean ▁q t cf ▁( ▁fri der i cia ▁correct ion ▁) ▁was ▁+ ▁5.0 ▁m sec ▁occur ring ▁at ▁2 ▁hours ▁for ▁0.5 ▁mg ▁and ▁+ ▁1 0.0 ▁m sec ▁occur ring ▁at ▁1 ▁hour ▁for ▁2.5 ▁mg ▁ .
▁what ▁benefit ▁has ▁ flex ica m ▁shown ▁during ▁the ▁studies ▁?
▁ir besar tan ▁is ▁not ▁removed ▁by ▁ha e modi al ysis ▁ .
▁en tyvi o ▁is ▁given ▁by ▁a ▁doctor ▁or ▁nurse ▁and ▁patients ▁should ▁not ▁need ▁to ▁store ▁or ▁handle ▁en tyvi o ▁ .
▁improvement s ▁were ▁reported ▁in ▁cardiac ▁ , ▁ner vous ▁ , ▁skin ▁/ ▁sub cuta ne ous ▁tissu e ▁ , ▁respirator y ▁/ ▁tho ra cic ▁/ ▁media stin al ▁ , ▁mus culos kelet al ▁/ ▁connect ive ▁tissu e ▁/ ▁vas cular ▁ , ▁and ▁gastro inte stin al ▁organ ▁systems ▁ .
▁13 ▁following ▁short ▁term ▁treatment ▁( ▁media n ▁du ration ▁22 ▁days ▁) ▁ , ▁weight ▁gain ▁ ≥ ▁7 ▁% ▁of ▁base line ▁body ▁weight ▁( ▁kg ▁) ▁was ▁very ▁common ▁( ▁4 0.6 ▁% ▁) ▁ , ▁ ≥ ▁15 ▁% ▁of ▁base line ▁body ▁weight ▁was ▁common ▁( ▁7.1 ▁% ▁) ▁and ▁ ≥ ▁25 ▁% ▁was ▁common ▁( ▁2.5 ▁% ▁) ▁ .
▁the ▁active ▁substance ▁in ▁mel oxid yl ▁is ▁an ▁allowed ▁substance ▁as ▁described ▁in ▁table ▁1 ▁of ▁the ▁ann ex ▁to ▁commission ▁regula tion ▁( ▁eu ▁) ▁no ▁37 ▁/ ▁2010 ▁:
▁dos ing ▁recommendations ▁to ▁tit rate ▁according ▁to ▁individual ▁to ler ability ▁must ▁be ▁close ly ▁followed ▁ .
▁after ▁remo val ▁of ▁the ▁convention al ▁ , ▁flat ▁ta chos il ▁from ▁the ▁steril e ▁package ▁it ▁should ▁be ▁pre - mo isten ed ▁in ▁sa line ▁solution ▁and ▁then ▁applied ▁immediately ▁ .
▁this ▁means ▁that ▁aba sag lar ▁is ▁similar ▁to ▁a ▁bi ological ▁medicine ▁( ▁also ▁known ▁as ▁the ▁' ▁reference ▁medicine ▁' ▁) ▁that ▁is ▁already ▁author ised ▁in ▁the ▁european ▁union ▁( ▁eu ▁) ▁ .
▁cere zy me ▁has ▁no ▁or ▁negli gi ble ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁the ▁cart ridge ▁in - use ▁( ▁in ▁the ▁insulin ▁pen ▁) ▁or ▁carried ▁as ▁a ▁spare ▁may ▁be ▁store d ▁for ▁a ▁maximum ▁of ▁4 ▁weeks ▁not ▁above ▁25 ▁° ▁c ▁and ▁away ▁from ▁direct ▁heat ▁or ▁direct ▁light ▁ .
▁do ▁not ▁store ▁above ▁25 ▁° ▁c ▁ .
▁the ▁active ▁substance ▁is ▁e pto termin ▁alfa ▁( ▁a ▁reco mbin ant ▁human ▁osteo ge nic ▁protein ▁1 ▁produced ▁in ▁a ▁reco mbin ant ▁chi nese ▁ham ster ▁ova ry ▁( ▁cho ▁) ▁cell ▁line ▁) ▁ .
▁a ▁local ▁reaction ▁may ▁occur ▁( ▁s light ▁pain ▁at ▁palp ation ▁ , ▁it ching ▁or ▁limited ▁oed ema ▁) ▁that ▁disappear s ▁within ▁1 ▁or ▁2 ▁weeks ▁at ▁most ▁ .
▁do ▁not ▁store ▁above ▁25 oc ▁ .
▁the ▁decision ▁to ▁stop ▁using ▁or encia ▁should ▁be ▁discuss ed ▁with ▁your ▁doctor ▁ .
▁if ▁the ▁other ▁eye ▁medicine ▁is ▁an ▁eye ▁o int ment ▁it ▁should ▁be ▁used ▁last ▁ .
▁you ▁are ▁suffering ▁from ▁any ▁condition ▁that ▁has ▁an ▁effect ▁on ▁your ▁breath ing ▁( ▁such ▁as ▁as th ma ▁ , ▁w hee zing ▁ , ▁or ▁short ness ▁of ▁breath ▁) ▁ .
▁t m z ▁is ▁spontane ously ▁hydro ly zed ▁at ▁physio logic ▁ph ▁primari ly ▁to ▁the ▁active ▁species ▁ , ▁3- met hyl - ▁( ▁tria zen - ▁1- yl ▁) ▁im ida zole -4 - car box ami de ▁( ▁m tic ▁) ▁ .
▁dose ▁adjust ments ▁are ▁not ▁required ▁in ▁patients ▁with ▁mild ▁to ▁moderat e ▁renal ▁im pair ment ▁( ▁creati nine ▁clear ance ▁ ≥ ▁30 ▁ml ▁/ ▁min ▁) ▁ .
▁10,000 ▁bir ds ▁with ▁an ▁average ▁body weight ▁of ▁1 ▁kg ▁) ▁ .
▁effects ▁suspect ed ▁to ▁be ▁due ▁to ▁over dos e ▁have ▁not ▁been ▁reported ▁ .
▁before ▁travel ling ▁consult ▁your ▁doctor ▁ .
▁the ▁in fusion ▁solution ▁has ▁to ▁be ▁ad minister ed ▁over ▁a ▁period ▁of ▁not ▁less ▁than ▁the ▁in fusion ▁time ▁recommended ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁no ▁dose ▁adjust ment ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁ hb va x pro ▁10 ▁micro gram s ▁ , ▁suspens ion ▁for ▁inject ion ▁in ▁pre - fill ed ▁sy ringe
▁in ▁the ▁ absence ▁of ▁compatibil ity ▁studies ▁ , ▁this ▁veterinar y ▁medicinal ▁product ▁must ▁not ▁be ▁mix ed ▁with ▁other ▁veterinar y ▁medicinal ▁products ▁ .
▁medicine s ▁should ▁not ▁be ▁dispose d ▁of ▁via ▁was te ▁water ▁or ▁household ▁was te ▁ .
▁no ▁treatment ▁experience ▁is ▁available ▁for ▁this ▁sub pop ulation ▁of ▁patients ▁ , ▁and ▁therefore ▁the ▁use ▁of ▁pra da xa ▁is ▁not ▁recommended ▁in ▁this ▁population ▁ .
▁if ▁you ▁have ▁any ▁further ▁questions ▁ , ▁ask ▁your ▁doctor ▁or ▁your ▁ pharma ci st ▁ .
▁blue ▁in k ▁contain ing ▁: ▁ shell ac ▁ , ▁ propyl ene ▁gly col ▁ , ▁ammo nium ▁hydro xi de ▁and ▁indi go car min ▁( ▁e 132 ▁)
▁the ▁safety ▁and ▁ef fica cy ▁of ▁od ef sey ▁in ▁patients ▁co - infect ed ▁with ▁hi v -1 ▁and ▁ hb v ▁or ▁h c v ▁has ▁not ▁been ▁established ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁insu man ▁com b ▁50 ▁contain s
▁education ▁about ▁the ▁2 ▁intra mus cular ▁formula tions ▁of ▁olan za pine ▁ , ▁including ▁packaging ▁difference s
▁there ▁is ▁in sufficient ▁data ▁on ▁the ▁reli ability ▁of ▁the ▁heli coba cter ▁test ▁inf ai ▁for ▁recommend ing ▁its ▁use ▁in ▁patients ▁with ▁remo val ▁of ▁parts ▁of ▁the ▁stomach ▁ .
▁other ▁information ▁about ▁glu bra va
▁please ▁use ▁the ▁following ▁formula ▁:
▁however ▁ , ▁al do ster one ▁release ▁is ▁not ▁fully ▁control led ▁by ▁a ce ▁inhibi tors ▁because ▁ang io ten sin - ii ▁is ▁also ▁produced ▁by ▁non - ace ▁path ways ▁such ▁as ▁chy mas e ▁( ▁ phen ome non ▁known ▁as ▁" ▁al do ster one ▁break through ▁" ▁) ▁ .
▁what ▁lan tus ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁for ▁more ▁information ▁about ▁the ▁safety ▁of ▁in flix ima b ▁in ▁el der ly ▁patients ▁see ▁section s ▁4.4 ▁and ▁4. 8 ▁ .
▁information ▁on ▁the ▁importance ▁of ▁following ▁a ▁low - fat ▁die t ▁( ▁a ▁die t ▁supply ing ▁less ▁than ▁20 ▁% ▁of ▁energy ▁from ▁fat ▁) ▁;
▁eye ▁disorder s ▁: ▁cyst oid ▁ma cular ▁oed ema ▁ , ▁ toxic ▁amb ly opia ▁ .
▁the ▁dose ▁given ▁depend s ▁on ▁your ▁weight ▁and ▁on ▁the ▁kind ▁of ▁treatment ▁you ▁are ▁being ▁given ▁ .
▁treatment ▁with ▁re vas c ▁should ▁be ▁initiat ed ▁under ▁the ▁guidance ▁of ▁a ▁physician ▁with ▁experience ▁in ▁coa g ulation ▁disorder s ▁ .
▁if ▁few ▁or ▁no ▁β - amy lo id ▁plaque s ▁are ▁seen ▁in ▁the ▁pet ▁scan ▁( ▁a ▁negative ▁scan ▁) ▁ , ▁the ▁patient ▁is ▁un like ly ▁to ▁have ▁al z heim er ▁' s ▁disease ▁ .
▁very ▁common ▁: ▁may ▁affect ▁more ▁than ▁1 ▁in ▁10 ▁people
▁si tag lip tin ▁is ▁secret ed ▁in ▁considerable ▁amount s ▁into ▁the ▁milk ▁of ▁la cta ting ▁rat s ▁( ▁milk ▁/ ▁plasma ▁ratio ▁: ▁4 ▁: ▁1 ▁) ▁ .
▁patients ▁should ▁be ▁monitor ed ▁for ▁ liver ▁laborator y ▁test ▁ab normal ities ▁and ▁managed ▁as ▁recommended ▁in ▁section s ▁4.2 ▁and ▁4.4 ▁ .
▁the ▁net ▁effect ▁of ▁co - administration ▁is ▁not ▁clear ▁ .
▁table ▁1 ▁: ▁advers e ▁reaction s ▁identified ▁in ▁control led ▁clinic al ▁trial s ▁and ▁post - marketing
▁ry zo deg ▁is ▁ad minister ed ▁sub cuta ne ously ▁by ▁inject ion ▁in ▁the ▁abdominal ▁wall ▁ , ▁the ▁upp er ▁arm ▁or ▁the ▁th igh ▁ .
▁this ▁medicinal ▁product ▁contain s ▁50 ▁vol ▁% ▁et han ol ▁an hydro us ▁( ▁alcohol ▁) ▁ , ▁i . e . ▁up ▁to ▁3. 16 ▁g ▁et han ol ▁an hydro us ▁per ▁vi al ▁ , ▁equivalent ▁to ▁80 ▁ml ▁of ▁beer ▁or ▁32 ▁ml ▁wine ▁per ▁vi al ▁ .
▁the ▁secreto ry ▁path way ▁appears ▁not ▁to ▁include ▁known ▁acid ic ▁or ▁basic ▁transport ▁systems ▁involved ▁in ▁the ▁ex cre tion ▁of ▁other ▁active ▁substance s ▁ .
▁your ▁doctor ▁will ▁check ▁your ▁blood ▁before ▁and ▁during ▁treatment ▁with ▁lyn par za ▁ .
▁statement ▁of ▁the ▁mr ls
▁a ▁supplement ary ▁retro spec tive ▁analysis ▁was ▁conduct ed ▁on ▁data ▁from ▁5 23 ▁patients ▁with ▁re lapse d ▁ova rian ▁cancer ▁ .
▁na use a ▁ , ▁vom i ting ▁ , ▁di ar r ho e a ▁ , ▁con s tip ation
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁comp et act ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁you ▁should ▁not ▁touch ▁this ▁area ▁ .
▁in ▁a ▁study ▁in ▁subject s ▁with ▁moderat e ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁class ▁b ▁) ▁ , ▁the ▁plasma ▁concentration s ▁of ▁free ▁pali peri done ▁were ▁similar ▁to ▁those ▁of ▁healthy ▁subject s ▁ .
▁as ▁recommended ▁by ▁the ▁world ▁health ▁organization ▁( ▁who ▁) ▁the ▁assessment ▁of ▁potential ▁ef fica cy ▁against ▁i p d ▁in ▁infants ▁and ▁young ▁children ▁has ▁been ▁based ▁on ▁a ▁comparison ▁of ▁immun e ▁response s ▁to ▁the ▁seven ▁common ▁ser o type s ▁shared ▁between ▁ preven ar ▁13 ▁and ▁ preven ar ▁ , ▁for ▁which ▁protect ive ▁ef fica cy ▁has ▁been ▁proven ▁ .
▁the ▁patch ▁release s ▁300 ▁micro gram s ▁of ▁the ▁active ▁substance ▁testosteron e ▁over ▁24 ▁hours ▁ .
▁bo vine ▁se rum ▁di met hyl ▁sul fox ide ▁water ▁for ▁inject ion
▁if ▁an ▁ab normal ity ▁is ▁found ▁and ▁an ▁alternative ▁et i ology ▁is ▁not ▁established ▁ , ▁consider ▁dis continu ation ▁of ▁a log lip tin ▁treatment ▁ .
▁other ▁: ▁as ▁with ▁any ▁anti hy per tensi ve ▁agent ▁ , ▁excessive ▁re duction ▁of ▁blood ▁pressure ▁in ▁patients ▁with ▁is cha e mic ▁cardio pathy ▁or ▁is cha e mic ▁cardiovascular ▁disease ▁could ▁result ▁in ▁a ▁my o card ial ▁in far ction ▁or ▁stroke ▁ .
▁ni nte dan ib ▁may ▁affect ▁the ▁way ▁your ▁wo und s ▁he al ▁ .
▁white ▁ , ▁bi con ve x ▁ , ▁capsule ▁shape d ▁ , ▁film - co ated ▁tablets ▁ .
▁hypo gam ma glob ul ina emia ▁and ▁re current ▁bacteria l ▁infection s ▁in ▁patients ▁with ▁chronic ▁lymph o cy tic ▁leuk a emia ▁ , ▁in ▁whom ▁pro phy la ctic ▁antibiotic s ▁have ▁failed ▁; ▁hypo gam ma glob ul ina emia ▁and ▁re current ▁bacteria l ▁infection s ▁in ▁plate au ▁phase ▁multiple ▁mye loma ▁patients ▁who ▁have ▁failed ▁to ▁respond ▁to ▁pneu moc oc cal ▁immun isation ▁; ▁con geni tal ▁aid s ▁with ▁re current ▁bacteria l ▁infection s
▁do ▁not ▁take ▁more ▁re pag lini de ▁kr ka ▁than ▁your ▁doctor ▁has ▁recommended ▁ .
▁then ▁hold ▁the ▁pipe tte ▁in ▁an ▁up right ▁position ▁ , ▁and ▁twist ▁and ▁pull ▁off ▁the ▁cap ▁ .
▁un change d ▁drug ▁account ed ▁for ▁approximately ▁20 ▁% ▁and ▁7 ▁% ▁of ▁the ▁ad minister ed ▁dose ▁in ▁the ▁fa e ces ▁and ▁urin e ▁ , ▁respective ly ▁ .
▁ara - c ▁: ▁cy tos ine ▁arab ino side ▁; ▁c p ▁: ▁ cyclo phos pha mi de ▁; ▁de x ▁: ▁de xa met has one ▁; ▁m t x ▁: ▁met ho tre xa te ▁; ▁6- mp ▁: ▁6- mer cap to puri ne ▁v m 26 ▁: ▁te ni po side ▁; ▁v cr ▁: ▁vin cris tine ▁; ▁i da ▁: ▁i dar ubi cine ▁; ▁i . v . ▁: ▁intra ven ous
